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The human metabolic syndrome is characterized by a heterogenic complex of symptoms, 
including central obesity. Obesity itself is linked to major features of the metabolic syndrome 
such as insulin resistance, dyslipidemia or type 2 diabetes mellitus. It has been shown that 
obesity risk and resulting metabolic alterations are associated with adipose tissue distribution, 
adipocyte size and secretion of adipocytokines, which are in turn influenced by environmental 
factors and genetic susceptibility. It might be assumed that currently known genetic variants 
associated with obesity and/or BMI (body mass index) as well as fat distribution explain up to 
20 % of the variability in BMI and so, studies employing novel strategies are inevitable. In 
addition to the role of genetic variation, mRNA levels of several genes have been shown to be 
differentially expressed in subcutaneous (SC) and visceral (Vis) adipose tissue and to be 
correlated with obesity-related traits. It is scarcely investigated whether the obesity risk 
variants also might account for the variability in mRNA expression. The present thesis deals 
with novel obesity candidate genes, characterized by a differential mRNA expression in 
various fat depots. The association of genetic variants in these genes with obesity as part of 
the metabolic syndrome, and related traits was investigated in well characterized German 
cohorts. The main method used for genotyping was described in detail in a comprehensive 
review providing explicit troubleshooting and description of modified protocols for specific 
experimental needs. Further, the influence of genotypes on the gene expression levels was 
examined. While the differential expression for FTO could be described for the first time, the 
variant rs8050136 was shown to be significantly associated with obesity but not with the 
expression. Genetic variants in FASN were shown to be significantly associated with obesity 
and related traits in a cohort of European ancestry for the very first time. Moreover, one 
polymorphism showed effects on the ratio of Vis/SC FASN mRNA expression. While CNR1 
is controversially discussed in the literature, the present work showed rather moderate effects 
of genetic variants on obesity. BMPR2 could be described as a novel obesity candidate gene. 
Amongst others, one variant was associated with obesity in a case-control design and with 
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BMPR2 mRNA expression in Vis adipose tissue. In conclusion, the present study revealed 
novel genetic variants promoting obesity, and therefore a metabolic risk, which might be 
partly explicable through an influence of these variants on the mRNA expression levels of the 
genes in the adipose tissue depots. These findings contribute to better understanding of the 
genetic background of obesity which is essential in order to translate experimental data into 
diagnostic, preventive and treatment strategies. 
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ABBREVIATIONS (engl., dt.) 
 
2-AG  2-arachidonylglycerol 
AU  Arbitrary Unit, beliebige Einheit 
BAT  Brown adipose tissue, braunes Fettgewebe 
BMI  Body mass index, Körpermasseindex 
BMP/R Bone morphogenetic protein/receptor 
CETP  Cholesteryl-ester transfer protein 
CNR  Cannabinoid receptor, Cannabinoidrezeptor 
CT  Computed tomography, Computertomographie 
CTNNBL1 Catenin beta, like 1 
DEXA  Dual energy X-ray absorptiometry 
dNTP  Deoxyribonucleotide triphosphate 
DPI3  Dihydrocyclopyrroloindole tripeptide 
ECS  Endocannabinoid system 
EGFP Enhanced green fluorescent protein 
6-FAM 6-Carboxyfluorescein 
FASN  Fatty acid synthase, Fettsäure-Synthase 
FRET  Fluorescence resonance energy transfer 
FTO/Fto Fat mass and obesity associated (human/mouse) 
GWAS Genome wide association study, genomweite Assoziationsstudie  
HSC  Hematopoietic stem cell, hämatopoetische Stammzelle 
HWE  Hardy-Weinberg equlibrium, Hardy-Weinberg Gleichgewicht 
IGT  Impaired glucose tolerance, gestörte Glucose-Toleranz 
iHS  Integrated haplotype score 
IL  Interleukin 
INSIG2 Insulin induced gene 2 
IRS-1  Insulin receptor substrate 1 
KFO  Klinische Forschergruppe 
L.D.  Linkage disequilibrium, Kopplungsungleichgewicht 
LEP  Leptin 
LEPR  Leptin receptor 
LYPLAL1 Lysophospholipase, like 1 
MC4R  Melanocortin 4 receptor 
ABBREVIATIONS   10
MCP  Monocyte chemoattractant protein 
MGB  Minor groove binder 
MRI  Magnetic resonance imaging, Magnetresonanztomographie 
mRNA messengerRNA 
MSC  Mesenchymal stem cell, mesenchymale Stammzelle 
MSRA  Methionine sulfoxide reductase A 
NGT  Normal glucose tolerant, normale Glucose-Toleranz 
NEGR1 Neuronal growth regulator 1 
NFQ  Non fluorescent quencher 
NTC  Non template control 
OGTT  Oral glucose tolerance test, oraler Glucose-Toleranztest 
PAI-1  Plasminogen activator inhibitor 
PAML  Phylogenetic analysis by Maximum Likelihood 
PCR  Polymerase chain reaction, Polymerase Kettenreaktion 
PCSK1 Proprotein convertase subtilisin/kexin type 1 
PET  Positron-emission tomography, Positronen-Emissions-Tomographie 
POMC  Proopiomelanocortin 
PPARG Peroxisome proliferator-activated receptor gamma 
QC  Quality control, Qualitätskontrolle 
RBP  Retinol binding protein 
RFLP  Restriction fragment lenght polymorphism 
RNA  Ribonucleic acid, Ribonucleinsäure 
ROX  6-Carboxy-X-rhodamine 
RPGRIP1 Retinitis pigmentosa GTPase regulator interacting protein 1 
RT  Reverse transcriptase 
SAA  Serum amyloid A 
SC  Subcutaneous, subkutan 
SD  Standard deviation, Standardabweichung 
SDS  Standard deviation scores 
SDS software Sequence detection system software 
SEM  Standard error of the mean, Standardfehler des Mittelwertes 
SH2BP1 SH2 domain binding protein 1 
SMAD Mothers against decapentaplegic 
SNP  Single nucleotide polymorphism, Einzelbasenaustausch 
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T2D  Type 2 Diabetes mellitus 
Taq  Thermus aquaticus 
TMEM18 Transmembrane protein 18 
TFAP2B Transcription factor activating enhancer binding protein 2 beta 
TNFA  Tumor necrosis factor alpha 
UCP 1/2 Uncoupling protein 1/2 
UTR  Untranslated region, untranslatierte Region  
Vis  Visceral, viszeral 
Vs.  Versus 
WAT  White adipose tissue, weißes Fettgewebe 
WC  Waist circumference, Bauchumfang 
WHR  Waist-to-hip ratio, Taille-Hüft-Verhältnis 
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SUMMARY 
 
The human metabolic syndrome is characterized through the coeval appearance of a 
cluster of metabolic alterations such as central obesity, insulin resistance, dyslipidemia, 
hypertension, and type 2 diabetes mellitus (T2D). The metabolic syndrome is influenced by 
complex interactions of both environmental as well as genetic components. Intra-abdominal, 
or visceral, obesity is considered to be the main factor responsible for metabolic sequelae 
such as insulin resistance or T2D. It has been shown that the obesity risk and consequent 
metabolic alterations are associated with adipose tissue distribution, adipocyte size, and 
secretion of adipocytokines. Besides monogenic forms, obesity and adipose tissue distribution 
is of polygenic nature. During the last decade, candidate gene and genome wide association 
studies increased the number of known genes and genetic variants promoting obesity risk 
rapidly. Moreover, mRNA levels of several genes have been shown to be differentially 
expressed in subcutaneous (SC) and visceral (Vis) adipose tissue. The expression levels were 
associated with various traits related to the metabolic syndrome such as body fat content, 
measures of glucose metabolism or insulin sensitivity. However, the underlying molecular 
mechanisms are poorly understood and it is estimated that the genetic variants identified so 
far do only account for approximately 20 % variability in body mass index (BMI). It is 
evident that more studies are necessary to clarify the complex genetic interplay regulating 
adipose tissue distribution and obesity, and to explain the mechanisms by which the genetic 
variants exert their effects. The present thesis describes investigations on gene’s mRNA 
expression pattern in SC and Vis adipose tissue depots to clarify the role of the genes in a 
tissue largely responsible for metabolic complications. Further, the association of single 
nucleotide polymorphisms (SNPs) in potential candidate genes with obesity and related 
anthropometric/metabolic traits is elucidated to clarify their contribution to the genetic risk of 
developing the human metabolic syndrome. Finally, it is investigated whether the variability 
in gene expression levels is mediated by the SNPs. 
The current knowledge on adipose tissue physiology and on the genetic background of 
obesity and adipose tissue distribution as well as the aims of the work are summarized in 
CHAPTER 1. The aim of the studies was to investigate the role of the fat mass and obesity 
associated gene, FTO, the fatty acid synthase gene, FASN, the cannabinoid receptor type 1 
gene, CNR1 and the bone morphogenetic protein receptor 2 gene, BMPR2, in the 
pathophysiology of the human metabolic syndrome. 
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Within the expression studies, real-time PCR was carried out in paired samples of SC 
and Vis adipose tissue derived from individuals with wide ranges of obesity and body fat 
distribution. To cover the entire gene locus including the coding sequence and the introns by 
common genetic variants (minor allele frequency > 5 %) a SNP-“tagging”-approach based on 
linkage disequilibrium (L.D.) pattern was applied. Therefore, SNPs from the HapMap 
database were selected and each gene was sequenced to detect novel genetic variation. L.D. 
analysis was carried out and one representative SNP for each L.D. group was genotyped for 
association studies. Genotyping was done in well-characterized cohorts (Leipzig, N~1800; 
and Sorbs, N~1000) using the TaqMan® technique or restriction fragment length 
polymorphism (RFLP). The TagMan® technique which was used as a main method was 
described in detail in CHAPTER 2 in form of a comprehensive review providing explicit 
troubleshooting and description of modified protocols for specific experimental needs. For 
genotype-phenotype association studies all cohorts have been extensively characterized 
regarding intermediate phenotypes such as anthropometric (age, BMI, waist-to-hip ratio 
[WHR], body fat content) and metabolic parameters (glucose and insulin measurements, 
lipids, adipocytokines). Adequate statistical analyses were conducted in all studies.  
 
In CHAPTER 3, the mRNA expression of the Fat Mass and Obesity Associated gene, 
FTO, was investigated. Noteworthy, the effect of FTO variants on obesity was initially 
detected in a genome wide scan for T2D in which the association between FTO SNPs and 
T2D was mediated via obesity. In mice, a mutation in the Ft gene, the original name of FTO, 
led to fused toes (hence the abbreviation Ft) but no obese phenotype was reported. Amongst 
others, FTO has been shown to be expressed in human adipose tissue but the function has 
remained unknown. In the present study, it was hypothesized that FTO mRNA expression in 
SC and Vis adipose tissue is linked to obesity. In addition to FTO, its neighboring gene, 
RPGRIP1L (RPGRIP1-like) was targeted as well. Furthermore it was investigated whether the 
previously published obesity-associated FTO variants, represented by rs8050136, might 
explain potential variability in FTO and RPGRIP1L mRNA expression. When compared in 
the two fat depots, FTO mRNA was higher expressed in SC adipose tissue, while RPGRIP1L 
mRNA expression was higher in Vis adipose tissue. Although FTO expression in both SC and 
Vis adipose tissue were correlated with measures of obesity and with each other, the Vis FTO 
mRNA expression remained an independent predictor of BMI even after adjustment for 
subcutaneous FTO mRNA expression. No correlations were observed between FTO mRNA 
expression levels and measures of glucose and insulin metabolism in either fat depot. In 
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contrast to FTO, no correlation of RPGRIP1L mRNA expression with anthropometric and 
metabolic parameters was seen which suggests that FTO rather than RPGRIP1L is involved in 
the pathophysiology of obesity. Although rs8050136 was associated with obesity, no relation 
with SC or Vis FTO mRNA levels was observed. The results presented in CHAPTER 3, 
provided the first data highlighting the relationship between FTO and RPGRIP1L mRNA 
expression in adipose tissue and anthropometric and metabolic parameters including measures 
of obesity. 
 
Fatty acid synthase (FASN) is a key enzyme in the pathway of de novo lipogenesis. It 
catalyses the main steps in the conversion of malonyl CoA to palmitate. Recent data 
demonstrated a strong association of increased FASN expression in adipose tissue not only 
with obesity, but also with T2D and insulin resistance, thus indicating a possible role of 
lipogenic pathways in the development of human obesity and/or T2D. Because of the 
important physiological role of its protein, the FASN is an attractive candidate gene to be 
investigated in association studies for obesity and related traits. Moreover, studies in Pima 
Indians from Southern Arizona and German children (Leipzig) revealed a novel Val1483Ile 
polymorphism protective against obesity. However, genotype-phenotype association studies 
examining the role of genetic variants of FASN in obesity in adult Caucasians have been 
lacking so far. Also, it has not yet been clarified, whether genetic variation within the FASN 
might be responsible for changes in FASN expression in adipose tissue. The study presented 
in CHAPTER 4 addressed these questions in adult and children cohorts. Several 
polymorphisms in the FASN associated with obesity in case-control studies in adults could be 
detected in the project. The strongest effect was found for rs2229422, which was supported by 
associations with BMI, WHR, fasting plasma insulin, and glucose infusion rate, as measured 
in a euglycemic-hyperinsulinemic clamp. In addition, rs17848939 was associated with the 
ratio of Vis/SC FASN mRNA expression which was also reflected in the association of this 
SNP with WHR. The protective effect of the Val1483Ile substitution could be replicated in 
the adult cohort. No effect of genetic variation in FASN on obesity was found in children 
indicating that the SNP effects most likely manifest in later stages of life and/or that these 
effects might be modified by gene-environment interactions. In conclusion, it could be shown 
for the first time that polymorphisms in FASN contribute to the increased risk of developing 
metabolic alterations during adult life. Moreover, the variants might exert their effects via an 
adverse effect on the adipose tissue distribution towards the visceral depot, as well as by 
modulating the FASN expression in this depot. 
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 As part of the endocannabinoid system (ECS), the CNR1 participates in the control of 
food intake via both central and peripheral mechanisms, and in lipid and glucose metabolism. 
In a previous study it has been shown that CNR1 was present in human Vis and SC 
adipocytes and CNR1 mRNA expression in Vis adipose tissue correlated with circulating 2-
arachidonylglycerol levels (2-AG), percent body fat, Vis fat area, and fasting plasma insulin. 
Despite its physiologic plausibility to serve as a candidate gene for obesity, genotype-
phenotype associations on genetic variants in CNR1 gene have been rather controversial, 
which is most likely due to the heterogeneity of studied populations. The studies 
demonstrated the necessity of various independent cohorts being involved in the analyses in 
order to evaluate the role of this obesity candidate gene. In CHAPTER 5, genetic analyses on 
CNR1 in two German populations are presented. In the present study, the SNP rs806368 was 
found to be associated with obesity in the Sorbs, but not in the Leipzig cohort. Also, several 
SNPs were associated with serum leptin levels, while lacking associations with obesity. This 
needs to be seen with caution, since it is unlikely that variants in CNR1 regulate leptin levels 
but have no effect on obesity. However, there was a moderate effect of two CNR1 SNPs on 2-
AG plasma levels. Finally, no SNP effect on fat CNR1 mRNA expression could be detected. 
This suggests that genetic variation in the CNR1 does not play a significant role in the 
pathophysiology of obesity in the German and Sorbian population. 
 
 Based on studies in mice there is strong evidence that developmental genes could be 
differentially expressed in human SC and Vis adipose tissue depots. Bone morphogenetic 
proteins (BMPs) and their receptors (BMPRs) play an important role in multiple key steps of 
embryonic development and differentiation. BMPs are involved in adipocyte development, 
including adipose cell fate determination, differentiation of committed preadipocytes and 
function of mature adipocytes. It was recently shown that the BMPR1A mRNA expression in 
both Vis and SC adipose tissue as well as genetic variants in this gene strongly correlated with 
obesity and its related traits. BMPR2 is responsible for the trans-phosphorylation of 
BMPR1A, which makes it a plausible candidate gene for obesity. This hypothesis is 
addressed in CHAPTER 6. Interestingly, BMPR2 was suggested as one of the potential 
targets of recent selection in European populations and therefore supposed to be a “thrifty 
gene” which might have provided advantage to store energy in times of food scarcity. 
Therefore in the present work studies searching for signatures of selection were initiated. The 
analyses revealed that BMPR2 has undergone an overall purifying selection and population 
measures supported the “thrifty gene” hypothesis. It could be shown that the BMPR2 mRNA 
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expression was significantly increased both in Vis and SC adipose tissue of overweight and 
obese compared to lean subjects whereas the shift in the mRNA expression level was 
remarkable in the visceral adipose tissue depot. Two SNPs (rs6717924, rs13426118) were 
found to be associated with obesity in the Leipzig cohort and combined analyses including a 
second cohort confirmed a consistent effect for rs6717924. In addition, SNP effects on BMI, 
adiponectin, percent body fat, fasting plasma insulin and 2-h plasma glucose levels could be 
observed. Moreover, rs6717924 was associated with higher BMPRR2 mRNA expression in 
Vis adipose tissue independent from BMI which may provide a possible causative link in the 
genotype-effect relation. These data suggested a role of BMPR2 in the pathophysiology of 
obesity. 
 
CHAPTER 7 comprises a closing discussion on the hypotheses investigated in the 
paper and with regard to the literature which was released after the publications included in 
this thesis. 
 
In summary, this thesis provided new insights in the complex genetic background of the 
human metabolic syndrome, in particular of one of its main features represented by obesity. 
The genotype-phenotype association analyses revealed two new obesity susceptibility genes, 
FASN and BMPR2. No doubt, the investigation of intermediate phenotypes is essential to 
accentuate the phenotype and therefore to understand the SNP effect more clearly. This aspect 
gets a new dimension by measuring mRNA expression and correlating it with the genotype. 
The study of the gene expression profiles in the adipose tissue depots of lean and obese non-
diabetic subjects and subjects with T2D in combination with the polymorphisms provided a 
helpful approach to understand how genetic variants might exert their effect. These findings 
open new avenues in obesity research ultimately leading to comprehensive functional studies 
which are essential to identify and understand the complete mechanistic action of the 
identified polymorphisms. 
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ZUSAMMENFASSUNG 
 
 Das humane „Metabolische Syndrom“ ist durch das gleichzeitige Auftreten mehrer 
metabolischer Störungen charakterisiert. Dazu gehören abdominale Adipositas, 
Insulinresistenz, Glucoseintoleranz, Dyslipidämie, Bluthochdruck und Typ 2 Diabetes 
mellitus (T2D). Bedingt wird das metabolische Syndrom durch komplexe Interaktionen 
zwischen Umwelt und genetischen Komponenten. Die intra-abdominale, oder viszerale 
Adipositas wurde dabei als ein Hauptrisikofaktor postuliert, der für viele metabolische 
Folgeerscheinungen wie z.B. Insulinresistenz oder T2D verantwortlich ist. Es wurde gezeigt, 
dass das Adipositasrisiko und daraus resultierende metabolische Störungen mit der 
Fettverteilung, Adipozytengröße und der Sekretion von Adipozytokinen assoziiert sind. 
Neben einigen Krankheitsformen, die durch einen monogenen Defekt verursacht werden, 
unterliegen Adipositas und Fettverteilung einem polygenen Einfluss. Kandidatengen- und 
genomweite Assoziationsstudien ließen im letzten Jahrzehnt die Zahl der bekannten Gene und 
Varianten, die ein Adipositasrisiko fördern, schnell ansteigen. Weiterhin wurde gezeigt, das 
die mRNA verschiedener Gene zum einem im subkutanen (SC) und viszeralen (Vis) 
Fettgewebe differenziell exprimiert, zum anderen auch in den Fettgewebsdepots von 
schlanken und adipösen Individuen. Die Expressionslevel dieser Gene waren unter anderem 
auch mit dem Gehalt an Körperfett und Messungen des Glucose- und Insulin-Stoffwechsels 
assoziiert. Die zu Grunde liegenden molekularen Mechanismen sind bisher wenig verstanden 
und die bisher identifizierten genetischen Varianten erklären erst circa 20 % der Variabilität 
des Körpermasseindex (body mass index, BMI). Zum tieferen Verständnis des komplexen 
genetischen Hintergrundes, welcher Fettverteilung, Adipositas und die damit verbundenen 
metabolischen Störungen beeinflusst und zur Detektion basaler Mechanismen, über die die 
genetischen Varianten ihren Einfluss ausüben können, sind weitere Studien notwendig. Die 
Studien, die in der vorliegenden Dissertation vorgestellt werden, untersuchen mRNA 
Expressionsmuster von Genen im SC und Vis Fettgewebsdepot um zu klären, ob diese eine 
Rolle in einem Gewebe spielen, das in hohem Maße für metabolische Komplikationen 
verantwortlich ist. Weiterhin wird die Assoziation von Polymorphismen in potentiellen 
Kandidatengenen mit Adipositas und zugehörigen anthropometrischen/metabolischen 
Parametern untersucht um herauszufinden, ob sie zum genetischen Risiko beitragen, einen 
Phänotyp in Richtung des metabolischen Syndroms zu entwickeln. Schlussendlich wird 
analysiert, ob die Genexpressionslevel durch die Polymorphismen beeinflusst werden. In 
Kapitel 1 werden der derzeitige Wissensstand zur Physiologie des Fettgewebes und zum 
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genetischen Hintergrund von Adipositas und Fettverteilung sowie die Ziele der Arbeit 
zusammengefasst. 
 Untersucht wurde die Rolle des fat mass and obesity associated Gens, FTO, des Gens 
der Fettsäure-Synthase, FASN, des Gens für den Cannabinoidrezeptor 1, CNR1, und des bone 
morphogenetic protein receptor 2 Gens, BMPR2, in der Pathophysiologie des humanen 
Metabolischen Syndroms. 
 Die Genexpressionsstudien wurden mittels real-time PCR in gepaarten SC und Vis 
Fettgewebsproben durchgeführt. Diese stammten von Probanden, die einen großen BMI-
Bereich und verschiedene Fettverteilungsmuster abdeckten. Um die gesamte Sequenz eines 
Gens (Exons und Introns) durch häufig vorkommende genetische Varianten (SNPs – single 
nucleotide polymorphisms) abdecken zu können (die Frequenz des minor Allels beträgt 
mindestens 5 %) wurde basierend auf dem Kopplungsungleichgewicht (L.D. – linkage 
disequilibrium) ein SNP-„tagging“ Ansatz angewendet. Zur Identifizierung neuer genetischer 
Varianten wurde das Gen sequenziert und die Ergebnisse durch die bereits beschriebenen 
genetischen Polymorphismen aus der HapMap Datenbank ergänzt. Nach der L.D. Analyse 
wurde aus jeder Kopplungsgruppe ein repräsentativer SNP für die Genotypisierung gewählt. 
Diese wurde mit Hilfe der TaqMan® Technik in gut charakterisierten Kohorten durchgeführt. 
Im Kapitel 2 wird diese Methode im Rahmen eines Buchkapitels als Review 
zusammengefasst, welches basierend auf den eigenen Experimenten einen Absatz zur 
Problembehandlung und die Beschreibung modifizierter Protokolle für bestimmte 
experimentelle Anforderungen enthält. Für Genotyp-Phänotyp-Assoziationsstudien wurden 
die Kohorten (eine Leipziger, N~1800; und eine Sorbische Kohorte, N~1000) ausführlich 
hinsichtlich intermediärer Phänotypen wie anthropometrischer (Alter, BMI, Taille-Hüft-
Verhältnis [WHR], Körperfettgehalt) und metabolischer Parameter (Glucose und Insulin, 
Lipide, Adipozytokine) untersucht. Umfangreiche statistische Analysen wurden in allen 
Studien durchgeführt. 
 
 Im Kapitel 3 wird die mRNA Expression von FTO untersucht. Interessanterweise 
wurde FTO in einer genomweiten Assoziationsstudie für T2D entdeckt, in der sich zeigte, 
dass die Assoziation zwischen SNPs und Diabetes durch den BMI beeinflusst wurde. In 
Mäusen führt eine Mutation in diesem Gen zu verschmolzenen Zehen, daher der originale 
Name von FTO - fused toes, Ft, aber ein adipöser Phänotyp konnte nicht beobachtet werden. 
In der vorliegenden Studie wurde die Hypothese untersucht, dass die FTO mRNA Expression 
im SC und Vis Fettgewebe mit Adipositas verknüpft sein könnte. Aufgrund der benachbarten 
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Lokalisation zum FTO wurde ein zweites Gen, RPGRIP1L (RPGRIP1-like), diskutiert. 
Weiterhin wurde untersucht, ob die publizierten Adipositas-assoziierten Varianten, 
repräsentiert durch den SNP rs8050136, eventuell die mögliche Variabilität der FTO und 
RPGRIP1L mRNA Expression erklären könnte. Beim Vergleich der beiden Fettdepots zeigte 
sich, dass FTO höher im subkutanen Fettgewebe, RPGRIP1L dagegen höher im viszeralen 
Fettgewebe exprimiert war. Obwohl die FTO Expression in beiden Geweben mit Adipositas-
Parametern und miteinander korrelierte, blieb die Vis FTO mRNA Expression auch nach 
Adjustierung auf die subkutane Expression ein unabhängiger Prädiktor für den BMI. Es 
konnten keine Korrelationen der FTO mRNA Expression zu Messungen des Glucose- und 
Insulin-Stoffwechsels in keinem der beiden Fettdepots gefunden werden. Für RPGRIP1L 
wurden keine Korrelationen zu anthropometrischen und metabolischen Parametern gefunden. 
Das lässt darauf schließen, dass eher FTO als RPGRIP1L in die Pathophysiologie der 
Adipositas involviert ist. Auch wenn eine Assoziation von rs8050136 mit Adipositas in dieser 
Kohorte gefunden werden konnte, so war der SNP jedoch nicht mit der FTO Expression 
assoziiert. Die Ergebnisse, die im Kapitel 2 präsentiert werden, zeigen zum ersten Mal Daten, 
die das Verhältnis zwischen FTO und RPGRIP1L mRNA Expression im Fettgewebe und zu 
anthropometrischen und metabolischen Parametern, eingeschlossen Parametern der 
Adipositas, beleuchten. 
 
Die Fettsäure-Synthase, FASN, ist ein Schlüsselenzym bei der de novo Lipogenese. 
Sie katalysiert die Schritte der Konversion von Malonyl-CoA zu Palmitat. Es konnte gezeigt 
werden, dass eine erhöhte FASN Expression im Fettgewebe nicht nur signifikant mit 
Adipositas assoziiert ist, sondern auch mit T2D und Insulinresistenz. Dies legt nahe, dass die 
lipogenen Stoffwechselwege eine mögliche Rolle bei der Entwicklung der humanen 
Adipositas und/oder T2D spielen könnten. Aufgrund der wichtigen physiologischen Rolle des 
Proteins ist das FASN Gen zudem ein attraktives Kandidatengen um es in Genotyp-Phänotyp-
Analysen für Adipositas und zugehörigen Parametern zu untersuchen. Erste Studien in den 
Pima Indianern aus Süd-Arizona und in deutschen Kindern zeigten, dass es einen 
Polymorphismus im Gen gibt (Val1483Ile), der vor Adipositas zu schützen scheint. Genotyp-
Phänotyp Assoziationsstudien, die die Rolle von genetischen Varianten in FASN bei 
Adipositas in erwachsenen Populationen untersuchen, fehlen jedoch. Außerdem ist auch noch 
nicht geklärt, ob genetische Varianten in FASN für die Veränderungen der FASN mRNA 
Expression im Fettgewebe verantwortlich sind. Die Studie, die im Kapitel 4 präsentiert wird, 
untersucht diese Fragen in Erwachsenen- und Kinderkohorten. In einer Fall-Kontroll-Studie 
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konnte gezeigt werden, dass mehrere Polymorphismen in FASN mit Adipositas assoziiert 
sind. Der stärkste Effekt wurde für rs2229422 gefunden, weiterhin unterstützt durch 
Assoziationen mit dem BMI, WHR, Nüchtern-Plasmainsulin und der Glucoseinfusionsrate. 
Ein weiterer SNP, rs17848939, wurde zudem mit dem Verhältnis der Vis/SC FASN mRNA 
Expression assoziiert, was sich ebenfalls in einer Korrelation dieses SNPs mit der WHR 
widerspiegelte. Der protektive Effekt der Val1483Ile Substitution konnte in der 
Erwachsenenkohorte repliziert werden. In der Kinderkohorte waren die genetischen Varianten 
in FASN nicht mit Adipositas assoziiert, was darauf hindeutet, dass die SNP Effekte sich 
wohlmöglich erst im späteren Leben manifestieren und/oder die Effekte durch Gen-Umwelt-
Interaktionen modifiziert werden. In der vorliegenden Dissertation wurde zum ersten Mal 
gezeigt, dass Polymorphismen in FASN zum erhöhten genetischen Risiko beitragen 
metabolische Störungen während des Erwachsenenlebens zu entwickeln. Weiterhin kann 
postuliert werden, dass die Polymorphismen ihren Einfluss möglicherweise über die 
Fettgewebsverteilung in Richtung des viszeralen Depots vermitteln und die FASN Expression 
in diesem Depot modulieren. 
 
 Als Teil des Endocannabinoidsystems (ECS) ist der CNR1 über zentrale und periphere 
Mechanismen sowohl in die Kontrolle der Nahrungsaufnahme als auch in den Fett- und 
Glucosestoffwechsel involviert. Expressionsstudien im Fettgewebe haben gezeigt, dass der 
CNR1 im humanen SC und Vis Adipozyten exprimiert wird und die Expression mit dem 
zirkulierenden 2-Arachidonylglycerol (2-AG), dem Anteil an Körperfett, der viszeralen 
Fettmenge und Nüchtern-Plasmainsulin korreliert. Trotz der physiologischen Plausibilität als 
Kandidatengen für Adipositas zu fungieren, wurden in verschiedenen Populationen 
kontroverse Ergebnisse gefunden. Dies ist vermutlich der genetischen Heterogenität 
geschuldet, was die Notwendigkeit aufzeigt, das jeweilige Risiko eines Gens für eine 
Erkrankung in verschiedenen Kohorten zu untersuchen. In Kapitel 5 werden genetische 
Analysen von CNR1 in zwei deutschen Populationen präsentiert. Die Ergebnisse der Studie 
zeigten, dass ein SNP, rs806368, zwar in der Sorbischen aber nicht in der Leipziger Kohorte 
mit Adipositas assoziiert ist. Auch wurde für einige Varianten ein Effekt auf den 
Leptinspiegel gezeigt, aber es ist eher unwahrscheinlich, dass diese CNR1 Polymorphismen 
die Leptinspiegel regulieren, ohne einen Effekt auf Adipositas zu haben. Es konnte ein 
geringer Effekt von zwei CNR1 SNPs auf die 2-AG Plasmaspiegel gezeigt werden. 
Schlussendlich wurde keine Assoziation der Varianten im Gen mit der mRNA Expression des 
Gens beobachtet. Die hier zusammengefasste Studie zeigte auf, dass allgemeine genetische 
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Varianten in CNR1 in der deutschen Population eher eine untergeordnete Rolle im 
genetischen Hintergrund der Adipositas und den damit verbundenen metabolischen Störungen 
zu spielen scheinen. 
 
 Basierend auf Studien in Mäusen sind Hinweise gefunden worden, dass 
Entwicklungsgene differenziell im human subkutanen und viszeralen Fettgewebe exprimiert 
sein könnten. Bone Morphogenetic Proteins (BMPs) und ihre Rezeptoren (BMPRs) spielen in 
einer Vielzahl von Schritten bei der Embryogenese und bei der Differenzierung von Geweben 
eine wichtige Rolle. Unter anderem wurde gezeigt, dass BMPs auch an der Differenzierung 
von mesenchymalen Stammzellen in Adipozyten beteiligt sind. Kürzlich konnte gezeigt 
werden, dass sowohl die BMPR1A mRNA Expression als auch genetische Varianten im 
BMPR1A stark mit Adipositas und dazugehörigen metabolischen Parametern korrelieren. Der 
BMPR2 ist verantwortlich für die Trans-Phosphorylierung von BMPR1A, was dessen Gen als 
Kandidat für genetische Studien interessant macht. Diese Hypothese wird in Kapitel 6 
untersucht. Zusätzlich wies eine Studie darauf hin, dass BMPR2 in europäischen Populationen 
einer kürzlichen Selektion unterlegen zu sein scheint, wodurch es als mögliches Thrifty Gene 
postuliert wurde. Thrifty gene bedeutet dabei, dass bestimmte genetische Varianten in Zeiten 
von Hunger möglicherweise einen Vorteil bei der Speicherung von Energie erbrachten. Daher 
wurde in der vorliegenden Studie auch nach Zeichen von Selektion gesucht. Die Ergebnisse 
der vorliegenden Studie zeigten, das BMPR2 tatsächlich einer negativen Selektion unterlag 
und Populationsanalysen unterstützten die Thrifty Gene Hypothese. Die BMPR2 mRNA 
Expression war sowohl im subkutanen als auch im viszeralen Fettgewebe übergewichtiger 
und adipöser Probanden im Vergleich zu Schlanken erhöht, wobei die Veränderung am 
deutlichsten für das viszerale Fettgewebe zu beobachten war. Zwei SNPs, rs6717924 und 
rs13426118, zeigten eine Assoziation mit Adipositas in der Leipziger Kohorte und 
kombinierte Analysen, die eine zweite Kohorte beinhalten, bestätigten den Effekt für 
rs6717924. Zusätzlich konnten Assoziationen von BMPR2 SNPs mit dem BMI, dem 
prozentualen Anteil an Körperfett, Nüchtern-Plasmainsulin und 2-h Glucose beobachtet 
werden. Darüber hinaus war der SNP rs6717924 unabhängig vom BMI mit der BMPR2 
mRNA Expression im viszeralen Fettgewebe assoziiert, was einen möglichen Hinweis auf die 
ursächliche Verbindung der Genotyp-Effekt-Beziehung bedeutet. Somit weisen diese 
Ergebnisse auf eine Rolle von BMPR2 in der Pathophysologie der Adipositas hin. 
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 Kapitel 7 enthält eine abschließende Diskussion zum Thema der vorliegenden 
Doktorarbeit. Es wird ebenfalls die Literatur berücksichtigt, die nach den Publikationen, die 
Teil dieser Dissertation sind, veröffentlicht wurde. 
 
Zusammenfassend kann konstatiert werden, dass die vorliegende Arbeit neue Einblicke in den 
komplexen genetischen Hintergrund des humanen metabolischen Syndroms gebracht hat, im 
speziellen auf eines seiner charakteristischen Merkmale – Adipositas und zugehörige 
anthropometrische und metabolische Parameter. Die Genotyp-Phänotyp Assoziationsstudien 
zeigten zwei neue Kandidatengene für Adipositas auf, FASN und BMPR2. Ohne Zweifel ist 
die Untersuchung intermediärer Phänotypen essentiell um den Phänotyp zu schärfen und 
damit die SNP-Wirkung klarer zu verstehen. Mit der Korrelation des Genotyps mit der 
mRNA Expression bekommt dieser Aspekt eine neue Dimension, die näher an die 
molekularen Mechanismen heranführen kann. Die Untersuchung der Genexpressionsprofile in 
den Fettgewebsdepots schlanker und adipöser nicht-diabetischer Probanden und Probanden 
mit T2D in Kombination mit den genetischen Polymorphismen ist ein hilfreicher Ansatz um 
zu verstehen, wie genetische Varianten ihren Effekt vermitteln könnten. Damit werden neue 
Möglichkeiten in der Adipositasforschung eröffnet, die zu umfangreichen funktionellen 
Studien führen, die essentiell sind, um den kompletten Mechanismus zu verstehen der vom 
Genotyp zum Phänotyp führt. 
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CHAPTER 1 
Introduction to the topic 
 
1.1 Human Metabolic Syndrome 
The human metabolic syndrome is a widely recognized concept which focuses on 
important complex multifactorial health problems (1). It became generally known as a 
heterogenic complex of features including central obesity, insulin resistance, dyslipidemia, 
hypertension, and type 2 diabetes mellitus (T2D) during the last decades (2,3). The metabolic 
syndrome is considered to be the strongest predictor for coronary heart disease. The 
components of the metabolic syndrome are pathophysiologically linked and in addition to 
environmental factors partly genetically determined (Figure 1). However, the pathogenesis of 
the clustering of risk factors referred to as the metabolic syndrome and its constituent 
elements remains unclear (4). One of the major risk factors, obesity, is itself linked to several 
of the major symptoms of the human metabolic syndrome like insulin resistance, glucose 


















Figure 1: Fragile metabolic balance. Several cross-linked influencing factors, some of them can be 
arranged on both pans, lead to weight gain either positive or negative for health. HT hypertension; DL 
dyslipidemia; IR insulin resistance. 
 
1.2 Obesity 
Incidence for being overweight (body mass index (BMI) ≥ 25 kg/m2 – 29.9 kg/m2) or 
obese (BMI ≥ 30 kg/m2) increases rapidly, in the meantime every second inhabitant in 
Germany is considered to be overweight and prevalence of obesity increases worldwide. It is 
characterized by an increase of body fat content far in excess of conditions considered to be 
“normal” (15-31 % body fat in adults, depending on age and sex). Genetic factors combined 
with today’s lifestyle with increased access to highly palatable, calorie-dense foodstuff, 
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decreased need for physical activity in daily life, as well as social cultural factors are 
postulated to be the main causes predisposing to obesity. It has been known for decades that 
obesity might have a major impact on metabolic complications like glucose intolerance and 
insulin resistance (5). Common medical conditions such as T2D, fatty liver, cardiovascular 
disease, gallstones, and even some cancers occur in large part as a result of insulin resistance 
induced by obesity. Adipose tissue not only serves to store energy but is also the body’s 
largest endocrine organ, secreting hormones, cytokines, and proteins that affect the function 
of cells and tissues throughout the body (6-10). Thereby it has been emphasized quite early 
that adipose tissue distribution, especially the visceral proportion, seems to play a crucial role 
in severity of metabolic complications caused by the increase of body fat content (11). 
 
1.2.1 Adipose tissue – developmental origin and its distribution in the human body 
Adipose tissue is a form of connective tissue mainly composed of adipocytes and 
adipocyte precursor cells but also cells of connective tissue (fibroblasts), vasculature 
(endothelial cells, smooth muscle cells), and cells of the immune system (monocytes, 
macrophages, lymphocytes) (12). Adipose tissue is assumed to have a mesodermal origin. 
Although the exact number of intermediate stages between a mesodermal/mesenchymal stem 
cell (MSC) and a mature adipocyte is uncertain, it is believed that MSCs give rise to a 
common early precursor (adipoblast), which in turn develops into committed white and brown 
preadipocytes that, under appropriate stimulatory conditions, differentiate into mature 
adipocytes of different types (6). However, as none of these precursor cells possesses any 
unique morphological characteristics or gene expression markers, it is not clear whether 
specific adipoblasts and/or preadipocytes for brown and white fat exist or whether there are 
different white preadipocytes for different white adipose depots. A recent study published by 
Isakson et al. found an increase of mesenchymal precursor cells in obese individuals in 
contrast to a decrease of the differentiation of preadipocytes into adipocytes, suggesting an 
impaired differentiation of preadipocytes in obesity (13). On the contrary, Ogawa et al. 
postulated that adipocytes may also derive from hematopoietic stem cells (HSC) as adipose 
tissue harvested from clonally engrafted mice showed enhanced green fluorescent protein 
positive (EGFP+) adipocytes after transplantation of single EGFP+ HSCs (14).  
As mentioned above, two types of adipose tissue determined by morphology and 
function are distinguished – white adipose tissue (WAT) and brown adipose tissue (BAT). 
Cells from BAT are characterized by smaller size (up to 30 µm cell size), are pluri-vacuolar 
and rich in mitochondria. Further, BAT has no macrophage infiltration and is relevant for 
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basal and inducible thermogenesis. It used to be assumed that this tissue regresses with 
increasing age and is completely lost by the time a person reaches adulthood (15). Over the 
past decade, studies in nuclear medicine using positron-emission tomography in conjunction 
with computed tomography (PET/CT) clearly demonstrated the presence of BAT in adult 
humans, e.g. localized in the armpit, at the mediastinum, big arteries or kidney (16,17). 
Recent studies suggest that BAT may be a potential pharmaceutical target to improve 
metabolic complications induced by obesity through stimulation of thermogenesis (18,19). 
Adipocytes occurring in WAT are up to 100 µm and nearly completely filled with one lipid 
droplet. Depending on subcutaneous (SC) or visceral (Vis, intra abdominal fat) localization 
the innervation/vascularisation is less (SC) or more dense (Vis), and macrophage infiltration 
is mainly present in WAT (20). White adipose tissue is the primary site of triglyceride, and 
therefore energy storage, and important also for insulation and mechanical protection. 
Lipogenesis and lipolysis are fine regulated through nutritional status, and hormonal and 
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Figure 2: Lipogenesis in white adipose tissue. The effects of nutrients and hormones on the 
expression of lipogenic genes are mostly mediated by SREBP-1 and by PPARG. Lipogenesis entails a 
number of discrete steps which are controlled via allosteric interactions, by covalent modification and 
via changes in gene expression. ↑ up regulation and ↓ down regulation of lipogenesis; SREBP-1 sterol 
regulatory element binding protein-1; PPARG peroxisome proliferator-activated receptor gamma; 
USF upstream stimulatory factors; ChoRF carbohydrate response transcription factor. The figure is 
modified from the review by Kersten S. (21). 
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WAT is dispersed throughout the body with major intra abdominal depots around the 
omentum, intestines, and perirenal areas, as well as in subcutaneous depots in the buttocks, 
thighs and abdomen (6). In addition, WAT can be found in many other areas, including the 
retro-orbital space, the face and extremities, within the bone marrow, epicardial and 
perivascular. Some adipose tissue is responsive to sex hormones, such as adipose tissue in the 
breasts and thighs, whereas other depots, such as fat on the neck and upper back, are more 
responsive to glucocorticoids. 
The distribution of WAT can vary enormously between individuals. Measurement of 
the ratio of waist to hip circumference was shown to be a helpful tool to estimate the risk for 
metabolic complications of obesity (23). Individuals with low WHR (subcutaneous or pear-
shaped obesity) are less prone to manifest metabolic complications of obesity, whereas 
individuals with a high WHR (visceral or apple-shaped obesity) are at high risk for these 
complications. There are two theories which may explain these differences: 1) the anatomic 
localization of the visceral fat predicts the possibility to drain its products into the portal 
circulation where they can preferentially act on the liver to affect metabolism; 2) the fat cells 
in different depots have different properties causing them to be linked to a greater or lesser 
extent to the development of metabolic disorders (24,25). Even though WHR is a simple tool 
to express fat distribution, magnetic resonance imaging (MRI), computed tomography (CT) or 
Dual-Energy X-Ray Absorptiometry (DEXA) measurements are required to clearly 
distinguish between subcutaneous or visceral adipose tissue derived obesity (26). 
 
1.2.2 Fat depots and their relation to the human metabolic syndrome 
Constitutive biological differences in visceral and subcutaneous adipose tissue depots 
reflect their physiological role (27). Even though both deposits serve as energy reservoir to 
maintain systemic equilibrium, amongst other there are differences in levels of lipid 
mobilization, adipokine production and adipocyte differentiation that might be of importance 
e.g. in responses to diet and exercice (Table 1) (26,27). 
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Table 1: Comparison of subcutaneous and visceral adipose tissue. 
Visceral > Subcutaneous adipose tissue Subcutaneous > Visceral adipose tissue
Protein & Enzyme Activity 
• Insulin receptor 
• Lipolytic capacity 
 
• Insulin receptor affinity 
• IRS-1 
• Anti-lipolytic insulin effect 







• Hormone sensitive lipase 
• Adiponectin 
 
IRS-1 insulin receptor substrate 1; PAI-1 plasminogen activator inhibitor; IL-6 interleukin-6; RBP4 
retinol binding protein 4. The table is not exhaustive (26,28). 
 
During positive caloric balance there are two factors important for the development of 
metabolic disease: how the fat is stored (hypertrophy vs. hyperplasia) and where the fat is 
stored (SC vs. Vis). First, although the amount and distribution of adipose tissue is associated 
independently with insulin resistance or T2D and other metabolic disorders, the size of 
adipocytes within the adipose tissue remains crucial (26,31). Enlarged adipocytes are 
characterized by an increased lipolytic state and are resistant to the anti-lipolytic effects of 
insulin (32). Second, the link between fat mass, fat distribution and insulin resistance seems to 
be a consequence of increased ectopic lipid accumulation (33). A basic hypothesis suggests a 
limited storage capacity of the white, predominantly subcutaneous adipose tissue, when 
delivered energy is too high, which leads to the visceral/ectopic lipid accumulation. Unger 
and McGarry postulated a thesis of lipo-toxiticity, i.e. that an intracellular lipid accumulation 
leads to a cell dysfunction such as insulin resistance e.g. in adipocytes, hepatocytes, or 
skeletal muscle cells (34,35). Further, secretion of adipocytokines has been shown particularly 
for Vis fat (Table 1) (36-38). It is evident that many of these adipokines have the ability to 
influence other tissues such as the liver, muscle and brain, e.g. the adipokine leptin affects 
appetite regulation, others have an important impact on the consequences of adipose tissue 
inflammation (e.g. IL-6, PAI-1, monocyte chemoattractant protein 1 [MCP-1]) and vascular 
biology (e.g. serum amyloid A [SAA]) (39-43). Another hypothesis postulates that an ectopic 
accumulation in organs such as liver could also occur as a consequence of genetic factors 
and/or conditional upon nutrition lipid synthesis, which leads to an increase of Vis or 
peripheral fat. It could be shown that the intracellular lipid content in the liver is associated 
with insulin resistance (44,45). This “non alcoholic fatty liver disease” (NAFLD) has a 
heterogenic clinical picture with a wide range of histological findings and fit in the hepatic 
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manifestation of the metabolic syndrome (33). Visceral adipose tissue accumulation is the fat 
depot most characterized as being associated with an increased risk of metabolic disease 
(31,46). However, altered fat distribution may have an even stronger effect on the 
development of components of the metabolic syndrome than the presence of extreme obesity 
(31). 
 
1.3 Genetics of obesity and adipose tissue distribution  
1.3.1 Genetics of obesity 
Measures of obesity belong to the most strongly heritable human traits (47,48). Family 
and twin studies have confirmed that genetic factors are likely to be responsible for 45-75 % 
of the inter-individual variation in BMI (47). Identifying “obesity genes” is an attractive and 
important way of teasing out some of the causal factors leading to obesity (49). Most notably 
rodent studies led to the discovery of candidate genes responsible for monogenic forms of 
obesity (50-53). Mutations in the leptin/leptin receptor (LEP/LEPR) gene, the 
proopiomelanocortin (POMC) gene, the gene for prohormone convertase 1 (PCSK1), or the 
melanocortin receptor 4 (MC4R) gene are well known to cause severe obesity already in early 
childhood (54). Although research on monogenic forms of obesity could add to the 
knowledge of body weight regulation, they are relatively rare within populations, and 
explaining only a small percent of the overall disease burden. It is obvious that the 
pathophysiology of obesity is much more complex, and for most individuals the genetic 
predisposition to obesity has a polygenic basis (55). Sizeable phenotypic effects arise only in 
combination with other predisposing variants since a polygenic variant by itself has a small 
effect on the phenotype. Association studies and genome wide approaches were applied to 
detect new obesity genetic variants. Variants e.g. in the genes for tumor necrosis factor alpha 
(TNFA) (56), uncoupling protein 2 (UCP2) (57) or peroxisome prolifereator-activated 
receptor gamma (PPARG) (58) were detected due to the biological, physiological or 
pharmacological evidence for the role of the gene in obesity. However, such classical 
candidate gene studies are exhausting and their contribution towards understanding the 
genetics of obesity is rather limited. Advances in high-throughput genotyping technology has 
led to the development of genome-wide association studies (GWAS), which are providing 
novel and important insights into disease processes (59) and help to pinpoint the genetic 
architecture of complex diseases. One of the first common genetic variants associated with 
adult and childhood obesity found through a genome wide approach was a variant near the 
insulin induced gene 2 (INSIG2) (60). Replication in large independent cohorts revealed 
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contrary results depending on the ethnicities of the investigated study population (60-65). Liu 
et al. found strong associations with BMI and fat mass in catenin, beta like 1 (CTNNBL1), a 
gene which might seem to play a role during adipocyte differentiation (66). Beside common 
variants near MC4R (67), the so far strongest GWAS-derived, and robustly replicated signal 
was found for variants in the fat mass and obesity associated gene, FTO (68-71). 
However, until 2008 none of the candidate genes/genomic regions identified has been 
found to explain > 10 % of variation in any obesity phenotype (66). In the last two years a 
“second sweep” of GWAS revealed round about 15 additional loci influencing BMI, amongst 
others genes which play a role in the central nervous system or specific in the hypothalamus 
suggesting a role in controlling food intake and energy balance (e.g. neuronal growth 
regulator 1, NEGR1; transmembrane protein 18, TMEM18; or SH2 domain binding protein 1, 
SH2BP1) (72-75). 
Since it has been shown that a certain pattern of adipose tissue distribution is a 
predictor of metabolic complications, genetic studies are currently focusing on identification 
of genes, which seem to contribute to the fat distribution pattern and/or whose function is 
modified in the adipose tissue depots from lean and obese non-diabetic, insulin resistant, or 
diabetic patients. 
 
1.3.2 Genes and gene expression pattern of adipose tissue distribution   
Definition of the mechanism involved in the regulation of fat distribution in general, 
and visceral fat mass in particular, is a key for understanding obesity and its accompanying 
morbidity and mortality (76). In 2009, a large GWAS revealed three new loci associated with 
either waist circumference (WC; near transcription factor activating enhancer binding protein 
2 beta, TFAP2B; methionine sulfoxide reductase A, MSRA) or gender-specific with WHR 
(near lysophospholipase-like 1, LYPLAL1) (76). TFAP2B genetic variants have also been 
shown to be associated with T2D in Japanese patients and in the UK population previously 
(77), and have been reported to correlate positively with TFAP2B transcript levels in adipose 
tissue (78). This leads to the suggestion that the link between genetic variants in TFAP2B and 
the pathophysiological outcome of T2D might be mediated through an effect of these variants 
on the adipose tissue distribution, and therefore provides possibly a cause-effect relationship. 
However, WHR and WC were scarcely addressed in genome wide and candidate gene 
association studies so far. 
Noteworthy, in context of the specificity of many critical biological processes and 
given the fact that most common diseases appear to result from a complex interaction between 
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various genetic loci and the environment, it is evident that studying the genetics of gene 
expression in cells representing the in vivo state provides strong advantages (75,79). There is 
emerging evidence that depot-specific differences exist in the expression of genes coding 
important functional proteins in adipocytes, like the metabolic enzyme and related signalling 
proteins, the adipogenic factors, and the products of adipocytes (Figure 3) (80). This may 
contribute to the well-known specific functional properties of the adipocytes from intra-
abdominal and subcutaneous regions. However, in obese subjects or subjects with T2D, the 
differential expression of genes in the appropriate adipose tissue depot may simply reflect the 
pathophysiological state rather than providing a primary cause for it. 
 
Gene Expression
visceral fat subcutaneous fat
Visceral > Subcutaneous adipose tissue Subcutaneous > Visceral adipose tissue
AR
NR3C1
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Figure 3: Genes differentially expressed in subcutaneous and visceral adipose tissue and changes 
during obesity. ↑ increased expression in adipose tissue in obesity; ↓ reduced expression in adipose 
tissue in obesity; vis/sc behind the arrow specifies the fat depot; PPARG peroxisome proliferator-
activated receptor gamma; GPC4 glypican 4; UCP1/2 uncoupling protein 1/2; GLUT4 solute carrier 
family 2 member 4 (glucose transporter); GYS1 glycogen synthase; TBX15 T-box 15; CNR1 
cannabinoid receptor 1; AR androgen receptor; HOXA5 homeobox A5; FASN fatty acid synthase; 
NR3C1 glucocorticoid receptor; RBP4 retinol binding protein 4. The figure is not exhaustive. 
(26,28,81-85).  
 
As shown by Lefebvre et al., there was a decreased PPARG mRNA level in Vis 
adipose tissue in subjects with a BMI < 30 kg/m2, but not in obese subjects. This indicates 
that relative PPARG expression is increased in omental fat in obesity which let them conclude 
that altered expression of PPARG might play a role in adipose tissue distribution and 
expansion (86). Angiotensinogen which was implicated in the pathogenesis of metabolic 
alterations and hypertension associated with obesity was shown to be higher expressed in Vis 
than in SC adipose tissue in obese patients (87). Further, gene expression studies in SC and 
Vis adipose tissue revealed a correlation of differential expressed genes with measures/factors 
of the human metabolic syndrome like BMI/obesity, insulin resistance/T2D which might 
exhibit new genetic candidates and were partly unexpected such as developmental genes (83). 
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Genotype-phenotype association studies in population based studies showed BMPR1A (bone 
morphogenetic protein receptor 1A) genetic variants being associated with obesity and 
obesity-related quantitative traits (88). Moreover, an association of these variants with the Vis 
BMPR1A mRNA expression could be detected suggesting a link between genetic 
predisposition and phenotypic outcome. Also, miRNAs, small non-coding RNAs, which play 
an important regulatory role in a variety of biological processes, have been shown to be 
correlated with adipose tissue morphology and key metabolic parameters such as Vis fat area, 
circulating leptin, adiponectin or interleukin-6. Further it could be shown that they reveal a 
significant fat depot-specific expression pattern suggesting a possible epigenetic influence on 
adipose tissue distribution (89). Identifying and clarifying the role of genes in fat distribution 
may therefore contribute to the understanding of the molecular mechanisms underlying the 
genetic susceptibility for the human metabolic syndrome. 
 
1.4 Aims of the presented work 
Obesity plays a key role in the development of the metabolic syndrome. 
Pathophysiological alterations in metabolism following the increase of fat mass such as 
insulin resistance, dyslipidemia or T2D, are thereby closely connected to the distribution 
pattern of the adipose tissue. Omental, especially Vis adipose tissue has been suggested to be 
the risk promoting part since adipocytokines and proinflammatory factors secreted by visceral 
adipocytes have been shown to be linked to the phenotypic outcome of the metabolic 
syndrome. The underlying molecular mechanisms that relate a certain adipose tissue 
distribution pattern to metabolic complications are poorly understood. With the exception of 
some cases of monogenic disorders obesity and adipose distribution has a polygenic 
background. Although candidate gene and GWAS identified numerous genes and 
susceptibility variants, it might be assumed that they do not explain more than 20 % of the 
genetic variability. Further studies are required to detect new candidate genes and also to 
elucidate their role in the genetics of obesity and/or adipose tissue distribution and associated 
metabolic complications resulting in a metabolic syndrome. 
To meet this challenge a combinatory approach unifying several strategies has been 
applied. First, the expression of genes, for which genetic variants could be found to be 
associated with obesity or related traits, is investigated in the SC and Vis adipose tissue 
depots under specific conditions (lean and obese non-diabetic subjects or subjects with T2D) 
to detect possible differences associated with the phenotypic outcome (Chapter 3). Second, 
based on the fact that conspicuous differential expressed genes could comprise putative 
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susceptibility variants modulating the metabolic risk, genotype-phenotype association studies 
are carried out (Chapter 4-6). The main method used for genotyping is described in detail in a 
comprehensive review providing explicit troubleshooting and description of modified 
protocols for specific experimental needs (Chapter 2). Ultimately, the link between 
expression and genetic susceptibility variants is examined which could expose a piece of the 
jigsaw on the underlying molecular mechanisms. 
In particular, this thesis deals with FTO (Chapter 3), FASN (Chapter 4), CNR1 
(Chapter 5) and BMPR2 (Chapter 6) as possible candidates playing a role in adipose 
distribution and obesity risk in German populations. Chapter 3 answers the questions 
whether FTO and the neighboring gene RPGRIP1L are fat depot-specificly expressed in 
subcutaneous and visceral adipose tissue of lean and obese nondiabetic subjects and subjects 
with T2D. Further, it is investigated whether the mRNA expression of FTO and/or the 
neighbouring RPGRIP1L in adipose tissue correlates with measures of obesity and fat 
distribution. Finally the association of the FTO obesity risk allele with FTO and RPGRIP1L 
mRNA expression is examined. Chapter 4 clarifies the role of genetic variation in FASN on 
obesity and related traits in adult and children cohorts of white European ancestry. The effect 
of FASN SNPs on FASN mRNA expression in the SC and Vis adipose tissue depot is 
elucidated. Chapter 5 investigates the contribution of genetic variants in CNR1 to the 
polygenetic background of obesity. Moreover, the question whether these variants might 
explain expression differences of CB1R in SC and Vis adipose tissue is addressed. Chapter 6 
gives insights to the mRNA expression of BMPR2 in adipose tissue depots and points out the 
correlations of BMPR2 expression with measures of obesity and related traits. Moreover, the 
association of BMPR2 genetic variants with anthropometric and metabolic parameters is 
highlighted, and the link between BMPR2 genetic variants and mRNA expression 
investigated. Chapter 7 provides critical discussion of the presented studies. 
In summary, this thesis led to the discovery of novel genetic variants which account 
for the polygenic mediated obesity risk in German populations. Furthermore, the study 
provides evidence that some of these variants might also modulate the gene expression level 
in adipose tissue depots leading to a shift towards an adverse metabolic constellation which 
could provide a link between genotype and the disease phenotype. 
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More than 99 % of genomic DNA sequence is identical among humans, and not 
surprisingly, slight variations in sequence can often produce a major effect on phenotype. 
Sequence variants may also mediate the manner in which humans are susceptible to disease or 
respond to environmental factors such as bacteria, viruses, toxins, chemicals, drugs, and 
therapeutic interventions. Single nucleotide polymorphisms (SNPs) are DNA sequence 
variations that occur when a single base in the genome sequence can be represented by at least 
two different nucleotides. In the last decade, numerous SNPs have been identified that 
explain, at least partially, the genetic architecture of complex diseases such as cancer, 
diabetes, vascular complications, some forms of mental illness, and a multitude of other 
disorders. Disease-related SNPs are commonly identified through candidate gene approaches, 
or more recently, through genome-wide association studies (GWAS). In either case, findings 
of association require verification in independent, population-based, study samples, usually 
comprised of several hundreds/thousands of individuals. A convenient technique to genotype 
a moderate number of markers in this kind of study is available with the TaqMan® platform 
(Applied Biosystems; Foster City, CA), which utilizes polymerase chain reaction (PCR) 
amplification and allelic discrimination to easily and efficiently generate genotype data in a 
cost-effective way. Here we introduce and describe this commonly used technique and 
include protocols which can be directly used in laboratories aiming to perform moderate- to 
large-scale genotyping studies. 
 
2.2 Introduction 
The dimorphic SNP, which occurs when a single nucleotide in the genome sequence is 
altered, is the most common form of human genetic variation (1,2). In any two genome 
copies, SNPs are reported to occur as frequently as one variant per kilobase, or at a frequency 
of 0.1 % (3). Although most of these SNPs are neutral, some may affect the gene/protein 
function and thus lead to phenotypic differences between carriers of various alleles. These 
phenotypic differences can result in enhanced susceptibility to various diseases or response to 
environmental factors. It has been estimated that a total of 10 million SNPs exist in the human 
population (equivalent to one variant per 300 bases) such that both alleles are observed at a 
frequency of ≥ 1 %, and that these 10 million common variants constitute 90 % of the 
variation in the population (4). At this frequency, SNPs are potentially valuable both for 
aiding biomedical research and developing pharmaceutical products or medical diagnostics. 




In the last decade, it has been shown that SNPs may also help to explain the genetic 
architecture of complex diseases. SNPs can contribute either directly or indirectly to the 
development of both monogenic and polygenic diseases, such as obesity (5,6), psychiatric 
illness (7) or cancer (8,9), and may mediate individual risk in disease severity and 
progression, as well as response to pharmacological treatments (2,10,11). Genetic studies 
utilize the candidate gene or genome-wide approach to identify such SNPs. Particularly, 
genome-wide association studies have resulted in identification of novel disease-related 
SNPs, which increased the number of known “pathological” SNPs for various complex 
diseases enormously. Following identification of disease-associated SNPs in candidate gene 
or genome-wide studies, further investigation and verification of these potential risk alleles is 
required using independent population-based samples. Because such study samples are 
typically comprised of several hundreds or thousands of subjects to achieve sufficient 
statistical power, large-scale screening for known polymorphisms necessitates techniques 
with a minimal number of steps and an ability to automate each one (12). Because re-
sequencing, while thorough, is still costly and time-consuming, targeted SNP genotyping 
using TaqMan® assays based on a polymerase chain reaction (PCR) provides a more 
economic and easy to handle procedure to efficiently generate thousands of genotypes for 
genetic association studies. 
The TaqMan® SNP Genotyping Assay (Applied Biosystems; Foster City, CA) is used 
to discriminate between two alleles of a specific SNP for use in genotyping studies. The 
method involves use of forward and reverse primers to amplify the polymorphic sequence of 
interest, plus two dye-labelled probes for allele-specific detection. At the 5' site, one probe is 
labelled with VIC® dye, which detects the “Allele 1” sequence, while the other one is labelled 
with 6-FAM™ dye (6’-carboxyfluorescein), which detects the “Allele 2” sequence (Figure 1). 
VIC® and 6-FAM™ are also referred to as reporter dyes. Based on the principle of 
fluorescence resonance energy transfer (FRET), at the 3' site the probes are labelled with a 
non-fluorescent quencher (NFQ) which absorbs the energy of the reporter dyes as long as 
both are bound to the probe and therefore, are in spatial proximity. Further, TaqMan® probes 
incorporate a minor groove binder (MGB) at the 3' end (Figure 1). The MGB molecule  
(e.g., dihydrocyclopyrroloindole tripeptide [DPI3]) binds to the minor groove of the DNA 
helix, and improves hybridization-based assays by stabilizing the probe/template complex. In 
comparison with unmodified DNA, MGB probes have higher melting temperatures and 
increased specificity (13). The increased binding stabilization permits the use of probes as 




short as 13 bases for improved mismatch discrimination and greater flexibility when 
designing assays for difficult or variable sequences (14).  
 
Figure 1: Principle of allelic discrimination using TaqMan® SNP Genotyping Assays. 
1. Assay components and DNA template: Forward and reverse primers to amplify the polymorphic 
sequence of interest, two 5' site dye-labelled probes for allele-specific detection. Fluorescence is 
quenched by a non-fluorescent quencher (NFQ) at the 3' site. A minor groove binder at the 3' end 
stabilizes the probe/template complex. 2. Denatured template and annealing assay components. 3. 
Polymerization and signal generation: Taq polymerase starts to synthesize a new strand and 
encounters the annealed probe. The 5'-bound fluorescence dye of the appropriate probe is separated 
(5'→3' exonuclease activity of Taq polymerase). Fluorescence signal is no longer quenched and can 
now be detected with laser excitation. By courtesy of Applied Biosystems LLC (part of Life 
Technologies Group). 
 
Following denaturation of the template and annealing of the assay components, the 
Taq polymerase starts to synthesize a new strand. During the reaction, the polymerase 
encounters the annealed probe and the 5'-bound fluorescence dye of the appropriate probe will 
be separated as a result of the 5'→3' exonuclease activity of the Taq enzyme (Figure 1). At 
this point, the fluorescence signal is no longer quenched and can now be detected with laser 
excitation. Depending on the genotype, one will detect homozygotes for either Allele 1 or 2, 
or heterozygotes that carry both alleles (Figure 2). 




The TaqMan® SNP Genotyping Assay is available from Applied Biosystems, Inc. 
(Foster City, CA). The manufacturer provides detailed product and user guides on their 
homepage, www.appliedbiosystems.com. In this chapter, we focus on these main steps, but 
also offer modifications and suggestions to improve assay efficiency and genotype data 
quality that can be easily incorporated in any laboratory. 
 
2.3 Materials 
2.3.1 Target DNA 
1. In general, 1-20 ng purified genomic DNA is recommended for TaqMan® SNP 
Genotyping Assays (see Note 1). 
 
2.3.2 Plastics 
1. 96- or 384-well plates, suitable for the thermocycler of choice and the ABI real-time 
System (see Section 2.3.4 Instruments and Software) 
2. Seal mats; optical adhesive, thermostable covers or optical caps 
 
2.3.3 Genotyping reaction 
1. TaqMan® SNP Genotyping Assay (Applied Biosystems; 20x, 40x or 80x concentrated) 
containing sequence-specific forward and reverse primers and two TaqMan® MGB probes. 
The assay should be stored at -15 to -20 °C and protected from light. 
2. 2× TaqMan® Genotyping Master Mix (Applied Biosystems) containing AmpliTaq Gold® 
DNA Polymerase ultra pure, buffer, dNTPs, ROX™ dye (6-carboxy-X-rhodamine, passive 
internal reference) and should be stored at 2 to 8 °C. Alternatively, genotyping mastermix is 
provided by companies like Thermo Fisher Scientific Inc. (ABgene®), Peqlab (Sensi Mix), 
Eurogentec (qPCR kits for probe assay). 
3. DNase-free water 
 
2.3.4 Instruments and software 
1. Thermocycler: the following instruments are specified by the company: GeneAmp® PCR 
System 9700, Applied Biosystems 9800 Fast Thermal Cycler, using the 9700/9600 emulation 
mode (see Note 2). 
2. Real-time PCR System - the following instruments are specified by the company: ABI 
PRISM® 7000 Sequence Detection System, Applied Biosystems (AB) 7300/7500 Real-Time 
PCR System, AB 7500 Fast Real-Time PCR System, AB 7900HT Fast Real-Time PCR 




System. Alternatively to ABI manufactured equipment several other companies offer 
platforms compatible with TaqMan® genotyping assays (e.g. LightCycler ® Systems for 
Real-Time PCR from Roche). 
3. Sequence detection system (SDS) software (Applied Biosystems); Primer Express® 
Software for Real-Time PCR 3.0 (Applied Biosystems). 
 
2.4 Methods 
Applied Biosystems provides the largest collection of ready-to-use SNP assays 
(TaqMan® SNP Genotyping Assays; TaqMan® Drug Metabolism Genotyping Assays; 
TaqMan® SNP Genotyping Assay Sets; TaqMan® Pre-Developed Assay), and most of them 
apply to use with human DNA. An assay search tool is available on the company’s homepage 
(https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=601
277). After choosing the gene or region of interest and selecting SNPs for genotyping, it is 
easy to check the availability of assays. Applied Biosystems also offers custom design assays 
(Custom TaqMan® SNP Genotyping Assays) and provides the Primer Express® Software for 
individual design for markers not available in the manufacturer’s database. 
 
2.4.1 Preparation of samples to perform SNP genotyping assays 
1. For better handling, we recommend preparing “master” plates with defined sample 
positions, plate names, and a consistent concentration and volume of genomic DNA per 
sample (e.g. 10 ng/µl). The total volume of DNA will depend on the type of plates used in the 
experiment (see Note 3). 
2. Aliquot the appropriate amount of genomic DNA, secure the master plates with seal mats, 
and freeze at -20 °C until ready to use. 
3. When ready to begin genotyping, remove master plates from -20 °C and let thaw. When 
thawed, vortex and centrifuge briefly to bring liquid to the bottom of the wells. 
4. Disperse the appropriate volume (e.g. 1 µl of 10 ng/µl concentrated DNA) to each well, 
seal plates with covers (mats, tapes, caps, etc.) and use directly or store at -20 °C until ready 
to use. 
 
2.4.2 Preparation of master mix for SNP genotyping 
1. Keep all reagents on ice during the course of the experimental set-up. 




2. Prepare TaqMan® genotyping master mix as shown in Table 1. The amounts of reagents 
can be varied according to the number of plates assayed; Table 1 gives reagent amounts 
needed to genotype one 96-well plate (see Note 4). 
3. Pipette 24 µl of the master mix to each well of a 96-well plate. 
4. Cover plate with an optical, thermostable, adhesive cover (or optical caps) and place plate 
in thermocycler. 
 
Table 1: Mastermix for 96-well genotyping reaction. 
Reaction component Volume (µl/reaction) Volume for 100 reactions (one 96 well plate) 
2× Genotyping master mix 12.5 1.25 ml 
20× SNP genotyping assay 1.25 125.0 µl 
DNAse free water 10.25* 1.025 ml 
Template 1.0*  




2.4.3 Cycling program for genotyping reaction (see Note 5) 
1. Because the analytical assays represent an endpoint analysis, the target amplification does 
not need to be carried out in the Real-Time PCR System. That is, a standard thermocycler can 
be used for amplification, and only the ultimate plate readout requires the AB Real-Time PCR 
System. 
2. Briefly centrifuge plates to collect liquid to the bottom of the wells. 
3. Place plate in thermocycler. 
4. Program thermocycler as shown in Table 2. 
5. Begin PCR amplification; the cycle duration should take approximately 2 hours. 
 
Table 2: PCR cycling program. 
Step Temperature Time Cycle 
Activation of AmpliTaq Gold enzyme 95 °C 10 min 1 
Denaturation 92 °C 15 sec 
Annealing/Extension 60 °C 1 min }40 
Cool down 4 °C or 10 °C (over night) ∞  
 
2.4.4 Plate readout – allelic discrimination (see Note 6) 
1. After amplification, briefly centrifuge plates to collect liquid to the bottoms of the wells. 
Perform plate readout directly or store processed plates at -20 °C until ready to read. 




2. Start the detection system first, and then open the SDS software. 
3. Create a new document and select “Allelic Discrimination” in the assay drop-down list. 
Click next to access the “Select Markers” page. 
4. If the marker list contains a marker suitable for your application skip to step 5. If the 
marker list does not contain a marker (set of two detectors discriminating between different 
alleles of a common locus) suitable for the application, create detectors (virtual representation 
of a TaqMan® probe and primer set and associated fluorescent dye that detects a single target 
nucleic acid sequence) and marker. 
4a. Click “New Detector”. In the new detector dialog box, type “Allele 1” for name. 
Leave the reporter dye set to Vic and quencher dye “none”, choose a colour, and then 
click OK. Click Create another, for name type “Allele 2” and select FAM for the 
reporter dye, and quencher dye “none”. Select purple, then Click OK. 
4b. Click “New Marker”. In the marker dialog box, type a name, select the Allele 1 
and Allele 2 detectors you created above. Then click OK. 
5. In the “Select Markers” window, select the marker for your application, then click  
“Add >>”. Select the passive reference depending on the genotyping mastermix you use (in 
most cases Rox). Click next. 
6. In the setup sample plate page, select the marker for wells: Click-drag to select wells, select 
the “Use” box for the marker. Click the “task” field for one of the detectors and select “NTC” 
for none template controls or “Unknown” for samples. This determines the way the SDS 
software uses the data collected from the well during analysis. 
7. Click finish. Now, with the help of the well inspector (“View > Well Inspector”) it is 
possible to enter sample names, although this step is not necessary if a masterplate setup is 
available (see Section 3.1) 
8. Select the “Instrument” tab. After creating and setting up an allelic discrimination plate 
read document in the SDS software, the plate read is performed at 60 °C. Change the sample 
volume to correspond to the reaction volume (see Section 2.4.2). 
9. Save the file (“File > Save”). Be sure that the file name specifies which 
samples/cohort/SNPs were used for the experiment. Then click “Post-Read”. 
10. After the run, click the analysis button to start genotype read. Normally, the analysis of 
the plate read document performs automatically but it also offers an option for alleles being 
called manually (see Note 7). An example for allele calling is presented in Figure 2. 
Ultimately, the allele calls need to be converted to genotypes (see Note 8). The appropriate 
allele labelling is included with every assay provided by the company. 





Figure 2: SNP allele detection after PCR on an ABI PRISM® 7500 Sequence Detection System. 
Blot of the fluorescence signals (Rn) obtained during the plate read for each well indicating the alleles 
in each sample. Depending on genotype, homozygotes for either Allele 1 or 2, or heterozygotes that 
carry both alleles will be detected. NTC = non template control. By courtesy of Applied Biosystems 
LLC (part of Life Technologies Group). 
 
2.5 Notes 
1. Depending on the quality of starting material, the best DNA extraction method needs to be 
individually determined by the researcher. We strongly recommend quantifying genomic 
DNA using spectrophometry and assessing integrity using agarose gel electrophoresis. The 
purified DNA (stock or diluted for final concentration) should be stored at ≤ -20 °C. 
Biological samples such as tissues, body fluids, infectious agents, and blood have the 
potential to transmit infectious diseases. Follow all applicable local, state/provincial, and/or 
national regulations. Wear appropriate protective equipment, which includes, but is not 
limited to: protective eyewear, face shield, clothing/lab coat, and gloves. All work should be 
conducted in properly equipped facilities using the appropriate safety equipment. 
 
2. While ABI recommends specific instruments, we have found that any conventional 
thermocycler can be used in this protocol. In our experience, it is rare that the thermal cycler 




does not perform adequately for the assay; however, because the potential exists, we 
recommend testing each TaqMan® probe in several plates on the thermocycler prior to using 
in a large-scale genotyping study. 
 
3. Non-template controls (NTCs, such as water) are included in the plate set-up for internal 
quality control purposes. We also highly recommend inclusion of positive controls, such as 
DNA samples with known genotypes (determined by a different method), as well as quality 
controls (QCs) representing blinded duplicates to the genotyped samples, to validate the 
reproducibility and accuracy of the assay. Including positive controls for each allele 
combination are particularly important in experiments with small sample sizes (e.g., N < 50) 
or for variants with rare minor allele frequencies or a low number of heterozygotes. 
 
4. In our experience, the assays are typically easy to handle and the amplification reaction is 
stable. Therefore, it is sometimes possible to reduce the genotyping reaction volume, which 
may help to reduce genotyping costs and preserve DNA samples. Considering the costs and 
time required for other techniques, such as sequencing, this protocol is efficient for sample 
sizes of 50 up to several thousand (use of different semiautomatic/automatic pipette solutions 
may be advantageous). 
 
5. Applied Biosystems provides an “Allelic Discrimination (AD) Getting Started Guide” for 
the AB real-time PCR System in which one can find detailed information about performing 
AD pre-run (although in our experience, this is not essential when working according to good 
laboratory practices [GLP]), amplification run, and AD post-read run. The authors strongly 
recommend reading this guide prior to beginning the TaqMan® genotyping experiment. 
 
6. The PCR amplification reaction is followed by the endpoint analysis for allelic 
discrimination using an Applied Biosystems real-time PCR System. The SDS software uses 
the fluorescence measurements obtained during the plate read to plot fluorescence (Rn) values 
based on the signals from each well. The plotted fluorescence signals indicate the alleles in 
each sample (TaqMan® SNP Genotyping Assays Protocol, Applied Biosystems 2006). 
 
7. Most of the TaqMan® Assays are robust, but we nevertheless recommend processing 1-2 
test plates per genotyping assay and cohort. By doing so, one will determine how the assay 
performs and how frequent the minor allele is. However, it may occur that the TaqMan® 




Assays do not perform well (i.e., the plate readout is difficult or not possible at all). 
Commonly, this is due to poor DNA quality (e.g., extracted from serum or small amounts of 
tissue which leads to low concentration and poor quality). Also, if the DNA concentration is 
not consistent between wells across the plate, the TaqMan® Assay may not perform 
optimally. Check and improve these factors if necessary and test again. If these problems are 
still encountered, add Taq polymerase to the master mix to increase the yield of PCR and run 
the plate for an additional 10 cycles. One can also test genotyping master mixes offered by 
other companies (please be aware of potential differences in PCR cycling conditions when 
using various master mixes) or change the thermal cycler. If any initial setting has been 
changed, start the experiment again with just one or two plates to check whether it performs 
differently. 
 
8. For data analyses use suitable programs, for phenotype-genotype association studies,  
e.g., SPSS (SPSS, Inc.; Chicago, IL, USA) or Graphpad Prism® (GraphPad Software, Inc.; 
La Jolla, CA, USA). For statistical calculations, we recommend coding the SNP alleles: 11 or 
22 for homozygotes for either Allele 1 or 2, or 12 for heterozygotes that carry both alleles and 
to convert them to their respective nucleotides afterwards. 
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Aims/hypothesis Recently, FTO was identified as a candidate gene contributing to 
both childhood and severe adult obesity. We tested the hypothesis that mRNA expression of 
FTO and/or of the neighbouring RPGRIP1L in adipose tissue correlates with measures of 
obesity and fat distribution. We also investigated whether the FTO obesity risk alleles might 
explain variability in FTO and RPGRIP1L mRNA expression. Methods In paired samples of 
visceral and subcutaneous adipose tissue from 55 lean and obese participants, we investigated 
whether FTO and RPGRIP1L mRNA expression is fat depot-specific, altered in obesity and 
related to measures of fat accumulation, insulin sensitivity and glucose metabolism. All 
participants were genotyped for the obesity-associated rs8050136 FTO variant. Results FTO 
mRNA expression was threefold higher in subcutaneous than in visceral adipose tissue. 
Subcutaneous FTO expression correlated with visceral FTO expression. FTO gene expression 
in both depots correlated with age and was negatively correlated to BMI and percent body fat. 
FTO mRNA levels were not related to measures of insulin sensitivity and glucose 
metabolism. RPGRIP1L mRNA expression was 1.6-fold higher in visceral than in 
subcutaneous adipose tissue, but did not correlate with anthropometric and metabolic 
characteristics. There was no association between rs8050136 and FTO or RPGRIP1L mRNA 
expression in adipose tissue. Conclusions/interpretation Expression of adipose tissue FTO 
mRNA is fat depot-specific and negatively correlates with measures of obesity. However, the 
direction of this relationship still needs to be elucidated. 
 
3.2 Introduction 
Genetic factors play an important role in the development of obesity (1), but the 
underlying genetic causes are poorly understood (2). Two independent studies using different 
approaches recently demonstrated a strong association between variants in the gene fat mass 
and obesity associated (FTO) and obesity (3,4). Frayling et al. (3) found the association 
between FTO variants (represented by rs9939609) and obesity in a genome-wide scan for 
type 2 diabetes and replicated it in a total of more than 38,000 individuals. The association 
between SNPs in the FTO gene and type 2 diabetes was shown to be due to obesity (3). In 
agreement with these findings, Dina et al. (4) reported a set of SNPs in the FTO gene 
(rs1421085 and rs17817449) that is consistently strongly associated with early-onset 
childhood and severe adult obesity. Both groups replicated the association between FTO and 
obesity in large cohorts (3,4). Moreover, recently Scuteri et al. (5) replicated the significant 
association between rs9930506 in the FTO gene and BMI, body weight and hip circumference 




in European and Hispanic Americans. The Fto gene was originally described in a mouse with 
fused toes (Ft mutation) (6,7). Homozygous Ft mutation is embryonic lethal (6); heterozygous 
mice have fused toes and hyperplasia of the thymus most likely due to impaired apoptosis (7). 
Interestingly, obesity has not been reported in these mice. However, the Ft mutation consists 
of at least six deleted genes and no conclusions can be drawn from this model regarding the 
function of FTO and the relationship between the FTO gene and obesity (2). Human de novo 
duplication on chromosome 16, which includes the FTO locus, has been shown to be 
associated with mental retardation, obesity, dysmorphic facies and severe bilateral 
clinodactyly of some fingers (8). Recent bioinformatics analysis revealed that FTO shares 
sequence motifs with Fe2+- and 2-oxoglutarate-dependent oxygenases (9). It has also been 
shown that FTO localizes to the nucleus and that recombinant murine FTO catalyses the 
demethylation of 3-methylthymine in single-stranded DNA (9). After the association with 
human obesity was discovered, the name was changed to ‘fat mass and obesity associated’ 
(FTO) (2), but the function of the FTO gene is still unknown. FTO gene is expressed in most 
tissues, including adipose tissue, beta cells and brain (3). The highest FTO expression levels 
have been detected in brain (3,9). Functional studies are necessary to define the biological 
role of FTO and the major FTO-‘sensitive’ organs.  
We therefore tested the hypothesis that FTO mRNA expression in visceral and 
subcutaneous adipose tissue is linked to obesity in a cohort of individuals with wide ranges of 
obesity and body fat distribution. In addition to FTO, retinitis pigmentosa GTPase regulator 
interacting protein 1-like (RPGRIP1L, also known as KIAA1005) is also thought to be 
involved in the development of obesity because of its genomic position near the FTO gene 
(3,5). The transcription start site of RPGRIP1L is situated only 200 base pairs from the 5′ end 
of FTO and ~61 kb from the 47 kb interval containing the BMI associations. RPGRIP1L is 
ubiquitously expressed with relatively high levels in hypothalamus and islet. We therefore 
also examined RPGRIP1L mRNA expression in visceral and subcutaneous adipose tissue and 
its relation to obesity. In addition, we investigated whether previously published obesity-
associated FTO variants (represented by rs8050136 in our study) might explain potential 
variability in FTO and RPGRIP1L mRNA expression. 
 
3.3 Methods 
3.3.1 Participants and measurement of participant characteristics 
Paired samples of visceral and subcutaneous adipose tissue were obtained from 55 
European men (N = 26) and women (N = 29) who underwent open abdominal surgery for 




elective cholecystectomy or explorative laparotomy. Using oral glucose tolerance tests 
(OGTTs), we identified individuals with type 2 diabetes (N = 19) or normal glucose tolerance 
(N = 36). All participants had stable weight with no fluctuations of > 2 % of body weight for 
at least 3 months before surgery. Patients with malignant diseases or any acute or chronic 
inflammatory disease as determined by a leukocyte count > 7,000×109/l, C-reactive protein  
> 50 mg/l or clinical signs of infection were excluded from the study. Samples of visceral and 
subcutaneous adipose tissue were immediately frozen in liquid nitrogen after explantation. 
The study was approved by the ethics committee of the University of Leipzig. All participants 
gave written informed consent before taking part in the study. 
 
3.3.2 Assays and measures of glucose metabolism and body fat content 
Basal blood samples were taken after an overnight fast. Plasma insulin was measured 
with an enzyme immunometric assay for an automated analyzer (Immulite; Diagnostic 
Products, Los Angeles, CA, USA). Plasma leptin levels were assessed by radioimmunoassay 
(Linco Research, St Charles, MO, USA). OGTT was performed after an overnight fast with 
75 g standardised glucose solution (Glucodex Solution 75 g; Merieux, Montreal, QC, 
Canada). Insulin sensitivity was assessed with the euglycemic–hyperinsulinemic clamp 
method (10). Percent body fat was measured by dualenergy X-ray absorptiometry. In 
addition, abdominal visceral and subcutaneous fat area was calculated as previously described 
(11,12). 
 
3.3.3 Analysis of human FTO and RPGRIP1L mRNA expression 
Human FTO and RPGRIP1L mRNA expression was measured by quantitative real-
time RT-PCR in a fluorescent temperature cycler using the TaqMan® assay; fluorescence was 
detected on an ABI PRISM® 7000 sequence detector (Applied Biosystems, Darmstadt, 
Germany). Total RNA was isolated from paired subcutaneous and visceral adipose tissue 
samples using TRIzol (Life Technologies, Grand Island, NY, USA), and 1 μg RNA was 
reverse transcribed with standard reagents (Life Technologies). From each RT-PCR, 2 μl 
cDNA was amplified in a 26 μl PCR using a kit (Brilliant SYBR Green QPCR Core Reagent 
Kit; Stratagene, La Jolla, CA, USA) according to the manufacturer’s instructions. Samples 
were incubated in the sequence detector for an initial denaturation at 95 °C for 10 min, 
followed by 40 PCR cycles, each cycle consisting of 95 °C for 15 s, 60 °C for 1 min and  
72 °C for 1 min. The following primers were used: human FTO 5’-CTGGCCAGTGAAAGG 
GTCTAAT-3’ (sense) and 5’-GGCAGCAAGTTCTTCCAAAGC-3’ (antisense); human 




RPGRIP1L 5’-GGTATTGGCAAGCTCAGGGTAA-3’ (sense) and 5’-TCAAGCCTCCAAG 
TCATCTCTGT-3’ (antisense). SYBR Green I fluorescence emissions were monitored after 
each cycle. Human FTO and RPGRIP1L mRNA expression was calculated relative to the 
mRNA expression of 18S rRNA, determined by a premixed assay on demand for human  
18S rRNA (Applied Biosystems, Darmstadt, Germany). Amplification of specific transcripts 
was confirmed by melting curve profiles (cooling the sample to 68 °C and heating slowly to 
95 °C with measurement of fluorescence) at the end of each PCR. The specificity of the PCR 
was further verified by subjecting the amplification products to agarose gel electrophoresis. 
 
3.3.4 Genotyping of the rs8050136 FTO variant 
The SNP rs8050136 was selected for genotyping as a proxy for SNPs belonging to one 
linkage disequilibrium (L.D.) group including the previously reported rs9939609 (3). The 
choice of rs8050136 was based on the better quality of genotyping compared with rs9939609. 
Genotyping of rs8050136 was performed using the TaqMan® allelic discrimination assay 
(Applied Biosystems) on an ABI PRISM® 7500 sequence detector (Applied Biosystems). To 
assess genotyping reproducibility, a random ~10 % selection of the samples was re-genotyped 
with 100 % concordance. Genotype data were consistent with Hardy–Weinberg equilibrium 
(HWE) (p > 0.05). 
 
3.3.5 Statistical analyses 
Data are shown as means ± SD unless stated otherwise. Before statistical analysis, 
non-normally distributed parameters were logarithmically transformed to approximate a 
normal distribution. Expression differences between visceral and subcutaneous adipose tissue 
were assessed using the paired Student’s t test. Linear relationships were assessed by least 
square regression analysis. Multivariate linear relationships were assessed by a general linear 
model. Associations between rs8050136 and FTO mRNA expression levels were assessed 
using generalized linear regression models under the additive and dominant/recessive mode of 
inheritance. Statistical analysis was performed using SPSS version 12.0 (SPSS, Chicago, IL, 
USA). We considered p values < 0.05 to be statistically significant. 
 
3.4 Results 
3.4.1 Participant characteristics 
The study population comprised 55 European volunteers (26 men, 29 women) and was 
characterized by a mean age of 61 ± 15 years, mean BMI of 34.3 ± 9.5 kg/m2 (women:  




37.7 ± 10.7 kg/m2; men: 30.4 ± 6.1 kg/m2, p < 0.05), mean waist circumference of 119 ± 26 
cm (women: 121 ± 28 cm; men: 115 ± 23 cm) and mean body fat mass of 36 ± 11 % (women: 
40.6 ± 11.1 %; men: 30.8 ± 8.4 %, p < 0.05). Analysis of 55 paired samples of visceral and 
subcutaneous adipose tissue revealed threefold higher FTO mRNA levels in subcutaneous 
than in visceral adipose tissue, while RPGRIP1L mRNA expression was 1.6-fold higher in 
visceral than in subcutaneous adipose tissue (Figure 1a,b). FTO and RPGRIP1L mRNA gene 
expression was not different between men and women in either fat depot. Moreover, 
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Figure 1: FTO mRNA and RPGRIP1L mRNA expression in individuals with wide ranges of 
obesity, body fat distribution, insulin sensitivity and glucose tolerance. Men, white bars/symbols, 
N = 26; women, black bars/symbols, n=29. a) FTO mRNA and b) RPGRIP1L mRNA expression in 
visceral (Vis) and subcutaneous (SC) adipose tissue. Values are means ± SEM. p = 0.01. c) 
Correlation between Vis and SC FTO mRNA expression (N = 55). p = 0.016; r2 = 0.11. d) 
Correlations between visceral and e) SC FTO mRNA expression and BMI. P < 0.001; r2 = 0.27 (d);  
p = 0.018; r2 = 0.11 (e). Human FTO and RPGRIP1L mRNA expression was calculated relative to the 
mRNA expression of 18S rRNA. Data were ln-transformed to achieve normal distribution.  
AU, arbitrary units. 
 
3.4.2 Association of FTO expression 
Visceral FTO mRNA was significantly correlated with BMI (Figure 1d), percent body 
fat, sex and age, but not with visceral fat area (Table 1). Univariate regression analyses 
revealed further significant correlations between subcutaneous FTO mRNA expression and 
BMI (Figure 1e), percent body fat, subcutaneous fat area, age, sex and leptin (Table 1). The 
relationship between FTO mRNA expression and BMI was significant independently of sex.  
 
Table 1: Univariate linear regression between anthropometric and biochemical 
parameters and visceral and subcutaneous FTO mRNA and RPGRIP1L mRNA 
expression. 
Parameter FTO/18S rRNA RPGRIP1L/18S rRNA 
 Visceral Subcutaneous Visceral Subcutaneous
 r p value r p value r p value r p value
Age 0.55 < 0.001 0.32 0.03 0.04 0.79 0.05 0.76 
Sex -0.33 0.02 -0.45 0.01 -0.03 0.87 0.23 0.15 
Visceral fat area -0.08 0.64 -0.18 0.27 0.19 0.43 -0.13 0.57 
Subcutaneous fat area -0.06 0.7 -0.31 0.04 0.21 0.37 -0.10 0.67 
Percent body fat -0.3 0.03 -0.41 0.003 0.16 0.34 -0.04 0.79 
Waist circumference -0.2 0.2 -0.28 0.06 0.35 0.06 0.03 0.87 
FPG -0.27 0.07 -0.19 0.2 0.23 0.16 -0.09 0.57 
HbA1c -0.17 0.25 -0.21 0.15 0.06 0.71 -0.29 0.07 
Glucose uptake, clamp -0.02 0.9 0.05 0.8 -0.19 0.33 -0.12 0.54 
FPI -0.06 0.7 -0.04 0.8 0.24 0.14 -0.08 0.63 
Leptin -0.29 0.04 -0.31 0.04 0.17 0.35 0.23 0.20 
 
Participants: N = 55; FPG, fasting plasma glucose; FPI, fasting plasma insulin. 
 
However, in our study population the most obese participants were also the youngest 
and upon statistical adjustment for BMI, the age relationship disappeared (Table 2). Since the 
univariate correlation with BMI was much stronger, the age effect was most probably 




secondary to BMI. In a stepwise regression analysis age did not enter the model after BMI at 
a p level of 0.05. There was no correlation between leptin and adiponectin serum 
concentrations, and visceral or subcutaneous FTO mRNA expression beyond the associations 
of these adipokines with BMI or percent body fat. The association between FTO expression 
and BMI remained significant upon adjustment for age and sex in the visceral (p = 0.003), but 
not in the subcutaneous depot (p = 0.08; Table 2). 
 
Table 2: Multiple regression analysis between age, sex, BMI and FTO mRNA expression 
in visceral and subcutaneous adipose tissue. 
β -Coefficient (p-value) Models 
(log) Visceral FTO mRNA (log) Subcutaneous FTO mRNA 
Model 1   
Age (log) 0.49 (0.003) 0.17 (0.39) 
Gender (female) -0.08 (0.08) -0.06 (0.36) 
Model 2   
Age (log) 0.26 (0.1) -0.003 (0.99) 
BMI (log) -0.66 (0.0006) -0.52 (0.049) 
Model 3   
Age (log) 0.27 (0.09) 0.002 (0.99) 
Gender (female) -0.02 (0.59) -0.01 (0.89) 
BMI (log) -0.62 (0.003) -0.51 (0.08) 
 
Participants: N = 55. 
 
Since no functional information is available on how FTO might contribute to human 
obesity, we also modelled the data by reverse logic, i.e. BMI as dependent variable (Table 3). 
Interestingly, visceral FTO mRNA expression remained an independent predictor of BMI 
even after adjustment for subcutaneous FTO mRNA expression. There were no significant 
relationships between both visceral and subcutaneous FTO expression and fasting plasma 
glucose concentration, HbA1c and parameters of insulin sensitivity, including fasting plasma 
insulin concentrations and glucose uptake during the steady state of a euglycemic–
hyperinsulinemic clamp (Table 1). In contrast to FTO, no correlation of RPGRIP1L mRNA 











Table 3: Multivariate linear regression analysis of visceral and subcutaneous FTO 
mRNA expression as predictor of BMI. 
Body-Mass-Index Models 
β -Coefficient p-value 
Model 1   
Age (log) -0.32 0.003 
Gender (female) 0.09 0.008 
SC FTO (log) -0.12 0.08 
Model 2   
Age (log) -0.20 0.06 
Gender (female) 0.07 0.02 
Visceral FTO (log) -0.29 0.003 
Model 3   
Age (log) -0.20 0.056 
Gender (female) 0.07 0.03 
Visceral FTO (log) -0.26 0.01 
SC FTO (log) -0.07 0.31 
 
Participants: N = 55; SC, subcutaneous. 
 
3.4.3 Adipose tissue FTO mRNA expression in function of rs8050136 
The SNP rs8050136 was selected for genotyping as a proxy for SNPs belonging to one 
linkage disequilibrium (L.D.) group based on HapMap Rel 21a/phaseII (http://www.hapmap. 
org/cgiperl/gbrowse/hapmap_B36/). This L.D. group includes rs9939609, which is a common 
variant previously shown to be strongly associated with obesity (3). No significant association 
of rs8050136 with visceral or subcutaneous FTO mRNA levels was found (Table 4). 
However, despite the lack of statistical power due to the small sample size, rs8050136 was 
still associated with obesity in our study group (data not shown). 
 
Table 4: FTO and RPGRIP1L mRNA expression in visceral and subcutaneous adipose 
tissue grouped by rs8050136 genotypes. 

























(N = 13) 
2.63 ± 0.39 0.72  
(add) 
6.44 ± 1.41 0.90  
(add) 
1.80 ± 0.64 0.74 
(add) 
1.11 ± 0.33 0.42 
(add) 
CA  
(N = 24) 
2.49 ± 0.34 0.60 
(dom) 
8.41 ± 3.79 0.73  
(dom)
1.81 ± 0.26 0.91 
(dom) 
1.00 ± 0.18 0.64 
(dom)
AA  
(N = 11) 
2.22 ± 0.41 0.96  
(rec) 
6.90 ± 1.72 0.56 
(rec) 
1.73 ± 0.27 0.69 
(rec) 
1.03 ± 0.19 0.41 
(rec) 
 
Data are means±SEM; generalized linear models were used to identify significant differences between 
genotypes under the additive (add), dominant (dom) and recessive (rec) models, after adjustment for 
age, sex and BMI; AU, arbitrary units; Vis, Visceral; SC, subcutaneous. 





Two independent studies recently revealed an association between common variants in 
the FTO gene on chromosome 16q12.2, which have been confirmed in more than 20 
independent cohorts (3–5), and BMI. FTO is highly expressed in brain, but also detectable in 
most tissues, including adipose tissue and pancreatic beta cells (3,9). The function of the FTO 
gene product and its potential role for human obesity, however, are completely unknown at 
the moment. It is possible that only central mechanisms related to the control of appetite and 
satiety are involved. On the other hand, adipose tissue represents a primary candidate for 
studying the functional relevance of FTO in obesity. Conceivably, expression differences 
between lean and obese individuals could contribute to our understanding of the FTO gene 
product. Based on its genomic position near FTO, as well as on similar expression profiles, 
RPGRIP1L is also considered a plausible candidate gene involved in the pathophysiology of 
obesity (3,5). In this study, we provide first descriptive information on the relationship 
between FTO and RPGRIP1L mRNA expression in adipose tissue and simple anthropometric 
parameters including measures of obesity.  
FTO mRNA expression was threefold higher in subcutaneous than in visceral fat. This 
difference could be due to a number of factors usually differentiating these two depots 
including gene transcription, insulin sensitivity and lipolysis, altered adipokine expression and 
others (13, 14). Decreasing subcutaneous fat mass does not significantly improve obesity-
associated metabolic abnormalities (15), whereas reduction of visceral fat mass has been 
shown to have significant beneficial effects on glucose metabolism and insulin sensitivity 
(16). Our data indicate that fat depot differences in FTO expression may contribute to the 
specific properties of visceral adipose tissue. The observation that FTO expression in the two 
depots was only modestly correlated suggests that in a given individual up- or down-
regulation in one vs. the other depot is controlled locally rather than in a coordinated fashion 
by systemic hormonal, neuronal and/or nutritional signals. Independent of the fat depot, we 
found significant negative correlations between FTO gene expression and BMI or percent 
body fat. Therefore our data suggest that FTO gene expression might be down-regulated in 
response to fat accumulation. As indicated by the models (Table 2), this inverse relationship 
was significantly stronger for the visceral depot. From our correlation analysis it is impossible 
to extricate the direction of causality. Nevertheless, since genetic variation in FTO has been 
shown to affect the risk of obesity, it is legitimate to test the hypothesis of whether FTO 
expression predicts BMI. We identified visceral FTO mRNA expression as a strong predictor 
of BMI independently of age and sex, and even independently of FTO mRNA expression in 




the subcutaneous depot. This suggests that especially viscerally expressed FTO may 
contribute to obesity. Obviously, the number of participants in our study was relatively small 
and the association between BMI and adipose tissue FTO mRNA expression levels will 
require confirmation in larger cohorts. We also cannot exclude the possibility that specific 
characteristics of our study population, i.e. the strong negative correlation between age and 
BMI, may have produced a spurious relationship between FTO gene expression and obesity 
parameters. However, the fact that the BMI association withstood all conceivable adjustment 
makes us confident that this finding is robust. Adipose FTO expression and obesity could be 
co-regulated by a common genetic or environmental factor and not functionally linked to each 
other. More sophisticated study designs are necessary to dissect causal from correlative 
relationships with FTO expression in fat. We did not find an association between FTO mRNA 
levels and either fasting plasma glucose concentrations, HbA1c or parameters of insulin 
sensitivity. However, we cannot rule out the possibility that our sample size was too small to 
detect significant relationships between FTO gene expression and measures of insulin 
sensitivity and glucose metabolism. At the least, our data suggest that adipose tissue FTO 
expression does not directly affect risk of type 2 diabetes. As such, our results are generally 
supportive of the findings by Frayling et al. (3), who reported that the original association 
between FTO SNPs and type 2 diabetes disappeared upon adjustment for BMI.  
Although expression of RPGRIP1L mRNA was also fat depot-specific in our study, it 
does not, in contrast to FTO, seem to be linked to the pathophysiology of obesity as no 
correlations with anthropometric and metabolic characteristics were found. Our data therefore 
favours FTO rather than RPGRIP1L as a possible target affected by reported obesity-
associated polymorphisms (3). Recently, mutations within RPGRIP1L have been shown to be 
responsible for several syndromes such as Joubert or Meckel syndrome (17,18). Joubert 
syndrome is an autosomal recessive multisystem disease characterized by cerebellar ataxia, 
developmental delay, hypotonia, irregular breathing pattern, eye movement abnormalities and 
cerebellar vermis hypoplasia and dysplasia with accompanying brainstem defects (18). 
Meckel syndrome is an autosomal recessive lethal condition characterized by central nervous 
system malformation, postaxial polydactyly, cystic kidney dysplasia and ductal proliferation 
in the portal area of the liver (17, 18). No obesity phenotype has been reported for these 
syndromes caused by RPGRIP1L mutations. Given the strength of the correlation between 
FTO expression and adiposity in the present study and the relatively small effect that variation 
in FTO has on BMI as reported by Frayling et al. (3), variation in the FTO genotype does not 
appear to play a major role in regulating FTO transcription in adipose tissue. This is supported 




by the fact that no association between the obesity risk polymorphism and FTO and/or 
RPGRIP1L mRNA expression in adipose tissue was found in our study. It is noteworthy that, 
despite our study’s lack of statistical power due to the small sample size, rs8050136 was still 
associated with obesity in this study group. In conclusion, expression of adipose tissue FTO 
mRNA is fat depot-specific and correlates with age, while being negatively correlated with 
BMI and total body fat. Adipose tissue FTO mRNA expression is not related to rs8050136 
genotype, which is in L.D. with the previously reported obesity-associated SNP rs9939609 
(3). However, we were unable to determine the causal direction of the association between 
obesity and alterations in FTO gene expression. Therefore further studies are necessary to 
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Inhibition of fatty acid synthase (FASN) induces a rapid decline in fat stores in mice, 
suggesting a role for this enzyme in energy homeostasis. To investigate the potential role of 
FASN in the pathophysiology of human obesity, the FASN gene was sequenced in 48 German 
whites. Thirty-five single-nucleotide polymorphisms (SNPs) were identified. Eight SNPs 
representative for their linkage disequilibrium groups and the Val1483Ile (rs2228305) 
substitution were genotyped for subsequent association analyses in 1,311 adults from 
Germany. Further, the tagging SNPs were genotyped also in German childhood cohorts (738 
schoolchildren, 205 obese children). Effects of genetic variation on FASN mRNA expression 
in visceral and subcutaneous adipose tissue from a subgroup of 172 subjects were analyzed. 
Several polymorphisms in the FASN (rs62078748, rs2229422, rs2229425, and rs17848939) 
were nominally associated with obesity in case–control studies including 446 obese subjects 
(BMI ≥ 30 kg/m2) and 389 lean controls (BMI ≤ 25 kg/m2) (adjusted p < 0.05). The strongest 
significant effect was found for rs2229422 (p = 1.3 × 10−5 adjusted for age, sex, type 2 
diabetes status), which was supported by associations with BMI, waist-to-hip ratio (WHR), 
fasting plasma insulin and glucose infusion rate (adjusted p < 0.05). Subjects with the 
Val1483Ile substitution appeared to be protected against obesity. In addition, rs17848939 was 
nominally significantly associated with the ratio of visceral/subcutaneous FASN mRNA 
expression (adjusted p = 0.04). No effect of genetic variation in FASN on obesity was found 
in children. In conclusion, our data indicate a role of FASN genetic variation in susceptibility 
to obesity in adults. 
 
4.2 Introduction 
Obesity is a significant risk factor for many life-threatening diseases, and its global 
impact on health is enormous (1). Although the etiology of obesity is poorly understood, this 
disease has both environmental and genetic components. It has been postulated that increased 
expression and activity of the lipogenic pathways in adipose tissue could play a role in obesity 
development (2). The central enzyme in the pathway of de novo lipogenesis, fatty acid 
synthase (FASN), catalyses all steps in the conversion of malonyl CoA to palmitate (3). 
Although reports on genetic variation in human FASN are rare, there are a number of recent 
studies from rodents indicating that FASN may be involved in obesity through regulation of 
feeding behaviour (4–6). Treatment of mice with FASN inhibitors (cerulenin, C75) results in 
reduced food intake and substantial body weight loss (4). The FASN inhibitor, C75, acts both 
centrally to reduce food intake and peripherally to increase fatty acid oxidation, leading to 




rapid and profound weight loss, loss of adipose mass, and resolution of fatty liver in diet-
induced obese mice (7). The human FASN map on chromosome 17q25 (complement strand) 
within a region of linkage for body fat content in Pima Indians (8). Sequence analysis of 
FASN in this genetically and environmentally homogeneous population of Southern Arizona 
characterized by obesity and high prevalence of type 2 diabetes mellitus (T2D) (9,10), 
revealed a novel Val1483Ile polymorphism that was shown to be associated with percent 
body fat and 24-h substrate oxidation rates measured in a respiratory chamber (11). It has 
been suggested that the Val1483Ile substitution in FASN is protective against obesity, an 
effect possibly explained by the role of this gene in the regulation of substrate oxidation (11). 
The Pima data have recently been supported by studies in white children, reporting a sex-
specific protective effect of the Val1483Ile variant for obesity as well as its beneficial effect 
on lipid profile in obese boys (12). However, comprehensive genetic analyses of FASN such 
as the one reported in Pima Indians are still lacking in white populations. Recently, we 
examined whether FASN mRNA expression in visceral and subcutaneous fat correlates with 
anthropometric and metabolic parameters in subjects with a wide range of obesity, body fat 
distribution, insulin sensitivity, and glucose tolerance (13). Our data clearly demonstrated 
significant association of increased FASN expression in adipose tissue not only with obesity, 
but also with T2D and insulin resistance, thus indicating a possible role of lipogenic pathways 
in the development of human obesity and/or T2D (13). Therefore, in the present study we 
sequenced the gene in subjects from Eastern Germany and assessed the effects of identified 
polymorphisms on human obesity/T2D and pathophysiologically relevant traits. We further 
investigated whether genetic variation within the FASN might be responsible for changes in 
FASN expression in adipose tissue. 
 
4.3 Experimental subjects 
4.3.1 Leipzig adult cohort 
In total, 640 patients with T2D and 671 healthy subjects were recruited at the 
University Hospital in Leipzig, Germany. BMI was calculated as weight divided by squared 
height. Waist and hip circumferences were measured and waist-to-hip ratio (WHR) was 
calculated. The healthy subjects included 246 males and 425 females (mean age 46.5 ± 14.4 
years, mean BMI 27.5 ± 5.4 kg/m2) and patients with T2D included 301 males and 339 
females (mean age 63.3 ± 11.3 years, mean BMI 29.8 ± 5.2 kg/m2; the data represent mean ± 
SD). In addition oral glucose tolerance test and fasting plasma insulin measurements were 
performed in all nondiabetic subjects. The oral glucose tolerance test was performed 




according to the criteria of the American Diabetes Association (14). The test was carried out 
after an overnight fast with 75 g standardized glucose solution (Glucodex Solution 75 g; 
Merieux, Montreal, Canada). Venous blood samples were taken at 0, 60, and 120 min for 
measurements of plasma glucose concentrations. 196 out of 671 subjects had impaired 
glucose tolerance. As impaired glucose tolerance is a T2D predicting factor, only remaining 
502 subjects with normal glucose tolerance were included as healthy controls in T2D 
association study. In a subgroup of 380 nondiabetic subjects, body fat content and insulin 
sensitivity were measured. Percent body fat was measured by dual-energy X-ray 
absorptiometry. Insulin sensitivity was assessed with the euglycemic–hyperinsulinemic clamp 
method as previously described (15,16). In addition, paired samples of visceral and 
subcutaneous adipose tissue and DNA were obtained from a subgroup of 172 white men  
(N = 84) and women (N = 88), who underwent open abdominal surgery for gastric banding, 
cholecystectomy, weight reduction surgery, abdominal injuries, or explorative laparotomy. 
The age ranged from 16 to 99 years and BMI from 20.8 to 54.1 kg/m2. Thirty-eight subjects 
had T2D and 15 subjects had impaired glucose tolerance. All subjects had a stable weight 
with no fluctuations of > 2 % of the body weight for at least 3 months before surgery. Patients 
with severe conditions including generalized inflammation or end stage malignant diseases 
were excluded from the study. Samples of visceral and subcutaneous adipose tissue were 
immediately frozen in liquid nitrogen after explantation. The white status of study subjects 
was self-reported. All studies were approved by the ethics committee of the University of 
Leipzig and all subjects gave written informed consent before taking part in the study. 
 
4.3.2 Childhood cohorts 
Leipzig Schoolchildren cohort: This cohort is part of the Leipzig Schoolchildren 
Project that investigated anthropometric and clinical parameters in 2,675 children aged 6 to 17 
years from 1999–2000 (17). DNA was available from 738 children (358 boys and 380 girls; 
mean age 12 ± 3 years; mean BMI-SDS 0.09 ± 0.98). The BMI was standardized referring to 
national reference data (18) and children with a BMI ≥ 1.88 SDS (= 97th percentile) were 
classified obese. A total of 508 children and adolescents with BMI between −1.0 SDS and  
1.0 SDS (243 boys and 265 girls; mean age 12 ± 3 years; mean BMI-SDS −0.05 ± 0.54) were 
selected from the 738 schoolchildren to serve as healthy normal weight control group to 
Leipzig obese children cohort. 
 




Leipzig obese children cohort: A total of 205 white children and adolescents (97 boys 
and 108 girls; 12 ± 4 years; BMI-SDS 2.71 ± 0.58) were recruited from the obesity clinic at 
the University Hospital for Children & Adolescents, Leipzig, Germany. All obese children 
had a detailed metabolic work up including an oral glucose tolerance test as described in 
detail elsewhere (19). The studies were approved by the ethics committee of the University of 
Leipzig. 
 
4.4 Methods and Procedures 
4.4.1 Analysis of human FASN gene expression 
Total RNA was isolated from paired subcutaneous and visceral adipose tissue samples 
using TRIzol (Life Technologies, Grand Island, NY), 1 μg RNA was reverse transcribed with 
standard reagents (Life Technologies). From each reverse transcription–PCR, 2 μl was 
amplified in a 26 μl PCR using the Brilliant SYBR Green QPCR Core Reagent Kit from 
Stratagene (La Jolla, CA) according to the manufacturer’s instructions. Samples were 
incubated in the ABI PRISM® 7000 sequence detector for an initial denaturation at 95 °C for 
10 min, followed by 40 PCR cycles, each cycle consisting of 95 °C for 15 s, 60 °C for 1 min, 
and 72 °C for 1 min. The following primers were used: human FASN (accession no. 
NM_004104) 5’-CGCGTGGCCGGCTACTCCTAC-3’ (sense), and 5’-CGGCTGCCACACG 
CTCCTCT-3’ (antisense). Human FASN mRNA expression was calculated relative to the 
mRNA expression of 18S rRNA, determined by a premixed assay on demand for human  
18S rRNA (PE Biosystems, Foster City, CA). Amplification of specific transcripts was 
confirmed by melting curve profiles (cooling the sample to 68 °C and heating slowly to 95 °C 
with measurement of fluorescence) at the end of each PCR. The specificity of the PCR was 
further verified by subjecting the amplification products to agarose gel electrophoresis. 
 
4.4.2 Sequencing of the FASN 
To identify genetic variants, all 43 exons, including intron/exon splicing sites (the total 
length of FASN mRNA is 8,481 bp, NM_004104), 2,280 bp upstream of the first translation 
initiation site and 840 bp of the 3’ untranslated region were sequenced in DNA samples from 
48 nonrelated German subjects (24 obese and 24 with normal weight). Sequencing was 
performed using the BigDye® Terminator (Applied Biosystems, Foster City, CA) on an 
automated DNA capillary sequencer (ABI PRISM® 3100 Avant; Applied Biosystems). 
Sequence information for all oligonucleotide primers used for variant screening is available 
upon request. 




4.4.3 Genotyping of the FASN SNPs 
Genotyping of selected single-nucleotide polymorphisms (SNPs) in all study subjects 
was done using the TaqMan® assay (Applied Biosystems) for the rs17848935, rs4485435, 
rs2229422, rs4246445, rs2229425, rs2228309, rs62078748, rs2228305 variants and by 
restriction fragment length polymorphism technique for the rs17848939 variant. The 
TaqMan® genotyping reaction was amplified on a GeneAmp® PCR system 9700 (95 °C for 
15 min, and 95 °C for 15 s, and 60 °C for 1 min, for 40 cycles) and fluorescence was detected 
on an ABI PRISM® 7700 sequence detector (Applied Biosystems). The restriction fragment 
length polymorphism genotypes were determined by PCR amplification of the respective 
fragments of the FASN on a GeneAmp® PCR system 9700 (94 °C for 3 min, and 94 °C for  
30 s, and 66 °C for 45 s, 72 °C for 45 s, for 35 cycles, and 72 °C for 10 min) and subsequent 
digestion with the NotI restriction enzyme and size fractionation and visualization by 
electrophoresis. To assess genotyping reproducibility, a random ~10 % selection of the 
sample was regenotyped for each SNP; all genotypes matched initial designated genotypes. 
Moreover, the DNA samples selected for sequencing were regenotyped by TaqMan® 
technique, as they were also included in the association analyses. The genotypes matched 
completely between the two techniques. 
 
4.4.4 Statistical analyses 
Prior to statistical analysis, non-normally distributed parameters (glucose infusion rate, 
2-h plasma glucose, fasting plasma insulin, visceral and subcutaneous FASN mRNA 
expression) were logarithmically transformed to approximate a Gaussian distribution. 
Differences in genotype frequencies were compared using logistic regression models between 
the obese cases and lean controls as well as between diabetic cases and healthy controls with 
normal glucose tolerance. Multivariate linear relationships were assessed by generalized 
linear model analyses. In the additive model, homozygotes for the major allele (MM), 
heterozygotes (Mm) and homozygotes for the minor allele (mm) were coded to a continuous 
numeric variable for genotype (as 0, 1, and 2, respectively). A dominant model was defined as 
contrasting genotypic groups MM + Mm vs. mm, and the recessive model was defined as 
contrasting genotypic groups MM vs. Mm + mm. In haplotype analyses, groups of subjects 
carrying 2, 1, or 0 copies of the haplotype were compared. To estimate haplotypes we used 
the PHASE version 2.1 software (20,21). The phase reconstruction method considers the 
unknown haplotypes as unobserved random quantities and aims to evaluate their conditional 
distribution in light of the genotype data. Statistical analyses were performed using the SPSS 




software package (SPSS, Chicago, IL) and the statistical analysis system of the SAS Institute 
(Cary, NC). All data are presented without correcting for multiple testing. Bonferroni 
corrections for multiple testing would require a p value of 0.006 for analyses of associations 
in the present case–control studies and p value of 0.007 for the association analyses with 
quantitative traits to consider the findings significant. P values < 0.05 but > 0.006 were 
therefore considered to be of nominal statistical significance. 
 
4.5 Results 
4.5.1 Genetic variation in the FASN 
The FASN gene (all 43 Exons with Intron/Exon splicing sites, 2 kb in the 5’ region and 
840 bp of the 3’ untranslated region) was sequenced in 48 white DNA samples (24 obese and 
24 lean subjects) to identify variation. Thirty-five SNPs including 14 novel variants were 
identified: 12 SNPs were in the 5’ region, 14 SNPs in exons, 7 SNPs in introns and 2 SNPs in 
the 3′ untranslated region (Table 1). The genotype distributions for all SNPs were consistent 
with Hardy–Weinberg equilibrium (p > 0.05), except for rs1140616 which was therefore 
excluded from further analyses. Linkage disequilibrium (r2 and D-prime (D’)) was calculated 
among the 16 common variants (minor allele frequency (MAF) > 0.05) using the EMLD 
statistical program (https://epi.mdanderson.org/~qhuang/Software/pub.htm) (Supplement 
Table 1). Based on L.D. between these common variants, eight groups were defined by the 
Tagger software (22) (Supplement Table 2). Because SNPs in high genotypic concordance 
would provide the same information for association studies, one representative variant for 
each L.D.-group was selected and genotyped in all subjects for association analyses 
(Supplement Table 2). In addition we genotyped the Val1483Ile (rs2228305) variant  
(MAF = 4 %) in the adult cohort, which has previously been reported to be associated with 
obesity in different ethnicities (11,12). Moreover, using the PHASE version 2.1 software 
(20,21), we identified five common haplotypes (frequency of each haplotype ≥ 0.05) among 
the eight different SNPs genotyped in all subjects. These five haplotypes, [GCTCTGCC], 
[GTCCTACT], [GTCGTACC], [ACCCCGCC], and [ACCCCGTC] accounted for > 80 % of 
the all observed haplotypes, where haplotypes are defined by the composition of alleles at 
each SNP in following order: [rs62078748]-[rs2228309]-[rs17848935]-[rs4485435]-
[rs2229422]-[rs17848939]-[rs2229425]-[rs4246445]. 




Table 1: Genetic variants detected in the FASN coding region, its 5’ region and 3’ UTR. 






1 -2268T>G G = 0.01 - - 
2 -2177T>C C = 0.49 rs59251877 - 
3 -2095C>A A = 0.05 - - 
4 -2051T>G G = 0.01 - - 
5 -1745T>C C = 0.33 rs59638227 - 
6 -1556T>C C = 0.02 - - 
7 -1195C>T T = 0.16 rs62078749 - 
8 -1004G>A A = 0.37 rs62078748 - 
9 -885G>C C = 0.48 rs62078747 - 
10 -605C>T T = 0.16 - - 
11 -54G>T T = 0.30 rs17848934 - 
12 -20G>A A = 0.03 - - 
13 c.567C>T T = 0.48 rs2228309 (p.=) (189Asn) 
14 c.591C>T T = 0.03 - (p.=)(197Ser) 
15 c.1436G>T T = 0.02 - (p.Gly479Val) 
16 c.1965+68C>T T = 0.02 rs45586937 - 
17 c.2155G>A A = 0.01 rs12946178 (p.Glu719Lys) 
18 c.3224-18C>T T = 0.15 rs17848935 - 
19 c.3267C>G G = 0.17 rs4485435 (p.=) (1089Ala) 
20 c.3651C>T T = 0.15 rs41283365 (p.=) (1217Gly) 
21 c.3741T>C C = 0.36 rs2229422 (p.=) (1247Ala) 
22 c.4122+9G>A A = 0.45 rs17848939 - 
23 c.4447G>A A = 0.04 rs2228305 (p.Val1483Ile) 
24 c.5268C>T T = 0.19 rs2229425 (p.=) (1756Ser) 
25 c.5336C>T T = 0.01 rs2229426 (p.Pro1779Leu) 
26 c.5470C>T T = 0.02 - (p.Arg1824Trp) 
27 c.5872G>A A = 0.02 - (p.Glu1958Lys) 
28 c.6374G>A A = 0.01 - (p.Arg2125Gln) 
29 c.6402T>C C = 0.33 rs1140616 (p.=) (2134Ile) 
30 c.6406+12C>T T = 0.01 - - 
31 c.6595+12C>T T = 0.38 rs4246445 - 
32 c.7047+31G>A A = 0.01 rs45466394 - 
33 c.7147-46G>A A = 0.01 - - 
34 *141A>G G = 0.03 - - 
35 *142C>T T = 0.38 rs11550611 - 
 












4.5.2 Association studies in adults 
Genetic variants in the FASN and obesity. Several representative SNPs were 
associated with obesity under logistic regression analysis in a case–control designed study 
including 446 obese subjects (BMI ≥ 30 kg/m2, mean age: 59 ± 12 years, mean BMI: 34.6 ± 
4.5 kg/m2) and 389 lean controls (BMI ≤ 25 kg/m2, 48 ± 18 years, 23.4 ± 1.4 kg/m2)  
(Table 2). Including age, sex, and T2D status in the analyses, frequency of minor alleles for 
the SNPs rs62078748, rs2229422, and rs2229425 was significantly higher in the obese group 
compared with lean controls (p values ranging from 0.001 to 1.3 × 10−5). This conferred a 
significantly higher risk of obesity in additive mode of inheritance ranging from odds ratio = 
1.51 (95 % confidence interval, CI, (1.19; 1.92)) for the rs62078748 to 1.85 (1.35; 2.56) for 
the rs2229425. In contrast, the minor allele for rs17848939 was nominally significantly more 
frequent in the lean group (p = 0.01; in additive mode of inheritance after adjusting for age, 
sex, and T2D). The analyses were performed also without subjects with T2D; the SNP allele 
frequencies in the obese group remained unchanged. However, even though we attempted to 
eliminate some redundancy in the association testing by selecting only one SNP per each 
defined L.D.-group, the tagging SNPs seem to be still correlated (e.g., between rs62078748 
and rs2229422 D′ = 0.86 and r2 = 0.63; Supplement Table 1).  
As it is possible that a single variant could explain all the observed association, all 
tests were re-analyzed conditional on the strongest association found for rs2229422. After 
including rs2229422 in the analyses, none of the remaining SNPs showed significant 
association with obesity. Consistent with the SNP data, two haplotypes were significantly 
associated with obesity. The frequency of the haplotype [ACCCCGCC] was significantly 
increased in the obese group (13.9 % vs. 10.0 % in the lean subjects) whereas the haplotype 
[GTCCTACT] showed increased frequency in lean controls (25.3 % vs. 19.4 % in the obese 
group (p = 0.003 and 0.002, respectively; in additive mode of inheritance after adjusting for 
age and sex). PHASE software provides a list of the best haplotype guess for each individual. 
To avoid misinterpreting the association results between haplotypes and phenotypic traits, we 
performed the analyses also in a dataset excluding all individuals where the phase probability 
at least at one site was < 0.8. This eliminated all subjects from the analyses who may have 
influenced the analyses by including their uncertain haplotypes. The results of analyses with 
the new dataset remained materially unchanged. The p value for association of the 
[ACCCCGCC] haplotype with obesity changed from 0.003 to 0.009 and remained the same 
for the [GTCCTACT] haplotype (p = 0.002). 
 




Table 2: Association of FASN genetic variants with obesity. 
SNP 
 
Controls Cases p-value 
(unadjusted) 
p-value1 
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Controls: BMI ≤ 25 kg/m2, N = 389; Cases: BMI ≥ 30 kg/m2, N = 446; 1adjusted for age, sex and T2D; 
2adjusted for age, sex, T2D and rs2229422; p-values and odds ratio (OR) with 95 % confidence 
intervals (CI) were calculated under logistic regression analyses in additive mode of inheritance;  








Genetic variants in the FASN and type 2 diabetes. In the present study, five out of 
eight representative SNPs were nominally significantly associated with T2D in 640 cases and 
502 healthy controls (with normal glucose tolerance) under logistic regression analysis  
(all p < 0.05 in additive mode of inheritance; Supplement Table 3). However, after adjusting 
the analyses for age, sex, and BMI, only rs2228309 remained moderately associated with T2D  
(p < 0.05; Supplement Table 3). Consistent with these data, none of the five common 
haplotypes showed significant differences in frequencies between diabetic and nondiabetic 
subjects (all p > 0.05; data not shown). 
 
Genetic variants in the FASN and parameters of obesity and glucose metabolism. In 
the cohort of 671 white subjects without T2D, several polymorphisms showed relationship to 
quantitative parameters of obesity and glucose metabolism. As the strongest effect in the 
obesity case–control study was observed for rs2229422, we focused our analyses on this SNP. 
The rs2229422 C allele was significantly associated with higher BMI and higher WHR (after 
adjusting for age and sex; Supplement Table 4). Moreover rs2229422 was nominally 
associated with fasting plasma insulin (adjusted for age, sex, and BMI) (Supplement Table 4). 
Finally, the C allele was associated with lower glucose infusion rate assessed by euglycemic–
hyperinsulinemic clamp (adjusted for age, sex, and BMI) (Supplement Table 4). The effect of 
the SNP on obesity-related traits was reflected in the haplotype analysis as well, which 
however did not show any associations beyond those observed for the SNP (data not shown). 
 
Val1483Ile genotype protects against obesity. In the present study, we also attempted 
to replicate the previously described relationship of the Val1483Ile substitution on obesity. In 
the entire cohort, Ile-allele carriers had nominally significantly lower BMI than noncarriers 
(Figure 1; p = 0.04 after adjusting for age and sex in additive mode of inheritance). After 
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Figure 1: Association of the Val1483Ile (rs2228305) variant with BMI. 
The data are presented as mean ± SEM. P-values were calculated after adjusting for age (and for sex in 
the entire cohort) in an additive mode of inheritance. 
 
  Also in the case–control study, an association with obesity was seen in males but not 
in females (adjusted p = 0.04 vs. p = 0.86 in additive mode of inheritance) (Table 3). Based on 
this, we tested a possible gender specific effect for the other investigated SNPs. Unlike for 
Val1483Ile, we did not observe gender differences in effects of the other SNPs on obesity and 
related traits. All p values in gender strata were consistent with those observed in the total 
cohort (data not shown). Although both the Val1483Ile and the rs2229422 are associated with 
obesity, they are not in strong linkage disequilibrium (D’ = 0.76 and r2 = 0.01) and thus, their 
effects seem to be independent of each other. 
 
Table 3: Association of the Val1483Ile (rs2228305) variant with obesity. 




Total Controls  
(N = 389) 
91.1 % 7.7 % 1.2 % 
 Cases  
(N = 446) 





0.65 (0.36; 1.16) 
Males Controls 
(N = 152) 
87.5 % 10.3 % 2.2 % 
 Cases 
(N = 181) 




0.41 (0.17; 0.95) 
Females Controls  
(N = 237) 
93.6 % 5.9 % 0.5 % 
 Cases 
(N = 265) 




1.08 (0.47; 2.47)  
 
 




Table 3 cont.: Controls included subjects with BMI ≤ 25 kg/m2, cases included subjects with  
BMI ≥ 30 kg/m2; p-values were calculated under logistic regression models after adjusting for age 
(and for sex in the entire cohort) in an additive mode of inheritance. 
 
4.5.3 Association studies in children 
In a case–control study including 508 lean and 205 obese children, no significant 
association of the FASN SNPs was found (p > 0.05 after adjusting for age, sex, pubertal stage, 
and height). In line with this, the FASN variants did not associate with measures of obesity 
(BMI, WHR) in either schoolchildren (N = 738) or obesity cohort (N = 205) (adjusted  
p > 0.05; data not shown). 
 
4.5.4 Association of genetic variants in the FASN with fat depot-specific FASN mRNA 
expression 
No association of the eight representative SNPs or derived haplotypes with FASN 
mRNA levels in either visceral or subcutaneous adipose tissue was found in 172 individuals 
with visceral and subcutaneous adipose tissue biopsies (all p > 0.05 after adjusting for age, 
sex, and BMI). To express FASN mRNA expression in visceral relative to that in 
subcutaneous fat, we calculated the visceral/subcutaneous FASN mRNA ratio. The 
rs17848939 was nominally significantly associated with the visceral to subcutaneous (Vis/SC) 
FASN mRNA expression ratio (p = 0.04 and 0.02 in additive and recessive mode respectively, 
after adjusting for age, sex, and BMI) (Table 4). We also performed statistical analyses 
excluding subjects with impaired glucose tolerance and T2D, but the results remained 
unchanged (data not shown). 
 
Table 4: Association of the rs17848939 variant with FASN mRNA levels. 
 rs17848939   
Genotype GG GA AA  P-value  
 N = 58 N = 82 N = 32    
Sex (Males/Females) 33/25 42/40 9/23  0.03  
Age (years) 57 ± 2 53 ± 1 60 ± 3  0.05  
BMI (kg/m2) 33.1 ± 1.1 30.5 ± 0.7 31.3 ± 1.4  0.18  
FASN mRNA expression    add dom rec 
Log Visceral fat 5.11 ± 0.30 4.53 ± 0.28 4.79 ± 0.47 0.44 0.58 0.49 
Log Subcutaneous fat 3.13 ± 0.26 3.18 ± 0.23 3.26 ± 0.39 0.52 0.87 0.27 
Log Visceral/Subcutaneous 2.11 ± 0.20 1.44 ± 0.22 1.51 ± 0.24 0.04 0.34 0.02 




Table 4 cont.: The data are presented as mean ± SEM; p-values were calculated after adjusting for age, 




The FASN has been comprehensively investigated in Pima Indians (11), but such 
studies are still missing in European populations. In the present study, we therefore re-
sequenced FASN in subjects from Eastern Germany and investigated identified 
polymorphisms in subsequent association analyses. In addition, we also evaluated the role of 
genetic variation in the FASN on its mRNA expression in visceral and subcutaneous adipose 
tissue. The key findings of the present study are: (i) Genetic variants in the FASN are 
significantly associated with human obesity and its related traits in adult Germans and (ii) 
Support of previously reported sex-specific effects of the Val1483Ile variant on obesity. In the 
present study, 35 genetic variants were identified by sequencing the FASN. Sixteen variants 
had MAF > 5 % and fell into eight L.D.-groups. Association analyses of representative 
variants for each of the L.D.-groups showed several polymorphisms (rs62078748, rs2229422, 
rs17848939, rs2229425) associated with obesity in case–control studies. Conditional analysis 
revealed rs2229422 to be the strongest obesity associated FASN genetic variant which was 
further supported through analyses in the cohort of white subjects without T2D. The 
polymorphism showed relationships to quantitative measures of obesity such as BMI and 
WHR. Although the rs2229422 showed nominally significant associations with T2D in the 
case–control study, the effect did not withstand corrections for BMI suggesting that the effect 
of the SNP on T2D was mediated through obesity. None of the investigated polymorphisms 
with MAF > 5 % has an evident functional relevance for the FASN protein i.e., no SNP 
causes amino acid substitution in the protein or results in a new frameshift. We therefore 
further evaluated whether FASN genetic variants might affect the mRNA expression in 
visceral and subcutaneous fat and thus explain the relationship with metabolic traits related to 
obesity and T2D. Recent studies carried out by our group showed that FASN mRNA 
expression in adipose tissue was related to measures of obesity, insulin sensitivity, and 
glucose tolerance (13). Furthermore, there was increased FASN mRNA expression in visceral 
as compared to subcutaneous adipose tissue in lean healthy subjects, as well as in obese 
patients with or without T2D (13). In the present study, the obesity risk rs17848939 G-allele 
was nominally significantly associated with the visceral to subcutaneous FASN mRNA 
expression ratio. Consistent with the previously described positive correlation of fat mRNA 




expression with measures of obesity, the rs17848939 variant also showed nominally 
significant association with BMI and % body fat (data not shown). These data suggest that 
genetic variation in FASN may at least partially explain variation in mRNA expression in 
visceral and subcutaneous adipose tissue. However, it needs to be noted that based on 
correlation data including mRNA expression together with genetic variation and a certain 
phenotype (such as BMI) one can not reveal the causative chain and so, to rule out that 
changes in mRNA expression simply reflect the state of obesity. 
As shown recently in a genome-wide study on mRNA expression in adipose tissue 
(23), the majority of the traits profiled (over 70 % or 17,080 traits) showed significant 
correlation with BMI. Therefore, studies targeting functional consequences of FASN obesity 
risk variants on FASN transcription will be inevitable to clarify whether or not genetic 
variants can explain variation in mRNA expression. In addition to above mentioned 
polymorphisms, we attempted to replicate previously reported correlations between the 
Val1483Ile substitution and obesity despite low MAF (4 %) of this variant in Europeans of 
German origin. The variant was first identified and shown to be associated with percent of 
body fat and substrate oxidation rates in Pima Indians (11). It has been hypothesised that the 
Val/Ile substitution, which is positioned in the FASN interdomain region (24), could alter this 
functionally essential site and thus potentially reduces FASN activity (11). Consequently, 
changes in FASN activity could affect substrate oxidation rates, which would result in the 
decrease in body fat observed in the Pima Indians (11). Further support for the protective 
effect of this variant against obesity came from studies in German children showing reduced 
BMI-SDS and improved lipid profile of boys carrying the Ile-variant (12). Findings in 
children cohorts suggested sex-specific effects of the polymorphism which was confirmed 
recently by independent studies in Spanish whites (25). Spanish men with the Ile-allele had 
lower BMI, WHR, fasting glucose, and blood pressure, and they showed increased insulin 
sensitivity (25). However, no association was found in women (25). Also in our study, in 
contrast to women, German adult men carrying the Ile-allele seem to be protected against 
obesity as suggested by the case–control study as well as by the association with lower BMI. 
Because Ile-carriers also have decreased adipose tissue FASN activity (25), it might be 
postulated that Val1483Ile is a functional variant in FASN. Sexual dimorphism in genetic 
associations in obesity, glucose, and lipid metabolism is not uncommon and has been reported 
for genes such as leptin (26), resistin (27), winged helix/forkhead transcription factor (28), 
peptide tyrosine tyrosine (29), Y2 receptor (29) and others. It could be hypothesised that the 
protective effects of the Val1483Ile are masked by hormonally controlled mechanisms in 




women. It needs to be mentioned though that several other variants (with very low MAF) 
identified by sequencing and which predict amino acid substitutions were not examined in the 
present study. Therefore, we can not exclude that rare variants other than Val1483Ile might be 
affecting human obesity as well.  
Children represent a valuable study population for identifying primary genetic 
determinants involved in susceptibility to complex polygenic diseases such as obesity. Unlike 
in adults their phenotype is less influenced by comorbidities and prolonged exposure to 
environmental factors. Interestingly, although we previously showed sex-specific association 
of the Val1483Ile variant with obesity in German children (12), no relationship with other 
SNPs associated with obesity in adults, was seen in our present study. Lack of association of 
FASN SNPs with childhood obesity indicates that the SNP effects most likely manifest in later 
stages of life and/or that these effects might be modified by gene-environment interactions. 
This aspect may need to be considered in association studies and may partially explain why 
genetic variation in FASN was not found to be associated with obesity in genome-wide 
association scans (GWAS). However, we are aware that effect sizes observed in the present 
study should have been picked up easily in well powered GWAS. Due to the relatively small 
sample size in our study, we see these effect sizes with caution. Also, we attempted to 
replicate the observed associations in our GWAS in a self-contained population of Sorbs from 
Germany (30). The GWAS was performed by using 500 K and 6.0 Affymetrix GeneChips. 
Unfortunately, no SNPs within the FASN locus were included on the chips, which made 
potential comparisons with our sequenced variants impossible. Similarly, the 1958 British 
Birth Cohort (BC58) publicly available data only provide three SNPs within the FASN 
(http://www.b58cgene.sgul.ac.uk/index.php). Thus the lack of associations with obesity in 
GWAS may partly be attributed to missing SNPs on the used GeneChip arrays. Further, 
similar MAF for SNPs rs62078748, rs2229422, rs17848939, rs2229425 in our control sample 
and HapMap populations might eventually support our association findings. Unfortunately, 
we were not able to compare our control sample with other populations in silico, since there 
are no publicly available data on allele frequencies for these SNPs at the moment. We are 
aware that our findings will need to be confirmed in independent studies. However, it should 
be noted that the strongest association signal observed for rs2229422 in our study did 
withstand very conservative Bonferroni corrections for multiple testing, which would require 
p value of 0.006 for analyses of associations in the present case–control studies. In addition, 
we could replicate previously described protective effects of the Val1483Ile variant against 
obesity, which further supports validity of these findings. Based on our data, we suggest that 




variation in the human FASN may play a role in the regulation of human body weight. 
Although these data support previous studies in rodents and replicate protective effects of the 
Val1483Ile against obesity, associations of common variants in FASN with obesity are novel 
and need to be replicated to confirm these findings and define their relative importance in the 
pathogenesis of human obesity. 
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Supplement Table 1: Measures of linkage disequilibrium (L.D.; D prime (D’) and r2) 
among FASN SNPs with minor allele frequency > 0.05. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1 1 0.99 0.99 0.99 1.00 0.79 0.99 0.99 0.99 0.80 0.99 0.91 0.90 0.82 0.60 0.59
2 0.49 1 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.88 0.79 0.78 0.37 0.29
3 0.19 0.10 1 0.42 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.64 0.99 0.99 0.99
4 0.55 0.86 0.02 1 0.99 0.62 0.99 0.99 0.27 0.56 0.26 0.86 0.74 0.77 0.45 0.37
5 1.00 0.52 0.17 0.59 1 0.77 0.99 0.99 0.99 0.78 0.99 0.91 0.90 0.81 0.58 0.52
6 0.14 0.10 0.04 0.04 0.14 1 0.99 0.99 0.99 0.91 0.99 0.99 0.75 0.13 0.99 0.99
7 0.42 0.86 0.08 0.74 0.45 0.09 1 0.99 0.99 0.99 0.99 0.93 0.76 0.71 0.27 0.18
8 0.95 0.47 0.18 0.52 0.95 0.25 0.40 1 0.99 0.99 0.99 0.89 0.87 0.74 0.63 0.56
9 0.17 0.09 0.92 0.01 0.15 0.04 0.07 0.17 1 1.00 1.00 0.99 0.78 0.99 0.99 0.99
10 0.13 0.10 0.04 0.03 0.13 0.82 0.09 0.23 0.04 1 1.00 0.99 0.99 0.91 0.99 0.99
11 0.18 0.10 0.91 0.01 0.16 0.04 0.08 0.17 1.00 0.04 1 0.99 0.79 0.92 0.99 0.99
12 0.46 0.77 0.08 0.63 0.46 0.11 0.78 0.44 0.07 0.13 0.08 1 0.92 0.99 0.26 0.22
13 0.71 0.39 0.08 0.39 0.67 0.10 0.31 0.65 0.10 0.20 0.11 0.55 1 0.99 0.55 0.56
14 0.16 0.28 0.04 0.26 0.16 0.01 0.27 0.12 0.04 0.04 0.04 0.45 0.29 1 0.74 0.75
15 0.19 0.04 0.10 0.06 0.18 0.08 0.02 0.24 0.10 0.10 0.09 0.02 0.14 0.07 1 0.99
16 0.18 0.02 0.11 0.04 0.15 0.09 0.01 0.19 0.09 0.11 0.09 0.01 0.14 0.07 0.95 1 
 
D’ given in upper shaded boxes and r2 given in lower boxes. 
1 = rs59251877; 2 = rs59638227, 3 = rs62078749, 4 = rs62078748, 5 = rs62078747, 6 = -605C>T,  
7 = rs17848934, 8 = rs2228309, 9 = rs17848935, 10 = rs4485435, 11 = rs41283365, 12 = rs2229422,  
13 = rs17848939, 14 = rs2229425, 15 = rs4246445, 16 = rs11550611. 




Supplement Table 2: Linkage disequilibrium (L.D.) groups of FASN variants among 48 
unrelated Caucasian subjects. 
 
Variants in each group are in L.D. (r2 ≥ 0.8, D’ = 1.0). Representative SNPs which were genotyped for 
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0.02 0.28 1.14 (0.90; 1.44) 
L.D. Group FASN genetic variants 
1 rs59251877, rs62078747, rs2228309 
2 rs59638227, rs62078748, rs17848934 
3 rs62078749, rs17848935,  rs41283365 
4 -605C>T, rs4485435 

























































0.03 0.17 0.84 (0.66; 1.08) 
 
P-values and odds ratio (OR) with 95 % confidence intervals (CI) were calculated under logistic 
regression analyses in additive mode of inheritance. MAF - minor allele frequency. 
 
Supplement Table 4: Clinical characteristics according to FASN SNP rs2229422 
genotypes in subjects without type 2 diabetes (N = 671). 
 rs2229422  
 TT TC CC p-value 
Frequency (%) 44.7 % 45.5 % 9.7 %  
Age (years) 46 ± 1 47 ± 1 48 ± 2  
BMI (kg/m2) 26.9 ± 0.3 27.6 ± 0.3 29.3 ± 0.8 0.002 
WHR 0.94 ± 0.01 0.96 ± 0.01 1.03 ± 0.03 0.007 
Fasting plasma glucose 
(mmol/l) 5.33 ± 0.03 5.34 ± 0.03 5.3 ± 0.06 0.28 
2-h plasma glucose 
(mmol/l) 6.75 ± 0.1 6.85 ± 0.11 7.29 ± 0.24 0.42 
Fasting  plasma insulin 
(pmol/l) 95 ± 10 124 ± 14 217 ± 47 0.03 
Glucose infusion rate 
(µmol/kg/min) 68.11 ± 2.52 64.81 ± 2.6 50.66 ± 6.28 0.04 
% body fat 28.62 ± 0.93 29.46 ± 0.92 32.0 ± 2.1 0.12 
HbA1c (%) 5.46 ± 0.02 5.46 ± 0.02 5.58 ± 0.06 0.59 
 
P-values for multivariate linear relationships were assessed by generalized linear model analyses in 
additive mode of inheritance (after adjusting for age and sex for variables BMI, % body fat and WHR, 
and for age, sex and BMI for remaining traits). 
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Aims The endocannabinoid system may contribute to the association of visceral fat 
accumulation with metabolic diseases. Here we investigated the effects of genetic variation in 
the cannabinoid type 1 receptor gene (CNR1) on its mRNA expression in adipose tissue from 
visceral and subcutaneous depots and on the development of obesity. Materials & Methods 
CNR1 was sequenced in 48 non related German Caucasians to detect genetic variation. Five 
representative variants including HapMap tagging single nucleotide polymorphisms (SNPs; 
rs12720071, rs806368, rs806370, rs1049353, rs806369) were genotyped for subsequent 
association studies in two independent cohorts (total N = 2774) with detailed metabolic 
testing: subjects from the Leipzig Study (N = 1857) and a self-contained population of Sorbs 
from Germany (N = 917). Results In a case-control study of lean (BMI < 25 kg/m2) vs. obese 
(BMI > 30 kg/m2) subjects, rs806368 was found to be nominally associated with obesity in 
the Sorbs cohort (adjusted p < 0.05), but not in the Leipzig cohort. Also, several SNPs 
(rs806368, rs806370, rs12720071) were nominally associated with serum leptin levels  
(p < 0.05 after adjusting for age, sex and BMI). However, none of these associations remained 
significant after accounting for multiple testing. Furthermore, none of the SNPs was related to 
CNR1 mRNA expression in visceral and subcutaneous fat. Conclusions The data suggest that 
common genetic variation in the CNR1 does not influence mRNA expression in adipose tissue 




Investigations into the mechanism of action of the major cannabis-derived 
psychotropic compound Δ9-tetrahydrocannabinol (THC) led to discovery of the 
endocannabinoid system (ECS) in the early 1990s (1). The ECS includes the cannabinoid 
receptor type 1 (CNR1) and 2 (CNR2), the endocannabinoids (ECs) anandamide and  
2-arachidonylglycerol (2-AG) and the EC anabolic and catabolic enzymes. The system 
participates in the control of food intake via both central and peripheral mechanisms, in lipid 
and glucose metabolism, and it may also stimulate lipogenesis and fat accumulation (2,3). 
CNR1 is present in human omental and subcutaneous adipocytes (4,5) and EC and CB1 levels 
are increased during adipocyte differentiation (6-9). Furthermore, CNR1 gene deficient mice 
are lean and resistant to diet-induced obesity (10,11). The EC system seems to be upregulated 
in human obesity (4) and abdominal fat accumulation is a critical correlate of dysregulation of 
the peripheral EC system (4,12,13). The importance of the ECS in the pathophysiology of 




obesity is further supported by the fact that pharmacologic blockade of the CNR1 with 
rimonabant leads to significant reduction of food intake and weight loss both in rodents and 
humans (2,14). Since maintenance of body weight is under genetic control modified by 
environmental factors, genetic variants affecting the EC system might be relevant players in 
the pathophysiology of obesity. It has been shown that a missense polymorphism (cDNA 385 
C→A) in fatty acid amide hydrolase (FAAH), one of the EC degrading enzymes, is associated 
with overweight and obesity in subjects of white and black ancestry, but not in Asians (15). 
By contrast, Jensen et al. did not find robust evidence of an association of the Pro129Thr 
FAAH variant with overweight or obesity, and any related quantitative traits in Danish 
subjects (16). Similarly, there have been controversial findings regarding the role of CNR1 
gene variants in the pathophysiology of obesity. While several study groups reported modest 
associations of CNR1 genetic variants with obesity and related traits (17-20), other studies 
could not confirm these findings (21,22). 
Recently, we demonstrated that CNR1 mRNA expression in visceral adipose tissue 
correlates with circulating 2-AG levels, percent body fat, visceral fat area, fasting plasma 
insulin (FPI) and insulin sensitivity determined by euglycemic-hyperinsulinemic clamps (12). 
Therefore, the aim of our present study was to investigate the influence of CNR1 SNPs on 
CNR1 mRNA expression in subcutaneous and visceral adipose tissue and on parameters 
related to the EC system. We sequenced CNR1 to detect new variation and examined the 
effects of CNR1 genetic variants on subphenotypes relevant to obesity in two distinct cohorts: 
one cohort from the city of Leipzig and one from the self-contained population of Sorbs in 
Germany. 
 
5.3 Materials & methods 
5.3.1 Leipzig cohort 
A total of 919 subjects without Type 2 diabetes (T2D; 739 subjects with normal 
glucose tolerance [NGT], 180 subjects with impaired glucose tolerance [IGT]) and 938 
patients with T2D, consecutively recruited at the University Hospital in Leipzig, Germany, 
were included in the study. The nondiabetic group included 304 males and 615 females (mean 
age 49.2 ± 13.7 years; mean body mass index (BMI) 28.14 [27.81; 28.48] kg/m2; mean waist-
to-hip ratio (WHR) 0.94 ± 0.17; mean fasting plasma glucose (FPG) 5.28 ± 0.56 mmol/l; 
mean fasting plasma insulin (FPI) 45.30 pmol/l [40.70; 50.40]). The patients with T2D 
included 484 males and 454 females (mean age 65 ± 11 years; mean BMI 29.20 [28.88; 
29.52] kg/m2; mean WHR 1.12 ± 0.14) (for normally distributed parameters data are given as 




arithmetic means ± standard deviation (SD) and for ln-normally distributed parameters the 
data represent geometric means and 95 % confidence intervals). 
Oral glucose tolerance tests (OGTT) were performed in all non-diabetic subjects as 
described previously (23). Since impaired glucose tolerance is a T2D predicting factor, only 
subjects with normal glucose tolerance (N = 739) were included as healthy controls in the 
T2D case-control study. In a subgroup of 396 NGT subjects, insulin sensitivity was assessed 
by euglycemic-hyperinsulinemic clamp performed as previously described (24). Percent body 
fat was measured by dual X-ray absorptiometry (DEXA). Only subjects without T2D were 
included in association analyses with SNPs in the obesity case-control study (N = 919;  
BMI ≤ 25 kg/m2, N = 313; BMI > 25 ≤ 30 kg/m2, N = 301; BMI > 30 kg/m2, N = 305) and in 
quantitative traits analyses. In a subgroup of 60 subjects, CNR1 mRNA, FAAH mRNA, sterol 
regulatory element-binding protein (SREBP1) mRNA expression in Vis and SC adipose tissue 
were available in addition to serum 2-AG and anandamide levels to analyze CNR1 genotype- 
phenotype associations (12). 
 
5.3.2 Measurement of obesity & glucose metabolism parameters 
BMI was calculated as weight (in kg) divided by the square of height (in meters). 
Waist and hip circumferences were measured and WHR was calculated. Basal blood samples 
were taken after an overnight fast. Plasma insulin was measured with an enzyme 
immunometric assay for the IMMULITE® automated analyzer (Diagnostic Products 
Corporation, CA, USA). Plasma leptin levels were assessed by radioimmunoassay (Linco 
Research, MO, USA). 
 
5.3.3 Sorbs cohort 
All subjects are part of a sample from a Sorbian isolate in Germany, the Sorbs. At 
present, approximately 1000 Sorbian individuals are enrolled in the study (25,26). Extensive 
phenotyping included standardized questionnaires for past medical history and family history, 
collection of anthropometric data (weight, height, WHR, body impedance analysis) and an 
OGTT. Insulin was measured with the AutoDELFIA® Insulin assay (PerkinElmer Life and 
Analytical Sciences, MA, USA). Serum glucose was measured by the hexokinase method 
(Automated analyzer Modular, Roche Diagnostics, Mannheim, Germany). A total of 917 
Sorbian subjects (534 female, 383 male; 725 subjects with NGT, 94 subjects with IGT and 98 
cases with T2D) were available for the present study (mean age 48 ± 16 years; mean BMI 
26.98 ± 4.93 kg/m2; mean WHR 0.88 ± 0.29; mean FPG 5.52 ± 1.13 mmol/l;  




mean FPI 33.65 [32.32; 35.03] pmol/l). Only subjects without T2D were included in 
association analyses with SNPs in the obesity case-control study (N = 819; BMI ≤ 25 kg/m2, 
N = 337; BMI > 25 but ≤ 30 kg/m2, N = 323; BMI > 30 kg/m2, N = 159) and in quantitative 
traits analyses. All studies were approved by the ethics committee of the University of 
Leipzig (Leipzig, Germany) and all subjects gave written informed consent before taking part 
in the study. 
 
5.3.4 DNA extraction & sequencing 
Genomic DNA was extracted using QIAmp® DNA Blood Mini Kit and QIAmp DNA 
Blood Midi Kit (Qiagen Inc., CA, USA) according to the manufacturer’s protocol. CNR1 
maps to chromosome 6q14–15. To identify genetic variants approximately 750 bp  
5’ upstream of exon 1, the exon 1 UTR, intron/exon splicing sites, the entire coding sequence 
(according to Ensembl ENST00000369501/ENSG00000118432 and NCBI GeneBank 
NM_016083), as well as 510 bp of the 3’-UTR were sequenced using the BigDye® 
Terminator (Applied Biosystems Inc., CA, USA) on an automated DNA capillary sequencer 
(ABI PRISM® 3100 Avant; Applied Biosystems Inc.). Sequence information for all 
oligonucleotide primers used for variant screening is available upon request. Sequence 
analysis was carried out using the SeqScape® software for Mutation Profiling version 2.1.1 
(Applied Biosystems Inc.) 
 
5.3.5 Genotyping of CNR1 SNPs 
Genotyping of selected SNPs was carried out using the human predesigned TaqMan® 
SNP genotyping assays (Applied Biosystems Inc.) for rs806370, rs806368, rs12720071, 
rs1049353 and rs806369. The genotyping reaction was amplified on a GeneAmp® PCR 2720 
system (Applied Biosystems) (95 °C for 15 min, 95 °C for 15 s and 60 °C for 1 min for 40 
cycles), using the ABsolute™ Blue QPCR Low ROX Mix (Thermo Fisher Scientific, MA, 
USA), and fluorescence was detected on an ABI PRISM® 7500 sequence detector (Applied 
Biosystems Inc.). To assess genotyping reproducibility, a random selection of approximately 
5 % of the samples was re-genotyped in all SNPs; all genotypes matched initial designated 
genotypes. In addition, 48 DNA samples used for sequencing were also genotyped. Again, 
genotypes matched initial designated genotypes obtained by direct sequencing, thus validating 
the accuracy of the genotyping method. 
 
 




5.3.6 Statistical analysis 
Prior to statistical analysis, non-normally distributed parameters were logarithmically 
transformed to approximate a normal distribution. For all normally distributed parameters 
data are given as arithmetic means ± SD, and for all logarithmically-normally distributed 
parameters the data represent geometric means and 95 % confidence intervals (CIs). 
Differences in genotype frequencies between the diabetic cases versus the healthy 
controls and the obese cases versus the lean controls were compared using logistic regression 
analyses, respectively. Multivariate linear relationships were assessed by generalized linear 
regression models. All analyses were carried out under the additive model unless stated 
otherwise and the presented p-values were adjusted for age, sex and BMI (for WHR, BMI and 
percent body fat as dependent variables, the analyses were adjusted for age and sex only).  
P-values of less than 0.05 were considered to provide nominal evidence for association and 
are presented without correction for multiple testing. The analysis of association with 
quantitative traits was restricted to nondiabetics to avoid diabetes status or treatment masking 
potential effects of the variants on these phenotypic traits. In the additive model, homozygotes 
for the major allele (MM), heterozygotes (Mm), and homozygotes for the minor allele (mm) 
were coded to a continuous numeric variable for genotype. A dominant model was defined as 
contrasting genotypic groups Mm + mm versus MM, and the recessive model was defined as 
contrasting genotypic groups MM + Mm versus mm. To assess the combined SNP effect in 
our two cohorts we performed a meta-analysis by using the metan command in STATA 
version 9.0 (StataCorp LP, TX, USA) based on the estimated effect sizes of each study, their 
standard error for quantitative traits and their confidence intervals for discrete traits (obesity). 
The meta-analysis was performed in a fixed-effects model by using the Mantel–Haenszel 
method. Statistical analyses were performed using SPSS version 15.0.1 (SPSS, Inc., IL, USA) 





The CNR1 was sequenced in DNA samples of 48 nonrelated subjects from Leipzig, 
Germany (12 healthy lean subjects, 12 lean subjects with T2D, 12 obese subjects with IGT 
and 12 obese subjects with T2D). Three novel variants were identified (-21029G>A, minor 
allele frequency (MAF) 0.011; -20803C>T, MAF 0.021; -20513A>G, MAF 0.011; positions 
relative to the translation initiation site). 




5.4.2 Association studies 
CNR1 polymorphisms with MAF greater than 0.05 were taken forward to genotype–
phenotype association analyses. Since all SNPs identified by sequencing had MAF of less 
than 0.05, only HapMap (101) tagging SNPs with MAF greater than 0.05 (rs806370, 
rs806369, rs1049353, rs12720071, rs806369; selection based on linkage disequilibrium with 
r2 > 0.8) were genotyped for subsequent genotype–phenotype association analyses. Genotype 
distribution for all SNPs was in Hardy–Weinberg equilibrium (p > 0.001). MAFs were 
comparable between both cohorts (Leipzig and Sorbs) and the call rates ranged from 93 to 
99% (Table 1). 
 
Table 1: CNR1 HapMap tagging SNPs. 
MAF Genotyping call rate SNP Change 
Leipzig cohort Sorbs cohort Leipzig cohort Sorbs cohort 
rs12720071 T>C 0.102 0.115 0.965 0.992 
rs806368 A>G 0.220 0.219 0.955 0.977 
rs806370 G>A 0.131 0.125 0.953 0.991 
rs1049353 C>T 0.260 0.249 0.948 0.984 
rs806369 G>A 0.298 0.304 0.944 0.973 
 
MAF: minor allele frequency 
 
5.4.3 Leipzig cohort 
None of the variants were associated with obesity in a case–control study (lean vs. 
obese) in 618 subjects without T2D (BMI ≤ 25 kg/m2, N = 313; BMI > 30 kg/m2, N = 305; 
adjusted for age and sex; Table 2). Inclusion of subjects with T2D into the regression models 
to increase sample size and statistical power did not change the results (data not shown). 
 
Table 2: Case-control analysis for obesity. 
SNP Subjects At-risk allele Odds ratio (95 % CI) p-value 
rs12720071 Leipzig cohort - 1.04 (0.67; 1.61) 0.88 
T>C Sorbs cohort - 1.04 (0.64; 1.70) 0.87 
 Combined analyses  1.04 (0.75; 1.44) 0.84 
rs806368 Leipzig cohort - 1.08 (0.79; 1.48) 0.62 
A>G Sorbs cohort G 1.51 (1.03; 2.21) 0.03* 
 Combined analyses  1.24 (0.97; 1.57) 0.08 
rs806370 Leipzig cohort - 1.14 (0.77; 1.68) 0.51 
G>A Sorbs cohort - 1.36 (0.87; 2.13) 0.17 
 Combined analyses  1.23 (0.92; 1.65) 0.17 
rs1049353 Leipzig cohort - 0.86 (0.63; 1.15) 0.31 
C>T Sorbs cohort - 0.89 (0.62; 1.27) 0.52 
 Combined analyses  0.87 (0.69; 1.09) 0.22 
rs806369 Leipzig cohort - 0.98 (0.72; 1.33) 0.91 
G>A Sorbs cohort - 1.07 (0.76; 1.50) 0.72 
 Combined analyses  1.02 (0.81; 1.28) 0.90 




Table 2 cont.: Case-control study in lean (BMI ≤ 25 kg/m2) vs. obese (BMI > 30 kg/m2) subjects. Odds 
ratios represent the effects of minor alleles. *significant in a dominant mode of inheritance. 
 
Association analysis of genetic variants on quantitative traits (BMI, WHR, percent 
body fat, FPG and FPI, 2-h plasma glucose, glucose infusion rate, lipids, leptin and 
adiponectin) in 919 subjects without T2D demonstrated nominal association of the 
rs12720071 C allele, rs806368 G allele and rs806370 A allele with lower leptin levels (all  
p < 0.05, Table 3). This did not withstand Bonferroni correction for multiple testing, which 
would require p-values of 0.001 to be considered statistically significant (accounting for five 
SNPs and eight traits). However, since Bonferroni correction is rather strict (i.e., potentially 
biologically interesting association may be rejected) and the five SNPs in CNR1 are not 
completely independent (some degree of linkage disequilibrium – r2 reaching up to 0.50), we 
also analyzed data by considering only eight quantitative traits when adjusting for multiple 
testing. Under these conditions we would achieve statistical significance for the association 
between rs806368 and circulating leptin (p = 0.003) (Table 3). None of the other traits 
showed evidence for association. 
 
Table 3: Association of CNR1 SNP variants with quantitative traits in the Leipzig (A) 
and the Sorbs (B) cohort. 






fat Leptin AdipoQ 
rs127200711         
p-value 0.959 0.782 0.458 0.100 0.146 0.1001 0.0071 0.9311 
β 0.001 -0.004 0.007 -0.036 0.182 -0.075 -0.341 0.008 
SE 0.013 0.013 0.009 0.022 0.125 0.045 0.126 0.098 
Combined β  
















   
Combined 
p-value 0.639 0.302 0.822 0.302 0.466    
rs806368         
p-value 0.980 0.805 0.868 0.840 0.125 0.317 0.003*# 0.589 
β -0.0002 0.002 0.001 -0.003 0.124 -0.029 -0.240 -0.033 
SE 0.009 0.009 0.006 0.015 0.081 0.029 0.081 0.061 
Combined β  
















   
Combined 
p-value 0.278 0.821 0.570 0.991 0.072    
rs806370         
p-value 0.846 0.519 0.705 0.367 0.909 0.911 0.044 0.824 
β 0.002 0.007 -0.003 0.017 -0.011 -0.004 -0.204 -0.016 
SE 0.011 0.011 0.008 0.018 0.100 0.034 0.101 0.071 
Combined β  
















   
Combined 
p-value 0.949 0.469 0.758 0.447 0.381    




Table 3 cont. 
rs1049353         
p-value 0.714 0.627 0.536 0.461 0.239 0.096 0.079 0.911 
β 0.003 -0.004 0.004 0.011 0.096 0.049 0.145 -0.007 
SE 0.009 0.009 0.006 0.015 0.082 0.029 0.082 0.062 
Combined β  
















   
Combined 
p-value 0.735 0.409 0.733 0.983 0.229    
rs806369         
p-value 0.413 0.934 0.300 0.692 0.248 0.448 0.757 0.697 
β -0.007 -0.001 -0.006 0.006 -0.091 -0.022 0.024 0.023 
SE 0.009 0.009 0.006 0.014 0.078 0.029 0.078 0.059 
Combined β  
















   
Combined 
p-value 0.625 0.589 0.627 0.768 0.963    
         





   
rs12720071         
p -value 0.434 0.259 0.946 0.831 0.761    
β 0.009 -0.012 -0.0004 0.005 0.012    
SE 0.011 0.011 0.004 0.023 0.040    
rs806368         
p -value 0.108 0.643 0.565 0.827 0.314    
β 0.014 -0.004 0.003 0.004 -0.032    
SE 0.009 0.008 0.005 0.018 0.031    
rs806370         
p -value 0.800 0.722 0.873 0.965 0.380    
β 0.003 0.004 0.004 0.001 -0.034    
SE 0.011 0.010 0.006 0.022 0.038    
rs1049353         
p -value 0.456 0.110 0.277 0.432 0.095    
β -0.006 0.012 -0.005 -0.013 -0.049    
SE 0.008 0.008 0.005 0.016 0.029    
rs806369         
p -value 0.965 0.490 0.759 0.358 0.638    
β 0.0003 -0.005 0.001 -0.015 0.014    
SE 0.008 0.008 0.005 0.016 0.029    
 
The dataset included subjects with normal glucose tolerance and impaired glucose tolerance (N = 919, 
except for percent body fat, leptin and adiponectin (AdipoQ; N = 300). p-values were calculated after 
adjusting for age and gender for the variables BMI, WHR and percent body fat; and for age, gender 
and BMI for the remaining variables. ß indicates effect directions of the minor alleles. p-values are 
given for the additive model. 1Owing to small sample size (< 6 genotypes for minor allele 
homozygotes), a dominant model was used for the variables percent body fat, leptin and adiponectin 
for the SNP rs12720071. */# significant in dominant/recessive mode of inheritance. OGTT: oral 
glucose tolerance test; PG: plasma glucose; WHR: Waist –to-hip ratio. 
 
 




5.4.4 Sorbs cohort 
The CNR1 variant rs806368 G allele was nominally associated with obesity in a case–
control study (lean vs. obese; BMI ≤ 25 kg/m2, N = 337; BMI > 30 kg/m2, N = 159; Table 2). 
Including T2D subjects (N = 98) to increase sample size resulted in a nominal significance  
(p = 0.035 in a recessive mode of inheritance), which did not, however, withstand corrections 
for multiple testing. None of the remaining variants were associated with obesity. Association 
analysis of genetic variants on quantitative traits (BMI, WHR, FPG and FPI, 2-h plasma 
glucose, lipids, leptin and adiponectin) in 819 subjects without T2D demonstrated no 
association for any of the SNPs (Table 3). Furthermore, the combined analysis for obesity, 
including both the Sorbs and the Leipzig cohort, did not demonstrate statistically significant 
associations of the SNPs with tested parameters either (Table 3). 
 
5.4.5 CNR1 genetic variants & fat-depot-specific CNR1 mRNA expression 
In the subgroup of 60 subjects for which CNR1 mRNA expression data in 
subcutaneous and visceral fat depots were available, no significant association was found 
between the CNR1 genotype and CNR1 mRNA expression in either depot (data not shown). 
However, rs806368 G allele and rs806370 A allele were nominally associated with higher  
2-AG levels (p < 0.05; Figure 1) in this group. We also looked at the Duke SNPExpress 
database, which permits interrogation of the effects of common SNPs on exon- and transcript-
level expression in two different human tissues: brain and peripheral blood mononuclear cells 
(29,102). None of the SNPs were associated with the transcript level of CNR1 both in brain 
and in peripheral blood mononuclear cells. 
 


































Figure 1. Mean 2-arachidonylglycerol in nondiabetic subjects (N = 60) of the Leipzig cohort 
grouped by CNR1 variant genotypes. *Indicates nominal association at a p-value of less than 0.05 in 
generalized linear model analyses after adjusting for age, sex and BMI. 
 
5.5 Discussion 
The maintenance of bodyweight is under genetic control but, rarely, mutations in 
single genes can result in severe obesity. In the pathophysiology of common obesity, multiple 
genes, environmental factors and gene–environment interactions play a crucial role (18). 
Since it has been demonstrated that overweight and obesity are associated with a missense 
polymorphism in FAAH, one of the EC degrading enzymes (15), other genes of the EC 
system have become potential targets for genotype–phenotype association studies. Therefore, 
the CNR1 was investigated as a plausible obesity candidate gene in the present study. We 
evaluated the effects of five representative variants within the CNR1 locus on CNR1 mRNA 
levels in visceral and subcutaneous adipose tissue and performed association studies in two 
independent cohorts with detailed metabolic testing from Eastern Germany (Leipzig cohort 
and a self-contained population of Sorbs). Using a case–control design with lean versus obese 
subjects, rs806368 was found to be nominally associated with obesity in the Sorbs cohort, but 
not in the Leipzig cohort. These differences between the cohorts might be attributed to 
different genetic structure within the examined CNR1 locus. However, linkage disequilibrium 
patterns in both cohorts were comparable and thus, the genetic information of these two 
populations seems to be well represented by the selected tagging SNPs. The association 
differences might rather originate from different lifestyles. Unfortunately we could not 
address this directly since lifestyle data were only available for the Sorbs cohort. Also, the 
small sample size of both cohorts might account for differences in association results. Several 
SNPs (rs806368, rs806370 and rs12720071) were nominally associated with circulating leptin 
concentrations. However, none of these associations remained significant after adjusting the 
analyses for multiple comparisons. Although it has been demonstrated that CNR1 mRNA 
expression correlates with EC serum concentrations and parameters of obesity, fat distribution 
and insulin sensitivity (12), no relationship between the SNPs and CNR1 mRNA expression 
was observed in the present study. So far, research on the relationship between CNR1 genetic 
variants and obesity has generated rather controversial results (Supplementary Table 1, 
www.futuremedicine.com/doi/suppl/10.2217/pgs.10.42/suppl_file/suppl_table.doc). In a 
southern Italian population, the CNR1 rs1049353 wild-type genotype (CC) demonstrated a 
trend towards increased BMI (18). By contrast, the T allele of this variant was found to be 




associated with abdominal adiposity in obese men from Belgium (30). Furthermore, 
rs12720071 C allele was found to be associated with increased subscapular skinfold thickness 
and waist circumference in men in the Olivetti Prospective Heart Study (OPHS) (20). Another 
polymorphism, rs806368, was associated with WHR in a southern Brazilian population (19), 
but not in others (20). Müller et al. did not find evidence for an association of several SNPs in 
CNR1 with obesity in their samples, comprising 364 obesity trios and 235 independent obese 
families (22). The largest study so far, including 5750 subjects, demonstrated that CNR1 
variants (rs2023239 and rs806381) increased the risk for obesity and modulated BMI in a 
European population of French origin (17). However, consistent with our study, no 
association of CNR1 SNPs with BMI, waist circumference and visceral adipose tissue or 
subcutaneous adipose tissue mass was observed very recently in the well-characterized 
Framingham study cohort (31). It needs to be mentioned that although not reaching the 
threshold for statistical significance for genome-wide association, one SNP (rs10485170) near 
CNR1 was demonstrated to be associated with obesity in a stage 2 confirmation design in a 
genome-wide association study reported by Meyre et al. (32). At the same time no 
associations of CNR1 variants have been reported in a genome-wide association study on 
obesity or T2D. Interestingly, we found rs806368 G and rs806370 A alleles nominally 
associated with lower serum leptin but higher 2-AG levels. Defective leptin signalling is 
associated with elevated hypothalamic but not cerebellar levels of ECs in obese db/db and 
ob/ob mice and Zucker rats (33). Acute leptin treatment of normal rats and ob/ob mice 
reduces anandamide and 2-AG in the hypothalamus. Thus Di Marzo et al. suggested that ECs 
in the hypothalamus may tonically activate CB1 receptors to maintain food intake and form 
part of the neuronal circuitry regulated by leptin (33). However, it seems unlikely that variants 
in CNR1 regulate leptin levels but have no effect on obesity or CNR1 expression as 
demonstrated for adipose tissue in our study. 
Our data are in accordance with most other previous studies (Supplement Table 1, 
www.futuremedicine.com/doi/suppl/10.2217/pgs.10.42/suppl_file/suppl_table.doc; [34,35]) 
and suggest that genetic variation in the CNR1 gene may have only a very modest effect on 
the development of human obesity. We are aware that the statistical power of our study is 
limited owing to small sample size. In our cohorts we had a power of 80% (at α = 0.05) to 
detect a difference of 0.57–1.01 kg/m2 per allele for BMI, 0.17–0.28 mmol/l for FPG,  
3.99–52.30 pmol/l for FPI, 0.36–0.74 mmol/l for 2-h plasma glucose during an OGTT under 
the additive model. Similarly, in the case–control studies for obesity, we had a power of 80 % 
(at α = 0.05) to detect SNP effects with odds ratios ranging from 1.27 to 1.41 and from 1.26 




to 1.37 in the Leipzig and Sorbs cohorts, respectively. Since the reported effect sizes for 
obesity SNPs are usually lower (odd ratios of 1.1–1.2), smaller effects may have been missed 
in our studies. Also, the small sample size for the mRNA expression study limits the 
significance of the analysis. Therefore, we cannot rule out that genetic variation in CNR1 may 
have minor effects on obesity development, which are probably not clinically significant. In 
conclusion, our data indicate that common CNR1 genetic variants may not play a significant 
role in the pathophysiology of obesity in German and Sorbian populations, but it is possible 
that rare functional variants of this gene contribute to the development of obesity. However, 
these variants are hard to detect owing to current sample size. 
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5.8 Executive summary 
Executive summary 
• The Endocannabinoid system participates in the control of food intake, lipid and glucose 
metabolism. 
• The Endocannabinoid system seems to be upregulated in human obesity. 
• The cannabinoid receptor 1 (CNR1) is present in human omental and subcutaneous 
adipocytes. 
• Pharmarcologic blockade of CNR1 with rimonabant leads to significant reduction of food 
intake and weight loss. 
Material & methods 
• The CNR1 gene was sequenced in 48 unrelated subjects to identify genetic variants. 
• Five tagging SNPs with a minor allele frequency of greater than 5 % were genotyped in 
healthy subjects and patients with type 2 diabetes from 2 extensively phenotyped German 
cohorts (Leipzig cohort and Sorbs cohort). 
• Association studies: logistic regression analyses were used in case-control studies for 
obesity; for quantitative traits multivariate linear relationships were assessed by 
generalized linear regression models. 
Results 
• Three novel variants were identified through sequencing. 
• None of the variants was associated with obesity in a case-control study in the Leipzig 
cohort. 
• Association analysis of genetic variants on quantitative traits revealed nominal 
association of rs12720071 C allele, rs806368 G allele and rs806370 A allele with lower 
leptin levels. 
• In the Sorbs cohort, the CNR1 variant rs806368 G allele was nominally associated with 
obesity in a case-control study 
• Association analysis of genetic variants on quantitative traits demonstrated no association 
for any of the SNPs in the Sorbs cohort. 
• No significant association was found between CNR1 genotype and CNR1 mRNA 
expression in omental or subcutaneous fat depot in a subgroup of 60 subjects from the 
Leipzig cohort. 
Discussion 
• So far, research on the relationship between CNR1 genetic variants and obesity has 
generated rather controversial results. 
Conclusion 
• Genetic variation in the CNR1 gene may not play a significant role in the 
pathophysiology of obesity in German and Sorbian populations.  
• It can not be ruled out that rare functional variants contribute to the development of 
obesity; large scale association studies will be inevitable to clarify this. 
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Supplement Table 1: Summary of genetic studies investigating the role of CNR1 variants 
in human obesity. 
Reference Investigated 
CNR1 SNPs 
Cohorts Main findings/Associations 
Gazzerro P 
et al. (18)  
rs1049353 C/T 200 subjects from 
southern Italy  
(> 65 years) 
obesity (p = 0.03) and BMI (p = 0.006) 
Aberle J  
et al. (34)  
rs1049353 C/T 451 German 
subjects (obese, 
dyslipidaemic, 
under low fat diet) 
No significant association with BMI. 
Russo P 
et al. (20)  
rs12720071 T/C 
rs806368 A/G 
1) 930 men from 
southern Italy (part 
of OPHS study 
population)  
2) 216 white men 
(part of WHSS 
study population) 
1) rs12720071: WC (p = 0.05) 
and SS (p = 0.031); 
 
 
2) rs12720071: WC (p = 0.006) and BMI  
(p = 0.012); rs806368: WC (p = 0.047) 
Müller TD 












1) 364 German 
obesity trios 
(extremely obese 
child or adolescent 





2) 235 independent 
German obese 
families (at least 
two obese sibs and 
both parents) 
1) TDT negative for these SNPs; slight trend 








2) trend from 1) not confirmed 




Supplement Table 1 cont. 
Peeters A 
et al. (30) 
rs1049353 C/T 1064 obese subjects 
(BMI ≥ 30 kg/m2) 
without diabetes & 
IGT & 251 healthy 
controls from 
Belgium 
Obese men: WHR (p = 0.009) and WC ( p= 0.008) 
(after Bonferroni correction) 
Jaeger JP  
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rs806366: BMI (p = 0.025), HDL-C (p = 0.0001),  
TG (P = 0.033);  
rs806368: LDL-C (p = 0.032), TG (p = 0.0001); 
rs806369: TG (p = 0.026); 
rs806370: HDL-C (p = 0.038) 
Lieb W 
et al. (31)  
18 SNPs 2415 subjects from 
the Framingham 
Offspring Study   
No association for obesity and related traits after 
correction for multiple testing. 
Benzinou M 
















with No. 2) 
SNPs  
1) 1932 obese cases 
and 1173 non-obese 




2) 2645 individuals 
(Swiss obese 
subjects and Danish 
individuals) 
3) No. 1) initial 
case-control study 
1) nominal evidence of association with childhood 
obesity and/or adult obesity for 12 SNPs  
(1.16 < OR < 1.40, 0.00003 < p < 0.04); rs806381 
and rs2023239 resisted correction for multiple 
testing 
 
2) BMI in Swiss obese (p = 0.015; p = 0.02) and 
Danish individuals (p = 0.0023; p = 0.021) 
 
 
3) rs10485170 T/C with adult obesity (p = 8x10-6) 
and rs6454674 A/C with childhood obesity  
(p = 1x10-5) 
 
Genome wide association studies are excluded. Results of haplotype analyses were not included in the 
table. SNP alleles are given in reverse strand orientation. SNP = single nucleotide polymorphism; IGT 
= impaired glucose tolerance; OR = odds ratio; WHR = waist to hip ratio; BMI = body mass index; 
WC = waist circumference; SS = subscapular skinfold thickness; HDL-C = high density lipoprotein 
cholesterol; TG = triglyceride; LDL-C = low density lipoprotein cholesterol; TDT = transmission 
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Objective: Human bone morphogenetic protein receptor 2 (BMPR2) is essential for 
BMP signalling and may be involved in the regulation of adipogenesis. The BMPR2 locus has 
been suggested as target of recent selection in human populations. We hypothesized that 
BMPR2 might have a role in the pathophysiology of obesity. Research design & methods: 
Evolutionary analyses (dN/dS, Fst, iHS) were conducted in vertebrate and human populations. 
BMPR2 mRNA expression was measured in 190 paired samples of visceral and subcutaneous 
adipose tissue. The gene was sequenced in 48 DNA samples. Nine representative single 
nucleotide polymorphisms (SNPs) were genotyped for subsequent association studies on 
quantitative traits related to obesity in 1830 German Caucasians. An independent cohort of 
925 Sorbs was used for replication. Finally, relation of genotypes to mRNA in fat was 
examined. Results: The evolutionary analyses indicated signatures of selection on the BMPR2 
locus. BMPR2 mRNA expression was significantly increased both in visceral and 
subcutaneous adipose tissue of 37 overweight (BMI > 25 and < 30 kg/m2) and 80 obese  
(BMI > 30 kg/m2) compared with 44 lean subjects (BMI < 25 kg/m2) (p < 0.001). In a case-
control study including lean and obese subjects, two intronic SNPs (rs6717924, rs13426118) 
were associated with obesity (adjusted p < 0.05). Combined analyses including the initial 
cohort and the Sorbs confirmed a consistent effect for rs6717924 (combined p = 0.01) on 
obesity. Moreover, rs6717924 was associated with higher BMPR2 mRNA expression in 
visceral adipose tissue. Conclusion: Combined BMPR2 genotype-phenotype-mRNA 
expression data as well as evolutionary aspects suggest a role of BMPR2 in the 
pathophysiology of obesity. 
 
6.2 Introduction 
Despite recent advances achieved by genome wide association studies (1-3), the 
genetic factors contributing to the development of obesity are still elusive. The prevalence of 
obesity has increased particularly during the past 50 years. Since it is rather unlikely that 
human genotypes changed significantly during this period, it was probably the advent of 
Western lifestyle and unrestricted food availability that caused this dramatic increase. A 
popular theory to explain this observation is the “thrifty genotype” hypothesis (4) proposing 
that humans with a genetically increased capacity to store energy had an evolutionary 
advantage, since they were more likely to survive periods of food scarcity. However, in 
modern societies with easy access to high-caloric food and very little physical activity this 
genotype results in obesity. Although the hypothesis has been widely accepted, a clear 




approach to identify “thrifty” genes has not yet been postulated. However, the availability of 
high density single nucleotide polymorphism (SNP) genotyping arrays as well as rapidly 
emerging bioinformatics tools offer a possibility to reveal selective forces on loci dispersed 
throughout the genome. Employing these approaches, bone morphogenetic protein receptor 2 
gene (BMPR2) was suggested as one of the potential targets of recent selection in European 
populations (5). Bone morphogenetic proteins (BMPs) are members of the transforming 
growth factor-β (TGF-β) superfamily and are involved in the control of multiple key steps of 
embryonic development and differentiation (6-8). BMPs are involved in adipocyte 
development, including adipose cell fate determination, differentiation of committed 
preadipocytes, and function of mature adipocytes (9). BMP signalling requires the formation 
of heteromeric complexes of BMP type 1 (BMPR1) and type 2 receptors (BMPR2) (10-12). 
Following BMP binding either to a single receptor type subunit followed by the recruitment 
of the second subunit or binding to a pre-existing loose complex of both receptor types, two 
downstream signalling cascades are activated: 1) SMAD proteins or 2) p38 mitogen activated 
protein kinase (p38MAPK) pathways (13). Over-expression of constitutively active BMP 
receptor 1A or 1B induces the commitment of C3H10T1/2 stem cells into adipocytes even in 
the absence of BMP2/4 (14). We could recently show that BMPR1A mRNA expression in 
both visceral and subcutaneous adipose tissue as well as genetic variants in this gene strongly 
correlated with obesity and its related traits (15). BMPR2, a serine threonine kinase located on 
chromosome 2q33-q34, is responsible for the trans-phosphorylation of BMPR1, further 
suggesting BMPR2 as candidate gene for obesity. 
Here, we initiated studies searching for signatures of selection for BMPR2 in 
vertebrates and human populations. We analysed the coding region of BMPR2 orthologs with 
the Phylogenetic Analysis by Maximum Likelihood (PAML). Furthermore, we used 
Haplotter/PhaseII database to screen for selection patterns within the BMPR2 locus including 
intronic regions. Since BMPR2 is also a plausible obesity candidate gene, we searched for 
evidence supporting the “thrifty gene” hypothesis by investigating its potential role in the 
pathophysiology of human obesity. We measured the expression of BMPR2 mRNA in paired 
samples of human visceral and subcutaneous adipose tissue in subjects who had undergone 
detailed metabolic testing. To determine, whether genetic variants in the BMPR2 are related to 
adipose tissue BMPR2 mRNA expression and to the obese human phenotype, we sequenced 
the BMPR2 and evaluated the association between representative variants and obesity related 
traits in two independent Caucasian cohorts from Germany. 
 




6.3 Research design and methods 
6.3.1 Study subjects 
Leipzig cohort: A total of 930 patients with type 2 diabetes (T2D) and 900 non-
diabetic subjects recruited at the University Hospital in Leipzig (Germany) were included in 
the study. Healthy subjects included 288 males and 612 females (mean age 49 ± 14 years; 
mean BMI 28.7 ± 5.7 kg/m2; mean WHR 0.94 ± 0.17; mean fasting plasma glucose  
5.29 ± 0.57 mmol/l; mean fasting plasma insulin 124 ± 228 pmol/l). Patients with T2D 
included 475 males and 455 females (mean age 64 ± 11 years; mean BMI 29.7 ± 5.4 kg/m2) 
(data are given as arithmetic means ± SD). In addition, oral glucose tolerance test (OGTT) 
and fasting plasma insulin measurements were performed in all non-diabetic subjects as 
previously described elsewhere (16). In a subgroup of 374 non-diabetic subjects, insulin 
sensitivity was assessed with euglycemic-hyperinsulinemic clamps and plasma leptin and 
adiponectin measurements were carried out. 
 
Tissue studies: Paired samples of visceral and subcutaneous adipose tissue were 
obtained from a subgroup of 190 Caucasian men (N = 91) and women (N = 99), who 
underwent open abdominal surgery (described in detail elsewhere) (16). The age ranged from 
16 to 99 years and body mass index from 21 to 55 kg/m2. In these subjects, in addition to 
above mentioned clinical parameters, abdominal visceral and subcutaneous fat area was 
calculated using computed tomography scans at the level of L4-L5 and percent body fat was 
measured by dual-energy X-ray absorptiometry (DEXA). 
 
Assays and measures of obesity and glucose metabolism: Fasting plasma insulin was 
measured with an enzyme immunometric assay for the IMMULITE automated analyzer 
(Diagnostic Products Corporation, Los Angeles, CA, USA). Plasma leptin levels were 
assessed by radioimmunoassay (Linco Research, St. Charles, Mo, USA). The OGTT was 
performed after an overnight fast with 75 g standardized glucose solution (Glucodex Solution 
75 g; Merieux, Montreal, Canada) and insulin sensitivity was assessed with the euglycemic-
hyperinsulinemic clamp method as described elsewhere (17;18). 
 
Sorbs cohort: The cohort was derived from the self-contained Sorbs population in 
Germany. Extensive phenotyping included standardized questionnaires for past medical 
history and family history, collection of anthropometric data (weight, height, WHR) and 
OGTT (diabetes definition according to the ADA criteria) (19). Insulin was measured with the 




AutoDELFIA®Insulin assay (PerkinElmer Life and Analytical Sciences, Turku, Finland). 
Nine hundred twenty five Sorbs (740 subjects with normal glucose tolerance (NGT),  
79 subjects with impaired glucose tolerance (IGT) and 106 cases with T2D; 542 females,  
383 males) were available for the present study (mean age 48 ± 16 years; mean BMI  
27.0 ± 4.9 kg/m2; mean WHR 0.87 ± 0.10; mean fasting plasma glucose 5.54 ± 1.18 mmol/l; 
mean fasting plasma insulin 40.7 ± 27.4 pmol/l). 
 
All studies were approved by the ethics committee of the University of Leipzig and all 
subjects gave written informed consent before taking part in the study. 
 
6.3.2 Evolutionary analyses 
We analysed patterns of evolution at the codon level across the BMPR2 phylogeny 
(Supplement Figure 1a). The non-synonymous to synonymous substitution rate ratio 
(ω=dN/dS) of 36 BMPR2 orthologs (http://www.ensembl.org,http://www.ncbi.nlm.nih.gov/ 
gene; Supplement Figure 1a,b) was estimated by maximum likelihood methods (20) using the 
CODEML program (PAML4a package) (21;22). In addition, phased (PHASE version 2.1) 
(23;24) SNP data of the HapMap populations (Europeans, Yoruba, Chinese, Japanese) were 
analysed for signatures of selection with DnaSP (version 5.00.03) (25), Sweep 1.8.1 and the 
Haplotter/PhaseII (http://hg-wen.uchicago.edu/ selection/haplotter.htm). Provided are 
population genetic measures which comprises the fixation index (Fst) and standardized 
integrated haplotype score (iHS) (5). 
 
6.3.3 Analysis of human BMPR2 mRNA expression  
Human BMPR2 expression was measured by quantitative real-time RT-PCR using 
SYBR Green methodology and fluorescence was detected on an ABI PRISM® 7500 sequence 
detector (Applied Biosystems, Darmstadt, Germany) as described in detail elsewhere (16). 
The following primers were used: human BMPR2 (NCBI accession no NM_001204.5)  
5'-CTTTACTGAGAATTTTCCACCTCCTG-3' (sense) and 5'-GCCAAAGCAATGATTAT 
TGTCTCATC-3' (antisense). Human BMPR2 mRNA expression was calculated relative to the 
mRNA expression of 18S rRNA, determined by a premixed assay on demand for human  
18S rRNA (PE Biosystems, Darmstadt, Germany). For 29 samples BMPR2 cDNA 
amplification failed and therefore, only 161 were included in the study. 
 
 




6.3.4 Sequencing of the BMPR2  
Sequencing of the BMPR2 (13 exons, exon-intron boundaries; NM_001204 in the 
NCBI GenBank; 1271 bp in the 5’ region and 1282 bp in the 3’ UTR) in 48 non-related 
Caucasian subjects (12 lean subjects with NGT, 12 visceral obese, 12 subcutaneously obese, 
12 with T2D) was performed using the BigDye® Terminator (Applied Biosystems, Inc., 
Foster City, CA) on an automated DNA capillary sequencer (ABI PRISM® 3100 Avant; 
Applied Biosystems Inc., Foster City, CA). Sequence information and PCR conditions for all 
oligonucleotide primers used for variant screening are available upon request. 
 
6.3.5 Genotyping of BMPR2 SNPs 
SNP genotyping was done using the TaqMan® SNP Genotyping assay according to 
the manufacturer’s protocol (Applied Biosystems, Inc., Foster City, CA). To assess 
genotyping reproducibility, a random ~5 % selection of the sample was re-genotyped in all 
SNPs; all genotypes matched initial designated genotypes. 48 samples used for sequencing 
were also re-genotyped by TaqMan® technique and perfectly matched the genotypes 
determined by sequencing. 
 
6.3.6 Statistical analyses  
Prior to statistical analysis, non-normally distributed parameters were ln-transformed 
to approximate a normal distribution. Differences in genotype frequencies between the obese 
or diabetic cases and healthy controls were compared using logistic regression analyses. 
Multivariate linear relationships were assessed by generalized linear regression models. All 
analyses were done under the additive model and the presented p-values are adjusted for age, 
sex (and BMI for glucose traits). Differences in mRNA expression between visceral and 
subcutaneous adipose tissue were assessed using the paired Student’s t-test. Two-sided  
p-values < 0.05 were considered to provide nominal evidence for association and are 
presented without correction for multiple hypothesis testing. The analysis of associations with 
quantitative traits was restricted to non-diabetics to avoid diabetes status or treatment masking 
potential effects of the variants on these phenotypic traits. To obtain the combined effect of 
our two cohorts we performed a meta-analysis by using the METAL software (26). The meta-
analysis was performed in a fixed effects model by using the Mantel-Haenszel method. 
Statistical analyses were performed using SPSS version 18 (SPSS, Inc.; Chicago, IL) and 
STATA (version 9.0), (StataCorp LP, Texas, USA). 
 





6.4.1 Evolutionary analyses 
The dN/dS analyses revealed that the BMPR2 is highly conserved among the 36 
species analysed (average ω = 0.1278; Supplement Figure 1), hence being subjected to an 
overall purifying selection. Positional analyses indicate that 53.6 % of positions are very 
strongly conserved, ω = 0.0037, 40.6 % are strongly conserved, ω = 0.1247, and 5.7 % are 
conserved, ω = 0.9974 (Figure 1). Except for one, none of the SNPs shows striking frequency 
differences between the observed populations as indicated by the fixation index Fst  
(Fst < 0.2). For rs4675278, Fst-values indicate differences between European and East Asian 
populations (European vs. Chinese Fst = 0.2760, European vs. Japanese Fst = 0.3703), which 
is reflected in different allele frequencies and a change of minor allele: European: 0.267  
A-allele; Chinese: 0.211 G-allele; Japanese: 0.136 G-allele, Yoruba: 0.442 A-allele. The 
integrated haplotype score (iHS) is based on the differential levels of linkage disequilibrium 
surrounding a positively selected allele compared to the background allele at the same 
position (Supplemental Table 1) (5). For the European population iHS values below -2 were 
found for rs1980153 and rs16839127 (Supplement Table 1), i.e., haplotypes on the derived 
allele background are longer compared to ancestral allele background. In contrast for 








Figure 1: Site class probability bar plot for each codon across the BMPR2 sequence indicating 
strength of conservation at each amino acid position. The degree of negative selection is equivalent 
to the strength of conservation. Included are 36 vertebrate orthologs. Human sequence was used as 
reference. Genetic domains above are annotated according to http://www.uniprot.org/uniprot/Q13873. 
Numbers represent the location of the domains (amino acids). 
 
6.4.2 Visceral and subcutaneous BMPR2 mRNA expression and obesity 
Analysis of 161 paired samples of visceral and subcutaneous adipose tissue showed 
significantly higher BMPR2 transcript levels in subcutaneous compared with visceral fat, 
independent of gender (Figure 2a). Even though the mRNA expression in men tended to be 
higher than in women, the gender differences did not reach statistical significance (Figure 2a). 
To investigate the expression according to body fat mass or fat distribution, we performed 
additional analyses in subgroups of lean (BMI < 25 kg/m2), overweight (25 kg/m2 < BMI < 30 
kg/m2), and obese (BMI > 30 kg/m2) subjects. Based on CT scans measurement (L4-L5) of 
abdominal visceral and subcutaneous fat areas, obese subjects were further categorized as 
predominantly visceral (Vis) or subcutaneous (SC) obese as defined by a ratio of Vis/SC fat 
area > 0.5 (16). BMPR2 mRNA expression was significantly increased in both visceral and 
subcutaneous adipose tissue of 37 overweight and 80 obese (57 subcutaneously obese and 23 
visceral obese) compared with 44 lean subjects (p < 0.001) (Figure 2b). Interestingly, the 
difference in BMPR2 mRNA expression between visceral and subcutaneous adipose tissue 
was only seen in lean individuals, but not in overweight or obese subjects (Figure 2b). We 
further asked whether impaired glucose metabolism in patients with either IGT (N = 15) or 
T2D (N = 30) may be associated with altered BMPR2 mRNA expression in different fat 
depots. Subgroup analyses demonstrated that IGT and T2D subjects were indistinguishable 
with regard to BMPR2 mRNA expression; therefore these groups were analysed together. 
Patients with IGT/T2D had significantly higher BMPR2 mRNA expression in both visceral 
and subcutaneous fat compared to NGT (N = 116) subjects (Figure 2c). We detected a 
significant correlation between visceral and subcutaneous BMPR2 mRNA expression (Figure 
3a). 
 
































































































Figure 2: BMPR2 mRNA expression in visceral (Vis) and subcutaneous (SC) adipose tissue in 
lean, obese and type 2 diabetic subjects. The data are means ± SEM; BMPR2 mRNA levels in (a) 
men (N = 80) and women (N = 81), (b) subgroups of lean (BMI < 25kg/m2; N = 44), overweight (25 
kg/m2 < BMI < 30 kg/m2; N = 37), SC obese (N = 57) and Vis obese (N = 23) (BMI > 30 kg/m2); (c) 
subjects with normal glucose tolerance (NGT; N = 116) and with impaired glucose tolerance (IGT; N 
= 15) or with type 2 diabetes (T2D; N = 30). * and *** indicate statistical significance at p<0.05 and  
p < 0.001, respectively when compared with expression in lean subjects (Figure b) or in subjects with 
NGT (Figure c); # indicates statistical significance for differences between fat depots (Vis vs. SC) for 
appropriate subject groups; ## and ### indicate statistically significant at p < 0.01 and p < 0.001, 
respectively; AU, arbitrary units. 
 
6.4.3 Correlation of BMPR2 mRNA expression with parameters of obesity, glucose 
metabolism, and insulin sensitivity 
Univariate regression analysis revealed significant positive correlations between both 
Vis and SC BMPR2 mRNA expression and BMI, % body fat, waist, WHR, fasting and 2-h 
plasma glucose, and fasting plasma insulin (Table 1; Figure 3). There was an inverse 
correlation between visceral and SC BMPR1A mRNA expression and glucose uptake during 
the steady state of a euglycemic-hyperinsulinemic clamp (Table 1). The correlations remained 
unchanged also after excluding subjects with IGT and T2D (data not shown). The correlation 
 




between BMPR2 mRNA expression in fat and glucose infusion rate during the steady state of 
an euglycemic–hyperinsulinemic clamp remained significant even upon adjusting for age, 
gender and % body fat (Table 2). 






















































































Figure 3: Correlations a) between visceral (Vis) and subcutaneous (SC) BMPR2 mRNA expression; 
b) between Vis BMPR2 mRNA expression and % body fat, c) between Vis BMPR2 mRNA expression 
and BMI, d) between SC BMPR2 mRNA expression and BMI. Data are ln-transformed to achieve 
normal distribution. 
 
Table 1: Linear regression analyses of visceral (Vis) and subcutaneous (SC) BMPR2 
mRNA expression with anthropometric and metabolic parameters (N = 161). 
 Vis BMPR2 mRNA SC BMPR2 mRNA 
 R (p-value) R (p-value) 
Age  0.275 (< 0.001) 0.183 (0.020) 
BMI  0.611 (< 0.001) 0.320 (< 0.001) 
% body fat 0.611 (< 0.001) 0.321 (< 0.001) 
WHR 0.540 (< 0.001) 0.322 (< 0.001) 
Fasting plasma glucose 0.303 (< 0.001) 0.259 (0.001) 
Fasting plasma insulin 0.777 (< 0.001) 0.499 (< 0.001) 
2-h plasma glucose 0.419 (< 0.001) 0.361 (< 0.001) 
GIR  -0.815 (< 0.001) -0.603 (< 0.001) 
 
GIR – glucose infusion rate during the steady state of the euglycemic-hyperinsulinemic clamp. 
 




Table 2: Multivariate linear regression analyses of visceral (Vis) and subcutaneous (SC) 
BMPR2 mRNA expression with anthropometric and metabolic parameters (N = 161). 
 Vis BMPR2 mRNA SC BMPR2 mRNA 
 β-Coefficient (p-value) β-Coefficient (p-value) 
Model 1   
Age (years) 0.049 (0.0004) 0.028 (0.021) 
Gender -0.010 (0.980) 0.030 (0.935) 
Model 2   
Age (years) 0.025 (0.029) 0.017 (0.142) 
Gender 0.010 (0.977) 0.032 (0.926) 
BMI 6.792 (< 0.001) 2.916 (< 0.001) 
Model 3   
Age (years) 0.030 (0.010) 0.019 (0.103) 
Gender -0.045 (0.893) 0.008 (0.981) 
% body fat 4.710 (< 0.001) 2.044 (< 0.001) 
Model 4   
Age (years) 0.011 (0.179) 0.005 (0.659) 
Gender -0.109 (0.663) 0.004 (0.990) 
% body fat 2.325 (< 0.001) 0.154 (0.771) 
GIR -2.898 (< 0.001) -2.047 (< 0.001) 
 
6.4.4 Genetic variation in the BMPR2  
 We sequenced the human BMPR2 in 48 DNA-samples and found 8 genetic variants 
(Supplement Figure 2). Further, 10 HapMap tagging SNPs, covering 100 % of the variation in 
the BMPR2 locus (according to HapMap Phase II; www.hapmap.org) (27), were selected 
from the database using the Tagger software and the following criteria: minor allele frequency 
(MAF) > 0.05 and r2 > 0.8. These SNPs were additionally genotyped in the 48 DNA-samples. 
We calculated the linkage disequilibrium (L.D.) between all SNPs using the EMLD statistical 
program (https://epi.mdanderson.org/qhuang/Software/pub.htm) (Supplement Table 2). Based 
on L.D., all SNPs identified through sequencing and with a minor allele MAF > 0.05 were 
represented by at least one HapMap tagging SNP (L.D. with r2 > 0.8) (Supplement Table 2). 
Since two HapMap tagging SNPs were in 100 % L.D. in our population (rs13426118 and 
rs1061157), only 9 tagging SNPs were therefore taken forward to genotyping for association 
studies in German Caucasians (Leipzig). For replication analyses we included the Sorbs from 
Germany. All SNPs were in Hardy-Weinberg equilibrium (p > 0.05). 
 
6.4.5 BMPR2 variants and association with obesity 
Leipzig cohort: In a case-control study including 447 lean (BMI < 25 kg/m2) and 701 
obese (BMI > 30 kg/m2) subjects, rs6717924 and rs13426118 were nominally associated with 
obesity (p < 0.05, adjusted for age and sex). Carriers of the minor allele for rs6717924 were at 




higher risk of being obese (odds ratio (OR) and (95 % CI) = 1.40 (1.06; 1.85), p = 0.018) 
whereas subjects with the minor allele for rs13426118 were protected against obesity (0.71 
(0.55; 0.93), p = 0.013 in an additive mode of inheritance after adjusting for age and sex) 
(Table 3, Supplement Table 3). 
 
Sorbs: The two SNPs nominally associated with obesity in the Leipzig cohort were 
genotyped in the Sorbs for replication. None of the SNPs showed significant association in 
the Sorbs case-control study (337 lean and 215 obese subjects) (Table 3, Supplement Table 
3). In a combined analysis including both the Sorbs and the Leipzig cohort, only rs6717924 
showed association with obesity (combined OR and 95 % CI = 1.35 (1.07; 1.70); p = 0.011) 
(Table 3). The combined effects of the SNPs on obesity were confirmed in a meta-analysis 
using the metan command in STATA based on the estimated effect sizes of each study and 
their confidence intervals. The allele/genotype frequencies in the phenotypic groups (lean vs. 
obese) remained unchanged also after excluding subjects with T2D. However, due to smaller 
sample size, p values did not reach statistical significance (data not shown). 
 
Table 3: Association analyses of the BMPR2 genetic variants with obesity in the Leipzig 








OR (95 % CI) p-value 
   Leipzig (a) N = 1148 
rs6717924 G A 0.14/0.11 1.40 (1.06; 1.85) 0.018 
rs13426118 A C 0.11/0.15 0.71 (0.55; 0.93) 0.013 
   Sorbs (b) N = 552 
rs6717924 G A 0.15/0.12 1.19 (0.77; 1.84) 0.43 
rs13426118 A C 0.13/0.11 1.22 (0.78; 1.91) 0.39 
   Combined analysis 
rs6717924 G A  1.35 (1.07; 1.70) 0.011 
rs13426118 A C  0.93 (0.72; 1.21) 0.61 
 
OR (95 % CI); odds ratio with 95 % confidence intervals; p-values were adjusted for age and sex. 
*ORs indicate effect directions of the minor allele in additive mode of inheritance. a) N = 701 cases 
(BMI > 30 kg/m2) vs. 447 controls (BMI < 25 kg/m2), b) N = 215 cases vs. 337 controls. Combined 
ORs and p-values represent the combined analysis of the two cohorts (Leipzig and Sorbs). The 








6.4.6 BMPR2 variants and association with obesity related quantitative traits  
Leipzig cohort: Consistent with case-control studies, we found nominal associations 
between rs13426118 and BMI in 900 subjects without T2D. As expected, carriers of the 
obesity risk allele (major) had a higher mean BMI (Supplement Table 4) than the non-
carriers. In addition, rs1980153 showed effects on adiponectin, rs4303700 on % body fat, 
rs12621870 on fasting plasma insulin, and rs17199235 on 2-h plasma glucose levels 
(Supplement Table 4). We also assessed the association of the 9 SNPs with T2D in a case-
control study including 930 cases with T2D and 722 healthy controls with NGT from the 
Leipzig cohort. No significant association with T2D was found under logistic regression 
analysis (p > 0.05; adjusted for age, sex and BMI; data not shown). 
Sorbs: The 2 SNPs (rs13426118, rs6717924) nominally associated with obesity in a case-
control study in the Leipzig cohort were also tested for associations with BMI and obesity 
related traits in 819 non-diabetic Sorbs. Although rs13426118 was nominally associated with 
BMI (p < 0.05, adjusted for age and sex; Supplemental Table 4), it showed opposite effect 
direction when compared with the Leipzig cohort. Moreover, rs6717924 was associated with 
fasting plasma insulin and 2-h plasma insulin (p < 0.05, adjusted for age, sex and BMI). 
Combined p - values of the two BMPR2 SNPs in our two study cohorts were assessed by a 
meta-analysis using the METAL software. Both SNPs, rs6717924 and rs13426118, showed 
nominal significant association with fasting plasma insulin (p = 0.022, and p = 0.044 
respectively). 
 
6.4.7 Association of rs6717924 with BMPR2 mRNA expression 
Carriers of the rs6717924 A-allele (i.e., obesity risk allele) had higher BMPR2 mRNA 
expression in visceral adipose tissue compared to carriers of the non-risk alleles (p = 0.042; 
adjusted for age, sex and BMI; Figure 5; N = 161). Consistent with the analyses in the entire 
cohort, the rs6717924 obesity risk allele was associated with BMI also in this subgroup  
(p = 0.017, adjusted for sex and age). Including visceral BMPR2 mRNA expression as a 
covariate abolished the SNP effect on BMI (p = 0.31) while the effect on mRNA expression 
remained significant (p < 0.001). None of the other SNPs was associated with either visceral 





































Figure 4: Association of rs6717924 with adipose tissue BMPR2 mRNA expression. Given are 
means±SEM. A minor allele; G major allele. 
 
6.5 Discussion 
BMPR2 plays an important role during embryonic development and remains 
ubiquitously expressed in later life. Employing genome wide screening strategies, the BMPR2 
locus has been suggested to be a target of recent evolutionary selection in human populations 
(5). So far, genetic variants in the BMPR2 have been described to be responsible for the 
majority of cases of the autosomal hereditable pulmonary arterial hypertension (28). 
Functional studies revealed that vascular BMPR2 mRNA expression is up-regulated in early 
stages of autoimmune diabetes in non-obese diabetic mice (29) and improved renal bone 
morphogenetic protein 7 (BMP7) and BMPR2 mRNA expression following treatment in 
streptozotocin-induced diabetic rats is of benefit against renal damage during diabetic 
nephropathy (30). However, little is known about the role of BMPR2 in the pathophysiology 
of human obesity despite evidence for involvement of BMPs in the regulation of adipogenesis 
(9). Also our recent studies on BMPR1A, partner in the receptor complex with BMPR2, 
suggest a regulatory role of these receptors in obesity (15). We therefore performed a 
systematic study on the potential role of BMPR2 in the pathophysiology of obesity by 
combining data from genetic, evolutionary, phenotypic and adipose tissue expression studies. 
We analysed the coding region of 36 vertebrate BMPR2 orthologs to screen for 
signatures of selections between species and showed that BMPR2 has undergone an overall 
purifying selection. Considering strong physiologic relevance of BMPR2 in developmental 
processes, it is not surprising that the coding region shows very strong conservation with 
more than half of amino acid positions being very strongly conserved. To assess intronic 




regions, we used Haplotter/PhaseII database to screen for selection patterns within the 
BMPR2 locus. Population genetic measures represented by high iHS in Caucasian populations 
(Supplement Table 1) indicated signatures of recent selection at the BMPR2 locus. 
Since BMPR2 is considered a plausible obesity candidate gene, we investigated its role 
in the pathophysiology of human obesity. We found significantly higher BMPR2 mRNA 
expression in fat in overweight and obese compared to lean individuals. In addition, BMPR2 
mRNA expression was significantly higher in subjects with IGT/T2D compared to controls 
with NGT. BMPR2 mRNA expression correlated with measures of obesity and fat 
distribution, as well as with traits of glucose metabolism and insulin sensitivity. Notably, the 
visceral BMPR2 expression increased remarkable, when the BMI shifted towards overweight. 
Furthermore, predominantly in lean individuals, BMPR2 was higher expressed in 
subcutaneous compared to visceral adipose tissue. Correlations of BMPR2 expression with 
obesity and relevant metabolic traits suggest that BMPR2 mRNA expression in human 
adipose tissue might be related to progression of obesity but it remains unclear whether it is 
due to the extended fat mass or vice versa. Consistent with recent studies on BMPR1A (15), 
positive correlation of BMPR2 mRNA expression with obesity suggests that obese individuals 
may have enhanced BMP-2/4 signalling, which may stimulate adipose tissue differentiation 
thereby contributing to increased fat mass. However, based on such correlational analyses, the 
direction of the causative chain can not be established and we can therefore not exclude that 
increased BMPR2 expression may be a consequence rather than the cause of increased fat 
mass. The genotype-phenotype association study showed two SNPs (rs6717924, rs13426118) 
nominally associated with obesity in the Leipzig cohort. However, they could not be 
replicated in the Sorbs, even though combined analyses of both cohorts supported the 
association of rs6717924 A allele with obesity. Similarly, association of BMPR2 SNPs with 
quantitative traits was moderate and would not withstand adjustment for multiple testing (e.g. 
Bonferroni correction). However, the rs6717924 obesity risk allele was associated with 
visceral BMPR2 mRNA expression and also with BMI in a subgroup of 161 subjects. 
Including visceral BMPR2 mRNA expression as a covariate abolished the SNP effect on BMI 
while the effect of mRNA expression levels remained significant. This suggests that the 
moderate SNP effect on BMI might be mediated through its effect on the visceral BMPR2 
mRNA expression level. Altered BMPR2 mRNA expression might result in changes in 
adipose tissue expansion during the activation of division and differentiation of adipocyte 
precursor cells. Undoubtedly, studies targeting functional consequences of BMPR2 obesity 
risk variants on BMPR2 transcription are inevitable to clarify whether genetic variants can 




explain variation in BMPR2 mRNA expression. Nevertheless, the iHS value of nearly 2 for 
the rs6717924 suggests that the haplotypes on the background of the ancestral allele A, which 
was associated with obesity and visceral mRNA levels, are longer compared to derived allele 
background, thus subject to recent positive selection. This suggests that the BMPR2 variant 
was likely to be selected to accumulate energy more efficiently. 
Taking higher BMPR2 mRNA levels in carriers of the rs6717924 A-allele into 
account, we used the Transcription Element Search System (TESS; 
http://www.cbil.upenn.edu/tess) to examine transcriptional binding sites surrounding this 
genetic variant, which might explain variation in BMPR2 expression. The sequence 
surrounding rs6717924 (G>A) matches human transcription binding site for a transcription 
factor IPF1 (insulin upstream/promoter factor 1) for the major allele G. IPF1 is needed for the 
formation of the pancreas and is assumed to act to determine the fate of common pancreatic 
precursor cells and/or to regulate their propagation (31). In this regard, it seems noteworthy 
that we observed nominal association of the rs6717924 with fasting plasma insulin levels in a 
combined analysis of both cohorts. Moreover, there is evidence that BMPs might regulate 
insulin secretion. BMP4 and its high-affinity receptor BMPR1A are expressed in 
differentiating and adult beta cells and transgenic expression of Bmp4 in mice beta cells 
enhances glucose stimulated insulin secretion and glucose clearance (32). Although BMPR2 
expression was higher in subjects with T2D, the genetic variation in BMPR2 does not appear 
to be a major player in the polygenic aetiology of T2D as no association of genetic 
polymorphisms with T2D was found. We are aware that statistical power of our study is 
limited due to relatively small sample size. In our cohorts we had a power of 80 % (α = 0.05) 
to detect a difference of 0.71-1.32 kg/m2 per allele for BMI, 0.08-0.15 mmol/l for fasting 
plasma glucose, 3.94-18.07 pmol/l for fasting plasma insulin, 0.23-0.43 mmol/l for  
2-h plasma glucose during an OGTT under the additive model. Similarly, in the case-control 
studies for obesity, we had a power of 80 % (α = 0.05) to detect SNP effects with odds ratios 
(ORs) ranging from 1.21 to 1.44 and from 1.35 to 1.37 in the Leipzig and Sorbs, respectively. 
Since the reported effect sizes for obesity SNPs are usually lower (ORs of 1.1–1.2), smaller 
effect may have been missed in our studies. In conclusion, our data on expression, genetics as 
well as evolutionary aspects suggest a role of BMPR2 in the pathophysiology of obesity and 
provide some evidence for thrifty genotype hypothesis. 
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BMPR2 phylogenetic tree 
 
Supplement Figure 1: Phylogeny for BMPR2 with estimates of ω for each 
species (a) and list of species analyzed (b). ω-values were obtained under the 
“free-ratio” model. C. = Common, N. = Northern. *indicates species with 
concatenated sequences. 
b  Scientific name Species Accession Number 
Anolis carolinensis Anole lizard ENSACAT00000004923 
Bos taurus Cattle ENSBTAT00000008419 
Callithrix jacchus Common marmoset ENSCJAT00000009881 
Canis famimiliaris Dog ENSCAFT00000036570 
Cavia porcellus Guinea pig ENSCPOT00000009672 
Choloepus hoffmanni Sloth ENSCHOT00000008739 
Dasypus novemcinctus Nine-banded armadillo ENSDNOT00000013861 
Dipodomys ordii Ord's kangaroo rat ENSDORT00000009208 
Echinops telfairi Lesser hedgehog tenrec ENSETET00000000699 
Equus caballus Horse* XP_001497350.2/  ENSECAT00000027148 
Erinaceus europaeus European hedgehog ENSEEUT00000006776 
Felis catus Cat* ENSFCAT00000014098 
Gallus gallus Chicken NP_001001465.1/  ENSGALT00000013786 
Gorilla gorilla Western gorilla ENSGGOT00000011031 
Homo sapiens Human ENST00000374580 
Loxodonta africanus African elephant ENSLAFT00000015205 
Macaca mulatta Rhesus monkey ENSMMUT00000016780 
Macropus eugenii Wallaby ENSMEUT00000006447 
Microcebus murinus Mouse lemur ENSMICT00000004437 
Monodelphis domestica Opossum ENSMODT00000020719 
Mus musculus Mouse ENSMUST00000087435 
Myotis lucifugus Little brown bat ENSMLUT00000014786 
Ochotona princeps Pika ENSOPRT00000009329 
Oryctolagus cuniculus Rabbit ENSOCUT00000001973 
Otolemur garnettii Northern greater galago ENSOGAT00000007769 
Pan troglodytes Chimpanzee ENSPTRT00000056194 
Pongo pygmaeus Orang utan ENSPPYT00000015214 
Procavia capensis Hyrax ENSPCAT00000012541 
Pteropus vampyrus Flying fox ENSPVAT00000005248 
Rattus norvegicus Norwegian rat* Q91WY9_RAT/ ENSRNOT00000035238 
Sorex araneus Common shrew ENSSART00000013016 
Spermophilus tridecemlineatus Thirteen-lined ground squirrel ENSSTOT00000002360 
Tupaia belangeri Northern tree shrew ENSTBET00000017571 
Tarsius syrichta Philippine tarsier ENSTSYT00000003507 
Tursiops truncatus Common bottlenose dolphin ENSTTRT00000004984 
Vicugna pacos Alpaca ENSVPAT00000009496  
Anole lizard 0.1362 
Chicken 0.0480 
Wallaby 0.1120 
Short-tailed opossum 0.0576 
N. tree shrew 0.0730 
Philippine tarsier 0.0882 
C. marmoset 0.2360 
Rhesus monkey 0.0882 
Orang utan 0.1276 
Western gorilla 1.1423 
Human 0.0957 
Chimpanzee 0.0001 
Mouse lemur 0.3690 
N. greater galago 0.0361 
Ground squirrel 0.0770 
Guinea pig 0.0960 
Mouse 0.0705 




C. bottlenose dolphin 0.1132 
Cattle 0.0455 
European hedgehog 0.0634 
Dog 0.1914 
Ord‘s kangaroo rat 0.1319 
Cat 0.1546 
Little brown bat 0.1688 
Flying fox 0.1192 
Alpaca 0.0299 
C. shrew 0.0798 
Sloth 
Nine-banded armadillo 0.0940 
Tenrec 0.1960 

















Suplement Figure 2: Genetic structure and SNPs analysed in the bone morphogenetic receptor 2 gene (BMPR2). The polymorphisms shown in black were 
discovered by direct gene sequencing. One of them was novel (w/o rs-number). Ten HapMap tagging polymorphisms (shown in green) were analysed for 























Supplement Table 1: Integrated haplotype scores (iHS) for tagging SNPs within the 
BMPR2 locus. 
 CEU YRI ASN 
rs6177924 1.986 -1.498 - 
rs1980153 -2.495 - - 
rs4303700 -1.667 - -0.601 
rs13426118 -1.711 -0.278 1.259 
rs16839127 -2.236 - - 
rs12693968 1.235 - -0.580 
rs4675278 -0.572 -1.801 -1.864 
rs12621870 -0.978 0.698 -1.971 
rs17199235 -1.278 - - 
rs1061157 -1.485 - 0.981 
 
Provided are iHS values for Europeans (CEU), Africans (YRI) and Asians (ASN) (5). 
 
 
Supplement Table 2: Measures of L.D. (D prime (D’) and r2) among 17 BMPR2 variants. 
 
r2 given in upper shaded boxes and D’ given in lower boxes. 
1 = -918_-919insAGC, 2 = -210_-211insC, 3 = rs6717924, 4 = rs1980153, 5 = rs4303700,  
6 = rs13426118, 7 = rs16839127, 8 = rs12693968, 9 = rs4675278, 10 = rs12621870, 11 = rs10714063, 
12 = rs7575056, 13 = 137484 A/C, 14 = rs17199235, 15 = rs2228545, 16 = rs1061157,  
17 = rs45502895. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
1 1 0.00 0.00 0.08 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 1.00 1 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.04 0.00 0.00 1.00 0.07 0.00 0.00 0.00 
3 1.00 1.00 1 0.03 0.04 0.01 0.01 0.18 0.07 0.03 0.87 0.87 0.00 0.02 0.00 0.01 0.08 
4 1.00 1.00 1.00 1 0.01 0.00 0.00 0.05 0.02 0.04 0.02 0.02 0.00 0.03 0.01 0.00 0.00 
5 1.00 1.00 1.00 0.51 1 0.04 0.31 0.08 0.17 0.08 0.05 0.05 0.00 0.05 0.01 0.04 0.03 
6 1.00 1.00 0.63 0.32 1.00 1 0.01 0.49 0.00 0.03 0.00 0.00 0.00 0.02 0.00 1.00 0.00 
7 1.00 1.00 1.00 0.51 1.00 1.00 1 0.02 0.05 0.02 0.00 0.00 0.00 0.01 0.00 0.01 0.12 
8 1.00 1.00 0.60 1.00 1.00 1.00 1.00 1 0.01 0.07 0.25 0.25 0.00 0.04 0.00 0.50 0.00 
9 1.00 1.00 1.00 0.44 1.00 0.14 1.00 0.20 1 0.45 0.09 0.09 0.02 0.31 0.06 0.01 0.01 
10 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1 0.05 0.05 0.04 0.63 0.12 0.03 0.00 
11 1.00 1.00 1.00 1.00 1.00 0.16 0.03 0.68 1.00 1.00 1 1.00 0.00 0.03 0.00 0.02 0.10 
12 1.00 1.00 1.00 1.00 1.00 0.16 0.03 0.68 1.00 1.00 1.00 1 0.00 0.03 0.00 0.02 0.10 
13 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1 0.07 0.00 0.00 0.00 
14 1.00 1.00 0.90 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1 0.20 0.02 0.00 
15 1.00 1.00 0.13 1.00 0.84 1.00 1.00 0.58 1.00 1.00 1.00 1.00 1.00 1.00 1 0.00 0.00 
16 1.00 1.00 1.00 0.12 1.00 1.00 1.00 1.00 0.21 1.00 1.00 1.00 1.00 1.00 1.00 1 0.00 
17 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1 




Supplement Table 3: Association of BMPR2 genetic variants with obesity in the Leipzig 




< 25 kg/m2) 
Obese subjects 
(BMI  





OR (95 % CI) 
Dominant 
p value 
OR (95 % CI) 
Recessive 
p value 
OR (95 % CI) 
Leipzig   
cohort (A) Male/Female 183/264 257/444     
 Age (years) 50 ± 18 59 ± 11     
 BMI (kg/m2) 23.4 ± 1.4 34.8 ± 4.8     
rs6717924 AA 7 (1.6 %) 11 (1.6 %)  0.018 0.011 0.854 
 AG 77 (18.0 %) 170 (25.1 %) 0.106/0.142 1.399 1.492 1.101 
 GG 344 (80.4 %) 496 (73.3 %)  (1.059; 1.848) (1.098; 2.027) (0.397; 3.051) 
rs1980153 TT 2 (0.5 %) 6 (0.9 %)  0.226 0.238 0.625 
 TA 65 (15.1 %) 111 (16.5 %) 0.080/0.091 1.222 1.231 1.506 
 AA 363 (84.4 %) 557 (82.6 %)  (0.883; 1.695) (0.872; 1.737) (0.292; 7.771) 
rs4303700 AA 17 (4.0 %) 30 (4.4 %)  0.236 0.203 0.776 
 AG 157 (36.3 %) 215 (31.7 %) 0.221/0.203 0.874 0.844 0.910 
 GG 258 (59.7 %) 433 (63.9 %)  (0.700; 1.092) (0.651; 1.095) (0.476; 1.739) 
rs4675278 AA 84 (19.4 %) 156 (23.0 %)  0.114 0.142 0.202 
 AG 122 (28.2 %) 192 (28.4 %) 0.335/0.372 1.138 1.209 1.225 
 GG 227 (52.4 %) 329 (48.6 %)  (0.969; 1.335) (0.938; 1.558) (0.897; 1.674) 
rs16839127 AA 0 (0 %) 3 (0.5 %)  0.560 0.674  
 AG 49 (11.4 %) 81 (12.0 %) 0.056/0.065 1.120 1.088 - 
 GG 381 (88.6 %) 590 (87.5 %)  (0.765; 1.639) (0.735; 1.610)  
rs12693968 AA 30 (7.4 %) 39 (5.9 %)  0.765 0.443 0.440 
 AG 124 (30.5 %) 225 (34.3 %) 0.227/0.231 1.033 1.110 0.815 
 GG 252 (62.1 %) 392 (59.8 %)  (0.835; 1.277) (0.850; 1.450) (0.484; 1.370) 
rs12621870 CC 36 (8.3 %) 47 (6.9 %)  0.461 0.739 0.250 
 CT 153 (35.4 %) 243 (35.7 %) 0.260/0.248 0.928 0.958 0.756 
 TT 243 (56.3 %) 390 (57.4 %)  (0.759; 1.133) (0.742; 1.236) (0.469; 1.218) 
rs17199235 GG 12 (2.8 %) 16 (2.4 %)  0.941 0.999 0.813 
 GA 98 (23.3 %) 163 (24.1 %) 0.145/0.144 0.990 1.000 0.907 
 AA 312 (73.9 %) 497 (73.5 %)  (0.769 ; 1.276) (0.747; 1.338) (0.403; 2.039) 
rs13426118 CC 10 (2.3 %) 7 (1.0 %)  0.013 0.022 0.139 
 CA 108 (24.9 %) 136 (20.0 %) 0.147/0.110 0.714 0.708 0.467 
 AA 316 (72.8 %) 537 (79.0 %)  (0.546; 0.932) (0.527; 0.951) (0.170; 1.281) 
Sorbs  
cohort (B) Male/Female 104/233 78/137     
 Age (years) 39 ± 15 58 ± 12     
 BMI (kg/m2) 22.3 ± 1.7 33.9 ± 3.6     
rs6717924 AA 2 (0.6 %) 3 (1.4 %)  0.425 0.498 0.476 
 AG 78 (23.5 %) 55 (26.2 %) 0.123/0.145 1.192 1.174 2.035 
 GG 252 (75.9 %) 152 (72.4 %)  (0.774; 1.838) 0.739; 1.864) (0.289; 14.342) 
rs13426118 CC 3 (1.0 %) 2 (1.0 %)  0.386 0.267 0.517 
 CA 67 (20.7 %) 51 (24.4 %) 0.113/0.132 1.219 1.315 0.533 
 AA 253 (78.3 %) 156 (74.6 %)  (0.779; 1.909) (0.811; 2.131) (0.080; 3.574) 
 
Case-control for obesity: (A) 447 lean subjects (BMI < 25 kg/m2) vs. 701 obese subjects  
(BMI > 30 kg/m2); (B) 337 lean subjects (BMI < 25 kg/m2) vs. 215 obese subjects (BMI > 30 kg/m2). 
P values were calculated after adjusting for age and gender. Odds ratios (OR) and 95 % confidence 
intervals (95 % CI) are given for the minor allele. Dominant model of inheritance indicates Mm + mm 
vs. MM. MAF = minor allele frequency. 




Supplement Table 4: Association of BMPR2 SNP variants with quantitative traits in the 
Leipzig (A) and the Sorbs (B) cohort. 















rs6717924 G>A          
p-value 0.247 0.791 0.551 0.347 0.261 0.958 0.165 0.071 0.222 
β 0.014 0.003 0.005 -0.019 -0.123 0.004 0.056 0.192 -0.099 
SE 0.012 0.012 0.008 0.020 0.109 0.085 0.040 0.106 0.081 
rs1980153 A>T          
p-value 0.666 0.470 0.204 0.226 0.430 0.554 0.739 0.688 0.019* 
β -0.006 -0.010 -0.012 -0.028 0.104 0.057 -0.016 0.050 0.223 
SE 0.014 0.014 0.009 0.023 0.132 0.097 0.047 0.124 0.094 
rs4303700 G>A          
p-value 0.206 0.743 0.470 0.768 0.103* 0.330 0.021* 0.976 0.691 
β -0.012 -0.003 -0.005 -0.005 0.140 -0.063 -0.075 0.003 -0.027 
SE 0.010 0.010 0.007 0.016 0.086 0.065 0.032 0.085 0.067 
rs4675278 G>A          
p-value 0.077# 0.966 0.529 0.661 0.338 0.827 0.728 0.177* 0.572 
β 0.013 -0.0003 0.003 -0.005 -0.061 0.011 0.008 -0.085 -0.027 
SE 0.007 0.007 0.005 0.012 0.064 0.049 0.023 0.063 0.047 
rs16839127 G>A          
p-value 0.994 0.346 0.876 0.837 0.287# 0.823 0.641 0.639 0.742 
β -0.0001 0.015 0.002 0.005 0.146 0.022 -0.023 -0.062 0.033 
SE 0.016 0.016 0.010 0.025 0.137 0.100 0.049 0.133 0.101 
rs12693968 G>A          
p-value 0.413 0.285 0.563 0.476 0.426 0.691 0.158 0.113 0.324 
β -0.008 -0.011 0.004 -0.012 -0.070 -0.027 0.045 0.134 -0.063 
SE 0.010 0.010 0.007 0.016 0.087 0.068 0.032 0.085 0.064 
rs12621870 T>C          
p-value 0.827 0.572 0.280 0.203* 0.025* 0.350 0.559 0.539 0.195 
β 0.002 -0.005 0.007 -0.019 -0.179 0.059 -0.017 -0.050 -0.078 
SE 0.009 0.009 0.006 0.015 0.080 0.063 0.028 0.082 0.060 
rs17199235 A>G          
P-value 0.745 0.744 0.570 0.042* 0.058* 0.111 0.642 0.487 0.526 
β 0.004 0.004 0.004 -0.037 -0.190 0.131 -0.017 0.074 -0.049 
SE 0.011 0.011 0.008 0.018 0.100 0.082 0.037 0.106 0.077 
rs13426118 A>C          
p-value 0.016* 0.222 0.939 0.774 0.319 0.588 0.923 0.413# 0.597 
β -0.030 -0.015 -0.001 0.006 -0.107 -0.045 -0.004 0.089 -0.045 
SE 0.012 0.012 0.008 0.020 0.107 0.083 0.042 0.109 0.085 











insulin p-Fat    
rs6717924 G>A          
p-value 0.924 0.438 0.998 0.261 0.033* 0.030* 0.545   
β 0.001 -0.007 <0.001 -0.025 -0.084 -0.140 0.018   
SE 0.011 0.009 0.006 0.022 0.039 0.064 0.029   
Combined p value 0.366 0.731 0.665 0.145 0.022     
rs13426118 A>C          
p-value 0.018* 0.406 0.790 0.616 0.061 0.443 0.096   
β 0.026 0.007 0.002 -0.011 -0.073 -0.049 0.047   
SE 0.011 0.008 0.006 0.022 0.039 0.064 0.028   
Combined p value 0.912 0.757 0.898 0.890 0.044     
 
 




Supplement Table 4 cont.: The dataset included subjects with NGT and IGT (N = 900, except for  
% body fat, leptin and adiponectin (N = 374) for the Leipzig cohort; N = 819 for the Sorbs cohort).  
P values were calculated after adjusting for age and gender for the variables BMI, WHR and % body 
fat; and for age, gender and BMI for the remaining variables. ß indicate effect directions of the minor 
alleles. P-values are given for the additive model. */# significant in dominant/recessive mode of 
inheritance; dominant model indicates Mm + mm vs. MM; BMI = body mass index; WHR = waist-to-
hip ratio; OGTT = oral glucose tolerance test; GIR = glucose infusion rate; AdipoQ = adiponectin. 
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In the recent years, the number of genetic variants and genes shown to play a role in 
the polygenic background of obesity and related metabolic complications such as insulin 
resistance, dyslipidemia or T2D has exploded by means of GWAS in large independent 
cohorts (90). In a well-powered study, this approach enables the detection of genetic variants 
and genes without a priori hypothesis and even with small effects on the investigated 
phenotype. On the one hand this often leads to surprising as well as intriguing novel findings, 
as demonstrated by the FTO (69). On the other hand, apparently attractive candidate genes, 
such as FASN may have been missed in GWAS. Despite lacking association with metabolic 
phenotypes in GWAS, a physiologically interesting gene may still deserve in depth analyses. 
Significant association between FASN SNPs and obesity could be detected in our study, 
raising the question why this has been missed in GWAS. It is likely that the association in 
GWAS did not reach the threshold for genome wide significance. However, it needs to be 
mentioned that in most studies FASN variants were not covered by the used SNP genotyping 
arrays. Also, variants in BMPR2, which plays a role in adipogenesis, were never highlighted 
in GWAS investigating obesity, T2D or related traits. Again, this may be due to a lacking 
genome wide significance for the association of the variants with the trait at a p level of 10-8. 
Significance thresholds obtained after multiple testing or Bonferroni correction may 
strengthen the analysis but plausible physiological candidate genes may get lost in the 
“background noise”. This demonstrates that well-designed candidate gene studies including 
replication cohorts as applied in case of FASN, CNR1, and BMPR2 are still eligible, and a 
combination of both GWAS and candidate gene approaches might be the avenue leading to 
more insights into the genetic complexity of metabolic alterations. 
Without doubts, statistical power affects both study designs; the larger the cohort the 
smaller the detectable effect size. Also studies presented in this thesis are affected by this 
issue. Although possible associations may have been missed in the investigated cohorts, the 
effect size of a variant has to be considered as well; in particular in the light of its potential 
physiological relevance. Assuming a polygenic background of a trait, the effects of many 
single SNPs are supposed to sum up to administrate an adverse effect. Simultaneously, there 
may be the same number of alleles with beneficial effects on health, thus masking the 
deleterious effects of single SNPs. In the context of the “common variant – common disease” 
hypothesis (SNP MAF > 5 %), strong SNP effects will be found even in “small” cohorts as 




shown e.g. for FASN. Nevertheless, to study the effects of rare genetic variants (MAF < 5 %), 
large-scale studies with cohorts comprising thousands of individuals are highly desirable. 
The population genetic structure as well as environmental factors play a crucial role in 
genotype-phenotype association studies. This may partially explain discrepancies in effects or 
even in effect direction between various independent studies. One prominent example is the 
population of Pima Indians from southern Arizona that is characterized by one of the highest 
prevalence of T2D worldwide (91). Numerous candidate genes for T2D have been 
investigated and identified in this population (92). It should be noted that whereas one part 
resident in Arizona develops severe metabolic complications, the Pima Indian counterparts 
resident in Mexico show a scanty phenotypic outcome. As it is unlikely that the genetic pool 
of these two populations has changed in the last years, the phenotypic differences are most 
likely due to strikingly different environmental factors, particularly due to the western style 
hyper-caloric nutrition of the group living in Arizona. Despite low average levels of genetic 
differentiation among Europeans, a close correspondence between genetic and geographic 
distances was found by Novembre et al. (93). The results emphasize that when mapping the 
genetic basis of a disease phenotype, spurious associations can arise if genetic structure is not 
properly accounted for. This might partly explain the inconsistencies in studies on CNR1 as 
reported in the literature, but also shown in the thesis. Although a gene might be considered a 
“good” candidate to modulate disease risk in one population, it does not necessarily need to 
have the same effect in another population. However, this indicates that replication studies as 
well as independent studies in populations other than e.g. Europeans are necessary to estimate 
the overall risk of a genetic polymorphism or gene on the outcome of a disease. This would be 
also necessary for the FASN and BMPR2 SNPs described in the present work. Better 
awareness of the genetic heterogeneity of studied populations made possible that even studies 
lacking significant associations could be considered for publication which leads to a better 
overall assessment of the influence of a genetic variant on disease risk. Nevertheless it is also 
part of the “dilemma” one faces when studying diseases with a polygenic background. 
 Children cohorts take a unique position in genotype-phenotype association studies. 
Unlike in adults their phenotype is less influenced by co-morbidities and prolonged exposure 
to environmental factors, making the genetic contribution more profound. Considering that 
phenotype is a result of genotype and environment interaction, it is not surprising that genetic 
factors may have a different impact in various stages of life. Variants in FTO have previously 
been linked to childhood obesity by others (69,70). However, in case of FASN our study 
suggests that SNP effects in this gene most likely manifest in later stages of life and/or they 




might be modified by gene-environment interactions. Furthermore, the gender dimorphism 
often plays an important role (94), as shown here for the Val1483Ile substitution in FASN. 
Sex related factors like hormones are known to exert dramatic effects, amongst others, clearly 
demonstrated by differences in adipose tissue distribution between men and women. 
Central obesity has adverse effects on metabolic parameters such as glucose tolerance, 
insulin sensitivity and lipid profiles (5). Beside known gender differences, adipose tissue 
distribution is also assumed to be genetically determined. Unfortunately, WHR has not been 
addressed as a “main” measure for adipose tissue distribution in GWAS and candidate gene 
studies until recently. This may be due to the necessity to clearly distinguish between 
subcutaneous or visceral adipose tissue derived obesity by means of MRI, CT, or DEXA. It is 
known that many genes are differentially expressed in subcutaneous and visceral adipose 
tissue depots and their mRNA expression correlates with measures of obesity which might 
reflect their physiological role. However, it can not be ruled out that expression is a 
consequence rather than the cause of increased fat mass or that the differential expression of 
the gene in adipose tissue is just secondary to another side of action. Studies investigating the 
influence of SNPs on the expression of these genes in adipose tissue depots may provide a 
hint on the cause-effect relationship, i.e. how a gene might influence the physiology. Since 
obtaining paired human biopsies from SC and Vis adipose tissue is often a laborious and time 
consuming undertaking, gene expression studies in fat are mostly conducted in small cohorts 
or in animal models, hence limiting the power for statistical analyses. This could partially 
explain a lack of association between the FTO SNP and expression. On the other hand, the 
results of genotype-expression correlations for FASN and BMPR2 clearly demonstrate the 
capability of this approach, as disease susceptibility SNPs are often located in introns, 
potentially containing regulatory sequences such as transcription factor binding sites, 
enhancer or repressor elements, and sites for epigenetic modifications. 
The regulation of gene expression through SNPs is one of the possibilities how genetic 
variants could exert their effect on metabolic pathways. Employing the “SNP-tagging” 
approach (95) based on linkage disequilibrium groups, the SNP found to be associated with 
obesity or related traits does not necessarily represent the “functional” variant. Therefore all 
SNPs belonging to one L.D. group would need to be examined in functional studies. Further, 
it needs to be taken into account that an enhanced gene expression does not necessarily lead to 
increased protein levels and vice versa. SNP association studies on protein levels are also 
promising as shown e.g. for CNR1 SNPs on leptin or 2-arachidonyglycerol or BMPR2 SNPs 




on insulin. Extensive functional studies are necessary to identify the part of the SNP/gene in 
the metabolic pathways leading to obesity, especially for genes of unknown function. 
 We could confirm the association of the previously reported FTO SNP rs8050136 with 
BMI in the Sorbs cohort which queue in the line of robust replications of this locus in 
European populations (96). In the present study, an inverse relationship between obesity and 
FTO gene expression in visceral adipose tissue in humans was found for the first time. 
Although a binding site for the transcription factor CUTL was predicted for the sequence 
containing rs8050136 preferentially binding to the A obesity risk allele (97), probably due to 
the small sample size, the SNP did not associate with the FTO mRNA expression in the 
present study. Recently, a down regulation of FTO expression was found in diabetic alpha and 
beta islet cells, however, the gene expression was less associated with BMI than has been 
found for other tissues (98). The down-regulation of FTO in adipose tissue at increasing BMI 
does not necessarily need to be in contrast to the findings of Stratigopoulos et al., who found 
a decreased FTO expression in human fibroblasts when CUTL1 was knocked down by siRNA 
(97). Since the transcription factor could act as repressor as well as activator, one might 
postulate tissue specific actions. In contrast, Samaras et al. found neither a depot specificity 
between SC and Vis adipose tissue FTO mRNA expression nor a relation to direct measures 
of total or central abdominal adiposity in 16 subjects (99). It is noteworthy that recent studies 
indicate that FTO might be involved in central regulation of energy homeostasis (100) by 
modulating food intake (101). Its proposed function to act as a 2-oxoglutarate-dependent 
nucleic acid DNA/RNA demethylase (102) was supported by the crystal structure of the FTO 
protein which reveals basis for its substrate specificity (103). In mice, a dominant point 
mutation in Fto resulted in reduced fat mass, increased energy expenditure and gene 
expression profiling revealed increased expression of some fat and carbohydrate metabolism 
genes and improved inflammatory profile in white adipose tissue of mutant mice (104). This 
provides functional evidence that FTO is a causal gene underlying obesity. Nevertheless, in 
humans, brain rather than adipose tissue is assumed to be the primary site of FTO action. 
 Even though the protective effect of the FASN Val1483Ile substitution in men was 
replicated in a second cohort of white men and also associated with a decreased adipose tissue 
FASN activity (105), no other study has investigated FASN genetic variants in association 
studies for obesity so far. It should be noted that the direction of FASN mRNA expression in 
adipose tissue in terms of obesity is still controversially discussed (106). Whereas the study 
presented in the paper suggests that the induction of FAS-catalyzed adipocyte lipogenesis 
may contribute to obesity, Ortega et al. speculate that adipose tissue may reach an inflexion 




point in which the lipogenic capacity is down-regulated in a natural inhibitory feedback 
process (106). FASN was described to be over-expressed in many cancers. Inhibitors of FASN 
have been shown to induce apoptosis in several cancer cell lines, and to induce tumor growth 
delay in several cancer xenograft models suggesting FASN to be a metabolic oncogene (107). 
Therefore, it might be speculated that genetic variants in FASN might modulate the 
prevalence of developing some form of cancer or the response to therapeutic interventions. 
 Genetic variants in CNR1 seem to have rather moderate effects on obesity in German 
populations. However, based on the current findings, genetic variants in CNR1 can not be 
completely ignored. The CNR1 is considered as a therapeutic target (108), and therefore 
pharmacogenetic studies are still potentially interesting. Recently, Perwitz et al. demonstrated 
that CNR1 blockade with rimonabant or knocking down the receptor with siRNA in a murine 
SV40 cell model led to trans-differentiation of white adipocytes into a mitochondria-rich, 
thermogenic brown fat phenotype (109). Beside the known role of CNR1 in the brain it also 
suggests adipose tissue as a primary site of action. Investigating the variant of the SNP which 
seems to be protective against obesity might also exhibit a possibility to elucidate the 
physiological role of this gene in the pathophysiology of metabolic alterations. 
 As recently shown for BMPR1A (88), and as presented in the thesis for BMPR2, 
genetic variants in two genes were associated with obesity and related traits whose proteins 
interact as receptor complex playing an important role in the commitment of mesenchymal 
stem cell into the adipogenic lineage. There is evidence that each fat depot has a unique 
developmental gene expression signature, independent from nutritional state, and supports the 
role of developmental genes in fat distribution and the development and/or function of 
specific adipose tissue depots (110). Moreover, in the present study, genetic variants in these 
genes have been shown to be associated with mRNA expression levels. The functionality of 
these variants is currently being investigated by means of luciferase assays. 
In conclusion, even though the identification of genetic variants which promote a risk 
to develop metabolic alterations and the investigations to clarify the functionality of the 
variants appear to be complex and challenging goals these studies are crucial to elucidate the 
role of genetic variants in complex diseases such as the metabolic syndrome. In the present 
thesis novel obesity risk variants were identified and it could be shown that their effect on 
gene expression levels might be a possible pathomechanistic link underlying the genotype-
phenotype associtations. 
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